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 ICP4, of Herpes Simplex Virus type 1 (HSV-1) is responsible for activation of viral Early and 
Late genes, and is necessary for viral replication. ICP4 contains two transactivation domains 
separated by a DNA binding domain. The complex structure of ICP4 indicates the possible 
diversity of the cellular and viral proteins it interacts with to function.  ICP4 interacts with a 
variety of transcription complexes to promote RNA Polymerase II mediated transcription. The 
structural basis for these interactions has not yet been clearly defined.  To more closely examine 
the structural requirements for ICP4 activities, mutants in conserved and degenerate regions of 
the N-terminus, in the presence and absence of the carboxyl terminus, were examined for effects 
on viral gene expression.   It was found that i) the amino terminal transactivation domain is 
strictly required for E gene transcription, ii) multiple conserved regions within the N-terminus 
contribute to transcription, and iii) the amino terminal and carboxyl terminal transactivation 
domains cooperate to mediate transcription.   Affinity purification assays demonstrated that 
many of the observed defects in transcription probably resulted from the deletion of regions 
involved in stabilizing TFIID.  Complementation analyses demonstrated that TFIID interactions 
are stabilized by the presence of one functional N-terminal and C-terminal transactivation 
domain within an ICP4 dimer. 
Affinity purification and mass spectrometry were used to determine the complexity of 
ICP4 mediated interactions throughout infection in addition to the structural requirements 
provided by ICP4 for these interactions.    Mass spectrometry and western blot data indicated 
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 v 
that ICP4 was found in complex with TFIID prior to other components of the transcription 
machinery including Mediator and TFIIH.  Additionally, the amino terminal 774 amino acids 
were sufficient for interactions with TFIID, Mediator and TFIIH.  While ICP4 has previously 
only been associated with preinitiation complex formation, components of initiation, elongation, 
mRNA processing, and mRNA export machinery were also found in complexes with ICP4, 
suggesting that ICP4 functions as a multifaceted RNA PolII transcription factor.  Together, the 
data presented herein provide an understanding of how the structural complexities of ICP4 
provide an interface for the formation of transcription complexes.  Additionally, a new model for 
viral transcription is presented.  
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1.0  INTRODUCTION 
Infection with Herpes Simplex Virus (HSV) exhibits a variety of pathologies ranging in 
severity from the common cold sore to life threatening encephalitis.  The more severe 
pathologies associated with HSV infections often occur in immunocompromised individuals.  
With the increasing number of AIDS patients and the development of resistance to current 
therapies, studying HSV infection is of the utmost importance.  Additionally, HSV is currently 
being investigated for use as a vector for gene therapy and oncolytic virotherapy for the 
treatment of a variety of diseases ranging from chronic pain to glioblastoma.  The use of HSV in 
gene therapy and oncolytic virotherapy requires a deep understanding of the virus at multiple 
levels, including the events regulating the viral transcriptional cascade. Herein, the mechanisms 
of cellular transcription will be compared to the current understanding of viral transcription, with 
a particular emphasis on the viral encoded transcription factor Infected Cell Polypeptide 4 
(ICP4).  The mechanisms utilized by ICP4 to redirect active transcription from the cellular 
genome to the viral genome will be discussed at length.  Additionally, the current gaps in 
knowledge with respect to viral transcription will be addressed.  
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1.1 PATHOLOGY AND EPIDEMIOLOGY 
1.1.1 Herpesviridae 
Herpes Simplex Virus has been documented in literature for at least 2500 years.  
Hippocrates of Kos initially described the disease as “herpes” Greek for “ to creep or crawl” in 
reference to the spreading nature of the blisters associated with the disease.  The nature of 
Herpes transmission was not documented until 1500 years later, in 1893, when a French 
dermatologist, Jean Baptiste Emile Vidal, reported the transmission of HSV between human 
subjects.  Nearly 100 years later, in the 1980s, treatment for HSV infections became available to 
the public.   
Herpes Simplex Virus is a member of the family Herpesviridae.  Classification into the 
family Herpesviridae is based on the structure of the virion, which consists of a lipid envelope 
studded with viral glycoproteins surrounding the icosadeltahedral capsid in which the linear 
double stranded viral DNA is packaged (Figure 1) (231, 242, 336, 337).  Between the capsid and 
the envelope is a proteinaceous layer referred to as the tegument.  The tegument contains 
proteins involved in the activation of viral replication (209).   In addition to having similar virion 
morphology, all members of Herpesviridae replicate within the nucleus, destroy the host cell 
upon the egress of viral progeny, and have the ability to establish a lifelong latent infection 
within the host (reviewed in ref 278).  Currently there are 9 known human herpesviruses with 
drastically different pathologies, host cell range and replication cycles. 
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Figure 1:  HSV Virion Structure.   
Cartoon image of a HSV virion (Figure adapted from 105).  
 
Herpesviridae can be further divided into three general sub-families, Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae, based on the host cell range, genome 
configuration, and replication cycle.  Members of Alphaherpesvirinae include Herpes Simplex 
Virus (HSV) -1, HSV-2, and Varicella Zoster Virus (VZV).  These viruses are characterized by 
their relatively short replication cycle and wide host range. These viruses establish latent 
infections within the ganglia of the host.  Members of Betaherpesvirinae include Human 
Cytomegalovirus (HCMV), Human Herpesvirus (HHV)-6A, HHV-6B, and HHV-7 and are 
characterized by a lengthy replication cycle and a limited host cell range.  Members of 
Gammaherpesvirinae include Epstein Barr Virus (EBV) and Kaposi’s Sarcoma Associated 
Herpesvirus (KSHV).  A limited host range and the ability to establish latency within lymphoid 
tissues characterize the Gammaherpesviruses.   
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1.1.2 Herpes Pathology 
HSV establishes a lifelong latent infection within the host.  Reactivation of latent virus 
can lead to a symptomatic infection, similar to the primary infection.  HSV infection can 
manifest with a variety of pathologies dependent, partially, on the initial site of inoculation.  The 
most common disease pathology is herpes labialis, which manifests as small vesicular blisters 
presenting on the lips or mouth.  Infection of the genitals leads to herpes genitalis, with similar 
vesicular blisters presenting on the genitals.  These blisters more readily form ulcers in the 
genital region due to the thinness of the epithelium in the genital tract.   In addition, HSV 
infection can lead to cutaneous infections such as herpes whitlow, an infection of the fingers that 
is problematic for healthcare workers (280), herpes gladiatorum, an infection of the body 
common amongst wrestlers (153), and herpes eczema, a potentially life threatening infection of 
the skin of eczema patients (35).  Ocular infection with HSV can lead to herpes stromal keratitis, 
the leading cause of infectious blindness in the developed world (reviewed in 160). Additionally, 
infection of immunocompromised individuals, such as infants, AIDs patients, and transplant 
patients, and less frequently, healthy individuals, can lead to a disseminated infection or 
encephalitis, which can be fatal if left untreated (279).   
In addition to the primary pathophysiology associated with HSV, a relationship between 
HSV and several other diseases, including atherosclerosis, Alzheimer’s Disease, and HIV 
transmission have recently been suggested (reviewed in 42).  Atherosclerosis is a hardening of 
the arteries and is the leading cause of heart attack.  HSV DNA can be found in circulating 
monocytes and in the coronary arteries of the aorta.  With respect to Alzheimer’s, HSV DNA has 
been detected in the brain of Alzheimer’s patients and has been shown to affect amyloid 
precursor protein (APP) processing (42); APP processing leads to the production of β-amyloid, 
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the major component of amyloid plaques found in the brains of Alzheimer’s patients.  While a 
causal relationship between HSV and either atherosclerosis or Alzheimer’s has not been 
established, HSV may contribute to disease progression.  HSV infection of the genital tract 
(generally HSV-2) leads to increased transmission rates (~3 fold) of HIV, due to accessible 
routes of entry for HIV in the ulcers formed from productive HSV infection (reviewed in 109, 
252, 341).   
Herpes is a ubiquitous pathogen that affects people globally.  Transmission of HSV 
occurs through physical contact with infectious virus, generally from mucosal membranes. 
Asymptomatic shedding of the virus frequently occurs, and as such, transmission often goes 
unnoticed.  It is estimated that 31% of children under the age of 13 are infected with HSV-1, 
with the incidence increasing from about 26% in children 6-7 years of age to 36% in children 12-
13 years of age (363).   By the age of 50 it is estimated that 70% of the population is seropositive 
for HSV-1 (289).  The CDC reported in 2010 that 16.2% of United States citizens are infected 
with HSV-2, with the vast majority of infected individuals unaware due to the asymptomatic 
nature of the virus and a lack of education regarding symptoms.  Generally speaking, most 
disease pathologies associated with HSV can be caused by either HSV-1 or HSV-2, however, 
HSV-1 is generally associated with oral infections and HSV-2 is generally associated with 
genital infections.  With increasing oral-genital contact arising from evolving sexual practices, 
the physiological distribution of HSV-1 and -2 is changing (28, 364).   
An FDA approved vaccine for the prevention of HSV infection has not yet been 
developed.  The current therapy for HSV infection is treatment with aciclovir, famciclovir, or 
valaciclovir, which are nucleoside analogues that differ slightly in chemical structure and 
absorption rates (reviewed in 257).  These compounds rely on phosphorylation by thymidine 
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kinase (51, 89).  Once phosphorylated, the viral DNA polymerase incorporates the nucleoside 
analogue into the replicating DNA causing chain termination (88).  Treatment for HSV infection 
is not generally necessary, given that symptoms will dissipate within 1-2 weeks.  However, 
treatment for HSV infection would help prevent transmission of HSV, thus leading to a reduction 
in transmission of HIV as well (341).  Additionally, severe cases of herpes, such as those 
associated with ocular infection, eczema herpeticum, disseminated infection, and encephalitis do 
require treatment.  Aciclovir resistant strains of HSV have been well documented and do pose a 
problem, particularly to immunocompromised hosts (102, 257).  Other drugs targeting the viral 
DNA polymerase such as foscaranet and vidarabine do exist, but are not widely used due, in part, 
to the severe toxicity.  The determination of novel drug targets and vaccine strategies to 
counteract HSV infection is a continuous process.   
1.1.3 Herpes as a therapeutic agent 
HSV is being investigated for potential medical contributions as a vector for vaccine 
development, gene therapy, and oncolytic virotherapy.  Generally speaking, three different 
strategies have been employed for the use of HSV as a vector: amplicons, replication defective 
viruses, and replication competent viruses.  Amplicons consist of plasmid DNA carrying the 
transgene of interest concatamerized and packaged into an empty virus particle.  Replication 
defective viruses have deletions in one or several essential genes, generally involved in 
transcription and immune surveillance.  Replication competent viruses contain deletions within 
genes that are not essential for replication in vitro, but cause severe attenuation in vivo.  These 
include ribonucleotide reductase, thymidine kinase, and the neurovirulence factor γ34.5.  Each of 
these strategies has advantages and disadvantages generally related to transgene expression, 
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delivery, immune response, and cytopathic effects and have been recently reviewed elsewhere 
(215).   
There are many benefits to using HSV as a vector for vaccine development.  Firstly, the 
dsDNA nature and large genome size make it capable of carrying large heterologous DNA 
inserts.  Additionally, HSV infects a broad host cell range and elicits durable immune responses 
through the induction of inflammatory cytokines and type I interferons. The use of replication 
defective vectors allows for efficient delivery of heterologous DNA, elicits an immune response, 
is noncytopathic, and circumvents the virus’s immune evasion strategies (137, 348).  Current 
studies are investigating the potential use of HSV vectors for HIV vaccine development with 
moderate success. 
The neurotropic nature of HSV makes it an ideal candidate for the delivery of transgenes 
to the nervous system.  HSV has been studied for use in a variety of neurological disorders 
including erectile dysfunction (159), chronic pain(103), diabetic neuropathy(359), and 
Parkinson’s disease(315).  The efficacy and duration of transgene expression needs to be further 
defined in these systems.  
In addition to use as a vector for vaccine development and gene therapy, HSV also has 
emerged as a promising vector for cancer therapy.  The use of a virus as an oncolytic vector 
requires that it be capable of destroying cancer cells while leaving normal cells intact.  The very 
first use of HSV based oncolytic vector was a conditionally replicating mutant deleted for tk 
(218, 246, 267), which allowed the virus to replicate in cancer cells, but not within neurons or 
other cells within the brain.  Deletions within the neurovirulence factor, γ34.5, in combination 
with alterations in glycoproteins or deletions of the ribonucleotide reductase, ICP6, have also 
been investigated as they maintain the intact tk gene, thus maintaining sensitivity to acyclovir.  
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HSV oncolytic vectors have been used in clinical trials to investigate their effects on 
glioblastoma, metastatic melanoma, oral squamous cell carcinoma, extracranial solid tumors, 
colorectal cancer, head and neck cancer, pancreatic cancer, and liver cancer (reviewed in 37, 
266).  Overall, many of these vectors are promising, showing minimal toxicity to normal cells 
and frequently extending the lives of patients.  Some vectors are currently in stage III clinical 
trials.  The overall efficacy, delivery, and targeting of oncolytic HSV vectors needs to be 
improved before widespread use as a therapeutic agent can occur.   
1.2 HSV LIFECYCLES 
HSV transmission occurs through the physical contact of epithelial cells, generally mucosal, with 
infectious virus.  Once the infectious virus has entered the host epithelial cell it undergoes a 
round of viral replication resulting in the death of the host epithelial cell and the production of 
progeny virions.  The progeny virions are then capable of infecting either nearby epithelial cells 
or the innervating peripheral neurons.  Infection of the peripheral neurons leads to the 
establishment of a latent infection within the neuron, characterized by the absence of viral 
protein production resulting from the repressed state of the viral genome that is maintained 
within the neuron as an episome for the lifetime of the host.  Upon certain assaults to the host 
immune system, the virus reactivates causing symptomatic disease at the site of initial infection.    
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1.2.1 The viral genome 
The viral genome encodes the viral genes necessary to mediate viral infection and replication.  
Therefore, a brief overview of the viral genome structure will be provided. The dsDNA genome 
is approximately 152 kb in length and is disproportionately G-C rich (219).  The genome 
encodes approximately 84 gene products and is composed of a unique long (UL) and a unique 
short (US) region flanked by a series of repeats (Figure 2).  The repeated regions on the UL 
region are termed ab and those on the US region are termed c.  The propensity for HSV to 
undergo homologous recombination and the presence of the repeats within the viral genome lead 
to four isomers of the viral genome dependent on the orientation of the UL and US regions (127).  
The presence of repeated regions provides for some genes to be present in two copies within the 
viral genome (168).  Many sequences within the repeated regions are integral to viral replication 
(168), including coding sequences for Infected Cell Polypeptdes (ICPs) 4, 0, γ34.5, and an origin 
of replication (OriS).   
 
Figure 2: Structure of the viral genome 
The genome contains a UL and US region of the genome that are flanked by inverted repeats.     
1.2.2 Lytic infection: Entry through Egress 
Infection of host epithelial cells with HSV involves both host cell receptors and viral 
glycoproteins found on the viral envelope (reviewed in 86).  The virus can enter cells through 
either a direct fusion mechanism or through endocytosis, which is sometimes pH dependent.  
UL USa  b b’  a’ c’ c  a
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Whether the virus enters through a fusion mechanism or through endocytosis appears to be 
highly cell type specific (64, 225, 241).  Viral entry is mediated by multiple viral glycoproteins 
embedded in the viral envelope, although 4 of them have been described as necessary and 
sufficient for viral entry: gB, gD, gH and gL (reviewed in 128).  gH and gL form a functional 
heterodimer that will be referred to as gH/gL from here on.  Viral entry begins by the binding of 
gB or gC to heparin sulfate on the cell surface.  It is believed that this binding promotes viral 
entry by tethering the virion to the cell surface.  Upon binding of gB to heparan sulfate, gD binds 
to one of three receptors, nectin-1 (179), herpesvirus entry mediator (HVEM) (230, 354), or 3-O-
sulfated heparan sulfate (329). Nectin-1 is the main receptor for cells that are generally infected 
by HSV including epithelial cells and neurons.  Current evidence suggests that nectin-1 is the 
primary receptor for entry in vivo, as in its absence viral infection of neurons is severely 
attenuated (235).  Upon binding of gD to one of its receptors, a conformational change occurs 
triggering the activation gB and gH/gL proteins and their receptors, leading to membrane fusion 
(86). 
Once the virus has fused with the cell a number of events occur.  Firstly, most of the 
tegument proteins are released into the cellular cytoplasm.  Notable tegument proteins include 
VP16 and virion host shutoff (VHS) (209).  VHS is an endoribonuclease that is responsible for 
the degradation of host cell mRNA, although it can also degrade viral mRNA (186).  VP16 is a 
potent viral transactivator that is carried into the cell in the tegument of the virus (38).  VP16, in 
combination with cellular factors HCF and Oct-1 transcribe the immediate early genes from the 
viral genome (178).  The de-enveloped nucleocapsid containing the viral DNA is transported to 
the nucleus in a microtubule dependent manner (305), and the viral DNA is injected into the 
nucleus of the host cell through the nuclear pore (12, 305).  It is in the nucleus that viral gene 
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transcription occurs in an ordered temporal cascade that is initiated by multiple viral and cellular 
factors.   
Viral transcription is a major focus of the work presented in this study, and as such will 
be discussed at length in a different section of this manuscript.  Of importance, RNA Polymerase 
II transcribes the viral genome (3) in an ordered fashion from the viral genome, which begins by 
the VP16 activated transcription of Immediate Early (IE) genes, followed by the ICP4 dependent 
activation of Early (E) genes, viral DNA replication, and ICP4 dependent activation of Late (L) 
genes (136).  Viral mRNA is capped and polyadenylated, however as most viral genes do not 
contain introns, most viral mRNA is not spliced.  The newly synthesized viral mRNA is exported 
from the nucleus with the aid of the IE protein ICP27 where it is translated by polysomes 
(reviewed in 286).   
Most of the E proteins are involved in DNA replication and nucleotide metabolism.  HSV 
encodes seven proteins essential for viral DNA synthesis.  These include UL9 (origin binding 
protein), ICP8 (ssDNA binding protein), UL30/UL42 (DNA polymerase), and UL5/UL8/UL52 
(helicase/primase) (346).  The viral genome contains three origins of replications, two within the 
repeated regions of the genome (OriS) and one within the UL region of the genome (OriL) (311, 
312, 352).  The exact function of the two different origins is currently not understood, although 
deletion studies indicate that OriL may play a significant role in vivo(9).  During DNA 
replication UL9 recognizes the origin (either OriS or OriL), and distorts the viral DNA(171).  
UL9 is necessary for early steps in DNA replication, but appears to be non-essential later in 
infection (23).  Upon UL9 binding, ICP8 also binds and augments the functions of UL9 in 
addition to distorting and destabilizing the viral DNA (24).  UL5/UL8/UL52 next binds, unwinds 
the DNA and adds a short RNA primer to initiate viral DNA replication (81, 377).  The 
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UL30/UL42 viral DNA polymerase is then capable of initiating viral DNA replication of both 
the leading and lagging strand (115).  Newly synthesized viral DNA is found as in a branched, 
head to tail concatamer in infected cells (146).  Currently, the favored hypothesis is that viral 
DNA replication occurs via a rolling circle mechanism; however, this has not been proven in 
infected cells.  A recombination dependent mechanism has also been suggested(145), which is 
similar to that of both T4 and λ phages (reviewed in 346).  
Once viral DNA has been synthesized, capsids are assembled and packaged with the viral 
DNA (reviewed in 59).  Capsids are composed of both major and minor capsid proteins.  Major 
capsid proteins include VP5, VP19C, VP23, and VP26 while minor capsid proteins include UL6, 
UL15, UL17, UL25, UL28, and UL33.  The minor capsid proteins are important for processing 
and packaging the viral DNA into pre-formed capsids and are present to different extents on 
different types of capsids.  Sucrose gradient fractionation from infected cell lysates reveals that 
there are three types of capsids that differ in density (113).  They have been named A, B, and C 
based on sedimentation densities, with A being the “lightest” and C being the “heaviest”.  C-
capsids are fully packaged, contain viral DNA, and are the type of capsid present in the 
infectious virion.  A-capsids do not contain viral DNA or the scaffolding protein.  It is thought 
that A-capsids result from abortive packaging.  Finally, B-capsids contain the scaffolding 
protein, but do not contain viral DNA (238).  It is thought that B-capsids arise from a structural 
alteration/angularization that prevents them from being packaged.  All three forms of capsids 
arise from an initial procapsid (25, 113, 134), which is the first closed capsid structure that can 
be visualized in infected cells and contains the major capsid proteins in addition to the scaffold 
protein.   
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Once the procapsid is formed, it is packaged with the viral DNA.  Packaging of the DNA 
occurs through a “ring-like portal” that is found at one unique vertex on the capsid (239, 240).  
There are seven proteins that are necessary for proper packaging of the viral genome.  These 
include the portal protein, UL6, the terminase complex of UL15, UL28, and UL33, UL25, which 
is important for retention of the viral DNA within the capsid, and UL17 and UL32 whose 
functions in capsid formation are currently unknown (59). The model for DNA packaging 
involves the UL end of the genome being inserted into the procapsid at the portal.  The terminase 
complex is necessary for the translocation of the viral DNA into the capsid and for cleavage of 
the concatameric viral DNA (14, 131).  A specific cleavage site has not been identified although 
it is contained in the a-sequence; it has been hypothesized that cleavage occurs when a “head 
full” of DNA is obtained, similar to phage (50).  
Once a packaged capsid has formed in the nucleoplasm of the cell, it must escape the 
nucleus and egress from the host cell.  Nuclear egress relies on the presence of a UL25/UL17 
complex on the capsid and two viral proteins involved in membrane budding, UL31 and UL34 
(8).  The UL25/UL17 complex is referred to as the C-Vertex Specific Complex (CVSC) (58, 
333).  It is thought that the CSCV helps ensure that C-capsids are preferentially enveloped.  It is 
hypothesized that the CVSC interacts with two viral proteins, UL31 and UL34, that are found in 
at the nuclear membrane, and that this interaction helps to direct budding (333).  UL31 and UL34 
also help to destabilize the nuclear envelope, which is believed to aid in nuclear egress.  During 
infection, the nuclear membrane becomes studded with a variety of proteins that are a part of the 
mature virion including VP16, VHS, VP22, US3, and a number of glycoproteins (8).  When the 
capsid buds through the nuclear membrane it acquires these proteins, which are associated with 
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the tegument.  Once through the nuclear membrane, the “perinuclear” virion travels through the 
trans-Golgi network, where it acquires its envelope and is exits the cell via exocytosis.   
1.2.3 Latency 
Subsequent to lytic infection, the newly synthesized viral progeny escape the host 
epithelial cells where they obtain access to the surrounding epithelial cells in addition to sensory 
neurons innervating the site of acute infection.  Newly synthesized viral progeny enter neuronal 
cells through pH-independent fusion events (265).  The viral capsid is then transported, in a 
retrograde fashion, to the nucleus of the neuron (reviewed in 62).  For transport to the neuronal 
cell body, HSV-1 relies on the cellular protein dynein (78).  Dynein is a molecular motor that 
physically moves along the microtubules contained in the axon of the neuron to transport 
vesicles, organelles, or in this case capsids, to the nucleus of neuronal cells (reviewed in 166).  It 
is hypothesized that multiple viral proteins associated with the inner tegument or the capsid 
itself, including VP26, UL25, and UL36 are involved in dynein mediated interactions (78, 80, 
330).  Upon entry into the nucleus of neurons, the viral genome associates with heterochromatin 
(71, 167, 237, 342) and remains within the neuron as an episome for the lifetime of the host.     
During latency the only gene products produced are referred to as the LATs (Latency 
Associated Transcripts) (310).  LAT is produced as a primary 8.3-8.5kb polyadenylated 
transcript, which is subjected to splicing to yield a stable 2kb intron.  The 2kb intron exists in a 
lariat structure, which stabilizes the transcript from degradation, thus allowing the RNA species 
to persist for days in infected cells (274, 323, 358).  The LAT transcript is expressed abundantly 
in the nucleus of some, but not all, infected sensory neurons, and is thought to play a large role in 
the determination of the neuronal cell population in which latency is established (17, 216).  
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Interestingly, no protein products have been detected from the LAT transcript, despite encoding 
multiple ORFs.  This leads researchers to believe that the effects of LAT are a direct 
consequence of a function of the DNA and RNA sequences as opposed to a protein product.  
Interestingly, while LAT expression is abundant in latently infected nuclei, lytic gene 
expression is severely inhibited.  In fact, it appears as though expression of LAT and lytic genes 
are mutually exclusive, suggesting a possible role for LAT in the repression of lytic transcription.   
To this end, LAT has been shown to increase the deposition of repressive heterochromatic marks 
while decreasing the deposition of transcriptionally permissive euchromatic marks on lytic genes 
such as ICP4, tk, ICP27, and ICP8 (342).  This may provide a potential mechanism for the 
repression of viral transcription and the establishment of latency.   
It has been recently established that HSV-1 encodes for 8 miRNAs that reside within the 
LAT transcript (61, 334, 335).  Interestingly, many of these miRNAs can be found within 
regions corresponding to ICP0, ICP4, and γ34.5, proteins associated with derepression of the 
genome, transcriptional activation, and neurovirulence, respectively (277, 334, 335).  
Mechanistically, these miRNAs may play a role in regulating, or preventing, viral gene 
expression during latency, by targeting the mRNA of two of the most potent transcriptional 
activators encoded by the viral genome.  While some in vitro data supports a model for the 
regulation of lytic gene expression via these miRNAs, to date there is no evidence that supports a 
role for these miRNAs in reactivation in vivo (234).   
While multiple studies have implicated LAT in repression of the viral genome, it does not 
appear to be necessary to establish latency.  Deletions within the LAT promoter (LAP), resulting 
in ablated expression of LAT, yield viruses that are capable of establishing latency, but are 
somewhat restricted in induced reactivation (130, 194). These data suggest that expression of 
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LAT, or a region within the LAP may be involved in activation of the viral genome.  However, 
this phenotype appears to be dependent on both the animal model and type of stress used to 
induce reactivation (72).  Interestingly, recent data has suggested that the 5’ exon region of LAT, 
which was deleted in the aforementioned studies, contains an enhancer element that acts as a 
binding site for both chromatin repressors and activators.  It has been shown that deletion of just 
this enhancer element, without affecting LAT production, also restricts induced reactivation (22, 
210), implicating the enhancer region, not LAT itself in reactivation. 
The current model for latency suggests that either activators or repressors bind to the 
enhancer region of LAT.  Whether an activator or repressor binds to this region may be 
determined by the phenotype of the neuron.  Supporting this notion is the fact that only 1/3 of 
infected neurons actually express detectable levels of LAT, suggesting that there are two 
transcriptionally different sets of neuronal cells; those that express LAT and those that do not.  It 
has been suggested that in the case of those that do express LAT, an activator binds the enhancer 
region.  To prevent expression of other lytic genes, the promoters of the nearby lytic genes 
(ICP0) are separated by a highly hetero-chromatinized CTCF insulating region (5).  This 
excessive amount of heterochromatin protects them from activation from the activators bound to 
the LAT enhancer (5, 180).  It is theorized that upon cellular stress, the heterochromatin in the 
CTCF region breaks down providing the activators bound to the LAT enhancer access to the 
ICP0 promoter.  ICP0 is known as a promiscuous transactivator, based on its ability to alter 
chromatin to a more derepressed state during reactivation (49, 99-101).  As such, ICP0 
expression would lead to derepression of the viral genome, thus allowing for transcription of 
multiple lytic genes, including ICP4, and reactivation to occur.  
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The current consensus in the field is that ICP0 is necessary to de-repress the viral genome 
to trigger reactivation.  However, it has been shown that while ICP0 is necessary for reactivation, 
is not necessary for initiating the exit from latency in vivo (326).  It is instead suggested that 
VP16, the transactivator of IE gene expression, plays this role.  Logistically, VP16 is carried into 
an epithelial cell within the tegument of the incoming virion to initiate the transcription of IE 
genes.  During latency, VP16, which is expressed with leaky late kinetics, would not initially be 
present, leading to questions regarding how the coordinated transcription of IE genes occurs.  
One current hypothesis for the exit from latency suggests that the VP16 promoter is expressed 
with alternative kinetics during latency, and that it is expressed prior to other lytic genes; thus, 
VP16 would coordinate the activation of a temporal cascade of transcription during the exit from 
latency (287, 325).  Additionally, it was shown through a variety of loss of function mutations 
and chemical inhibitors, that ICP0, ICP4, and viral DNA replication are not necessary for 
expression of VP16 in mouse ganglion and that VP16 was required for the activation of lytic 
gene expression (325).  The question remains though, of how VP16 is induced in latently 
infected neurons.  The authors suggest that there is a neuronal specific repressive factor (perhaps 
related to the LATs) that must be overcome for VP16 induction, and that VP16 must be 
produced to sufficient levels to induce IE gene expression.   
Interestingly, recent work from the Mohr, Chao, and Wilson labs has shown that 
reactivation from neuron cultures ex vivo is biphasic with an initial global expression of all 
classes of viral mRNAs, followed by a second phase corresponding to a temporal cascade of 
gene expression, much like what is seen in lytic infection (164).  The authors theorize that there 
is a decision period following the first phase of gene expression; either the genome can proceed 
to the second phase of gene expression, leading to reactivation, or the genome can become 
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repressed once again, presenting a potential molecular switch between latency and reactivation.  
The first phase of gene expression may correlate to global derepression of the chromatinized 
viral genome, perhaps as a function of expression of ICP0 (49, 99).  Depending on the neuronal 
and molecular environment, the second phase of gene expression and reactivation would occur.  
The authors suggest that the localization of the cellular factor HCF may have a pivotal role in 
this process.  Further studies investigating the epigenetics during each phase of gene expression 
during reactivation would provide clarity into the triggers allowing for progression from phase 
one to phase two.  
In the aforementioned studies, the Triezenberg and Sawtell groups suggest that VP16 is 
necessary for efficient lytic gene expression in the exit from latency while the Chao, Mohr, and 
Wilson group suggests that a general derepression of the heterochromatinized genome occurs 
prior to a lytic cascade of gene expression.  Of note, the coordinated second phase of gene 
expression required the presence and nuclear translocation of a functional VP16 (164).  These 
studies differ partly in the determination of gene expression.  The Triezenberg and Sawtell 
groups determined lytic gene expression based on protein abundance while the Chao, Mohr, and 
Wilson group use qPCR analyses to determine viral mRNA abundance.  Interestingly, in a 
previous study, the Sawtell group noted the presence of mRNA for many IE genes prior to 
reactivation stimuli in qPCR analyses, but did not note protein synthesis (326), suggesting, not 
only a moderately transcriptionally permissive state in their system, but also that viral mRNA 
processing and translation may play an integral role in reactivation.  Perhaps a global 
derepression of the genome occurs, leading to the transcription of many viral genes.  If sufficient 
viral mRNA export and translation occur yielding appreciable quantities of VP16, IE gene 
expression would be activated, leading to a further derepression of the viral genome by ICP0 and 
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the activation of E and L genes by ICP4.  It is also likely that the specific quantities of viral 
proteins produced as well as the availability and localization of certain cellular proteins, such as 
HCF, play an important role in determining whether a reactivation event occurs. 
Once the full exit from latency occurs, viral progeny are assembled and released.  The 
production of viral progeny within the neuron is slightly different than in a normal epithelial cell 
(see section on lytic phase).  In an epithelial cell, the capsid is packaged within the nucleus, 
travels through the nuclear membranes, obtains the tegument, and becomes enveloped as it 
traverses through the trans-Golgi apparatus (reviewed in 222).  The assembled virion is then 
transported along microtubules toward the periphery of the cell where they are released via 
exocytosis.  In contrast, in neuronal cells, the virus particles must travel in an anterograde 
fashion, down the lengthy axon to the tips, or growth cones, of the neuron.  Similar to retrograde 
transport, the newly released viral particles utilize a molecular motor, this time kinesin, to travel 
the distance of the axon.  It is believed that the mature virion does not fully assemble until it 
reaches the growth cones of the neuron.  In contrast to assembly in epithelial cells, the capsid 
acquires the tegument layers and travels separately from glycoprotein components of the 
envelope to the growth cones.  It isn’t until both components reach the growth cones that the 
capsid acquires the envelope and is released, likely via exocytosis (132, 189-191).  
1.3 CELLULAR TRANSCRIPTION 
HSV-1 transcription is a tightly regulated, efficient process that, because it utilizes many cellular 
proteins, has many aspects that are similar to cellular transcription.  However, the virus alters the 
cellular transcription machinery such that it has a higher affinity for viral activities compared to 
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cellular ones.  As such, a thorough understanding of cellular transcription is necessary to 
examine how viral infection exploits cellular mechanisms to transcribe the viral genome, leading 
ultimately to efficient replication of the virus concomitant with cellular death. 
1.3.1 Chromatin control of cellular gene expression 
Transcription is a highly dynamic, tightly regulated process.  The sheer size of the human 
genome requires it to be packaged and compressed into chromatin.  The core unit of chromatin is 
the nucleosome, which is made up of an octamer of histones: two H2A/H2B dimers and an 
H3/H4 tetramer (173, 355). Each nucleosome contains 147 base pairs of naked DNA wrapped 
around each histone octamer 1.65 times, thus leading to compaction of the DNA (213).  Many 
genes are only expressed upon intrinsic or extrinsic stimulation, and as such, the host cell must 
be capable of maintaining the human genome in a state such that it is compressed into chromatin 
but retain the ability to quickly and efficiently activate or repress some genes in response to 
certain stimuli.  In this respect, epigenetic modifications of the host genome, chromatin 
remodeling, and nucleosome spacing play a large role in the repression and activation of gene 
expression, and are generally thought of as one of the first levels of regulation related to gene 
expression.   
Activation and repression of transcription are intimately linked to the state of epigenetic 
modifications of the histones.  The histones within a nucleosome are structured such that a 
terminus of each histone is protruding from the nucleosome; this is referred to as the histone 
“tail”.  Each histone tail can undergo a variety of reversible post translational modifications 
including lysine acetylation, lysine and arginine methylation, serine phosphorylation, lysine 
ubiquitination, and multiple others (196).  These covalent modifications are carried out by a 
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variety of cellular enzymes; histones are methylated by methyltransferases (HMTs) and methyl 
groups are removed by demethylases, they are acetylated by histone acetyltransferases (HATs) 
and deacetylated via histone deacetylases (HDACs), and so on. These covalent modifications are 
then converted into a “histone code” with certain types of modifications and combinations 
therein, leading to activation or repression of the surrounding DNA (147).  The “histone code” is 
incredibly complex and not fully understood to date.   
The covalent modifications of histone tails, in addition to other factors, ultimately leads 
to either transcriptional permissiveness or repression.  Based on the histone tail modifications 
and the transcriptional state, chromatin can be classified into two general groups, euchromatin 
and heterochromatin (For a review see 39, 116).  The more compact form of chromatin, referred 
to as heterochromatin, is electron-dense when visualized under EM, and can be further divided 
into facultative and constitutive heterochromatin based on the reversibility of the histone tail 
modifications.  Constitutive heterochromatin is stable and is generally present at the centromere 
and telomeres of cellular chromosomes.  Constitutive heterochromatin is marked by tri-
methylation of H3K9, which is involved in recruiting repressive complexes such as 
heterochromatin protein 1 (HP1) (196).  HP1 binds to methylated H3K9 via its chromodomain, 
and recruits HMTs to methylate the adjacent histones.  It is in this manner that the constitutive 
heterochromatic mark can “spread” along the DNA.  Additionally, it is believed that HP1 acts as 
a scaffold for the recruitment and binding of other proteins that are involved in maintaining and 
spreading of heterochromatin.  Chromatin boundary elements encoded in the cellular DNA often 
prevent the spread of these heterochromatic marks (314).  While constitutive heterochromatin 
was originally believed to be irreversible, it has been shown that during cell division, constitutive 
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heterochromatic marks are lost as a result of a family of demethylases containing a JmjC domain 
(193, 353).   
Differing from constitutive heterochromatin, facultative heterochromatin can be readily 
reversed into euchromatin and is generally associated with tissue specific and developmental 
gene expression (For a review of facultative heterochromatin see 332).  Facultative 
heterochromatin is marked by hypoacetylation of histones and the tri-methylation of H3K27 by 
the polycomb repressive complex (PRC) 2.  Trimethylation of H3K27 is recognized by PRC1, 
which binds to the methylated histones via a chromodomain, and catalyzes the mono-
ubiquitination of H2AK119, halting RNA PolII mediated transcription (288).  Ubiquitination of 
H2AK119 also increases its affinity for the linker histone, H1, which results in increased 
compaction.  It is currently believed that non-coding RNAs may be involved in targeting the 
PRC to DNA to establish facultative heterochromatin.  Interestingly, H3K4me3 marks, which are 
generally associated with active euchromatin, have been found at sites associated with facultative 
heterochromatin; a “poised” RNA PolII has been found at these sites also.  The poised RNA 
PolII is phosphorylated on Ser5, but not Ser2, indicating that it is capable of initiating 
transcription, but not elongating.  It is postulated that the monoubiquitination of H2A, along with 
the physical presence of PRC1 prevents RNA PolII elongation, and that deubiquitination and 
demethylation, along with dissociation of the PRC and the addition of activating marks such as 
histone acetylation lead to activated transcription within these “bivalent” genes (288).   
The transcriptionally permissive state of chromatin is referred to a euchromatin and is 
characterized by the association of acetyl residues on H3K9 and H3K14 and methyl residues on 
H3K4 (39).  The addition of the acetyl group onto the positively charged lysine group results in 
the negation of the positive charge, which leads to weakened electrostatic interactions between 
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the lysine and the negatively charged DNA, and causes a more relaxed, or open, chromatin 
conformation.  Additionally, histone modifications, such as acetylation, can lead to recruitment 
of chromatin remodeling complexes, which as discussed below, alter nucleosome positioning to 
make DNA more accessible to DNA binding proteins such as transcriptional activators.  
Together, the modification patterns of histones provide a complex pattern of regulation by 
providing binding surfaces for a variety of different transcriptional complexes.   
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Figure 3.  Chromatin States.   
Nucleosomes consist of DNA wrapped around a histone core that is composed of two H2A/H2B 
dimers and an H3/H4 tetramer.  Histone tails can be modified via acetylation (Ac), methylation 
(Me), or ubiquitination (Ub).  The histone modification pattern is different for constitutive 
heterochromatin, facultative heterochromatin, and euchromatin.  A simplistic version of the 
different types of chromatin are displayed in this figure.   
Histone tail modifications, in combination with cellular transcription factors, help to 
direct chromatin remodeling complexes to activated genes (47, 321). There are four general 
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classes of chromatin remodeling complexes that use ATP hydrolysis to slide, move, or evict 
histones from the DNA making it accessible to transcriptional regulatory proteins.  The four 
classes of ATP dependent chromatin remodeling complexes include SWI/SNF, ISWI, 
Chromodomain (CHD), and Ino80, which differ in the architecture of the ATPase and in the 
composition of the non-catalytic subunits, leading to differing biological functions.  Chromatin 
remodeling complexes generally contain bromodomains, chromodomains, or PHD finger 
domains allowing for targeting to acetylated or methylated histones.  As discussed below, many 
promoters are free of nucleosomes, and as such chromatin-remodeling complexes likely play a 
role in exposing distal activator sites, increasing the size of nucleosome free regions, and 
ensuring proper elongation through chromatinized regions (47).   
 The physical localization of histones on the DNA template plays an important role in the 
determination of the transcription state of the genome.  With the advent of ChIP on ChIP and 
ChIP-seq technologies, the examination of histone modifications and their deposition along the 
entire genome has been possible.  Evidence from these studies revealed that there is a 
nucleosome free region (NFR) located near the transcription start site of most active genes.  
Additionally, there are specifically placed histones both upstream (-1) and downstream (+1) of 
the NFR, which may partially dictate the transcription start site (10, 369).  Generally, the 
nucleosomes surrounding the transcription start site contain covalent modifications or histone 
variants that are associated with activated transcription, and these modifications and variants 
decrease further from the transcription start site (149, 150, 199).  It has been shown that general 
transcription factors and RNA PolII are often bound within the NFR and likely act as the 
nucleation site for the transcription machinery.  Recently it has also been demonstrated that RNA 
PolII pausing near the transcription start site, prior to initiation, may play a significant role in 
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regulating the activation of transcription.  This pausing may direct ATP dependent chromatin-
remodeling complexes to evict or slide the +1 nucleosome allowing for proper initiation to occur 
(150, 281).  Together, histone post-translational modifications, the association of chromatin 
remodeling complexes, and nucleosome positioning provide a platform for the regulation of 
transcription within the host cell.   
1.3.2 Promoter elements 
Transcription initiation begins with cellular transcription machinery binding to promoter regions. 
In general, promoters can be categorized into two groups, focused and dispersed (reviewed in 
156).  Focused promoters contain well-defined core promoter elements for transcription factor 
binding at defined distances from the transcription start site.  Dispersed promoters contain 
multiple transcription start sites within approximately 50-100 bp of DNA, tend to lack many of 
the core promoter elements found in focused promoters, and are generally found within CpG 
islands.  Interestingly, focused promoters have been well defined in a variety of systems, 
however, only approximately 1/3 of mammalian promoters are classified as focused.  Focused 
promoters are more highly conserved amongst the evolutionary chain; all HSV promoters studied 
to date are focused.  However, the vast majority of mammalian promoters can be defined as 
dispersed and as such, have no definable promoter elements or transcription start site.  It has 
been postulated that nucleosome positioning, epigenetic marks, chromatin remodeling factors, 
and general transcription factors such as TFIIB and TFIIF play a substantial role in defining the 
transcription start site from dispersed promoters, whereas core promoter elements provide this 
function on focused promoters. 
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There are a variety of promoter elements (also called cis-regulatory elements) varying in 
sequence that promote the binding of specific transcription factors to focused promoters. While 
only ~10% of cellular promoters contain a TATA box, it remains the most widely studied 
promoter element.  The TATA box is located approximately 35 bp upstream of the transcription 
start site and has a general consensus sequence of TATAAA.  The transcription factor TBP binds 
to the TATA box and directs general transcription factors, including TBP associated factors 
(TAFs), and RNA PolII to the promoter region.  Another common promoter sequence is the 
Initiator (Inr) element which has a consensus sequence of YR in mammals and YYANWYY in 
humans, where Y=pyrimidine, R=purine, N=any nucleotide, and W=A or T.  The Inr is generally 
located at the transcription start site.  TAF1 and TAF2 of TFIID have been shown to bind 
cooperatively to the Inr to activate transcription (43).  Additional elements include the BRE 
(TFIIB Recognition Element), which as its name implies, is bound by TFIIB (187), the DPE 
(Downstream Promoter Element), which is recognized by TAF6 and TAF9 (33), the MTE (Motif 
10 Element), which are also recognized by TAF6 and TAF9 (322), and the DCE (Downstream 
Core Element), which is recognized by TAF1 (192).  Figure 4 displays many core promoter 
elements, their consensus sequences, localization relative the transcription start site, and cognate-
binding partners(324).  Many of the core promoter elements function together to activate 
transcription.  For example, both the DPE and the MTE function with Inr sequences to enhance 
the affinity of TFIID to promoter DNA (34, 203).  The exact positioning, function, and 
cooperativity between core promoter elements and chromatin modifications, and their effects on 
the activation of gene expression is still largely undefined and consequently, widely studied.  
Nonetheless, it is evident from multiple genetic experiments on focused promoters, that core 
promoter elements are vital to directing activated gene expression.  
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Core	  Promoter	  
Element	   Consensus	  Sequence	  (5'	  to	  3')	   Bound	  Protein	  
BRE	  u	   (G/C)(G/C)(G/A)CGCC	   TFIIB	  
TATA	   TATA(A/T)A(A/T)(A/G)	   TBP	  
BRE	  d	   (G/A)T(T/G/A)(T/G)(G/T)(T/G)(T/G)	   TFIIB	  
Inr	   PYPYAN(T/A)PYPY	   TAF1/TAF2	  
MTE	   C(G/C)A(A/G)C(G/C)(G/C)(G/C)AACG(G/C)	   na	  
DPE	   (A/G)G(A/T)CGTG	   TAF6/9	  
DCE	   CTTC;	  CTGT;	  AGC	   TAF1	  
 
Figure 4: Promoter elements, consensus sequences, and binding partners.  
This figure was adapted from (324).   
 
1.3.3 Pre-Initiation Complex Assembly 
 
Many of the core promoter elements in a focused promoter serve to promote the 
establishment of RNA PolII and associated general transcription factors on promoter sequences, 
which is referred to as pre-initiation complex (PIC) assembly.  The PIC is composed of TFIID, 
TFIIA, TFIIB, TFIIF, RNA PolII, TFIIE, and TFIIH.  The favored model for PIC assembly 
TAF1
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involves a stepwise assembly of general transcription factors and coactivators to a promoter.  
This stepwise model was established in vitro by performing native gel electrophoresis and 
DNAse footprinting assays using sequential additions of partially purified general transcription 
factors and RNA PolII (32).  These assays and others that followed, suggest that TFIID binds to 
the promoter first and is stabilized by the addition of TFIIA, then TFIIB. This drives RNA PolII 
and TFIIF to bind to the promoter, followed by TFIIE and TFIIH.  
PIC formation on promoters has been described as the initial step in transcriptional 
activation.  Binding of TFIID to promoter regions nucleates PIC formation.  TFIID is composed 
of TATA Binding Protein (TBP) and 12-14 TBP Associated Factors (TAFs) (104).  TBP binds 
specifically to TATA boxes in the minor groove of DNA, thus providing interaction with the 
promoter DNA. TAFs have many functions including stabilizing the structure of TFIID, 
interacting with other core promoter elements, and acetylating histones.  Activators, such as 
VP16 and Gal4 (and many others) interact with different surfaces of the TAF components of 
TFIID to direct it to the promoter regions.  Within the past 20 years it has been noted that 
complexes that contain many TAFs, but lack TBP exist within the nuclear environment.  These 
complexes are referred to as TBP Free TAF Containing complexes (TFTC) and the best 
characterized is the SAGA complex (2).  
The SAGA (Spt-Ada-Gcn5-Acetyltransferase) complex shares many features with 
TFIID, although it has different promoter specificity; some genes are TFIID dependent, while 
others are SAGA dependent (For review see 2, 18, 308).  SAGA is composed of multiple 
subunits including the kinase Tra1, the HAT Gcn5, and TAFs 5,6, 9, 10, and 12.  Of note, these 
TAFs are also considered part of the “core complex” of TFIID (356). Just like TFIID, SAGA 
contains features that allow for interaction with a variety of transcriptional activators, bind to 
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histones, and modify chromatin.  Interestingly, while SAGA does not contain TBP, different 
subunits of the SAGA complex are required for the recruitment of TBP at SAGA dependent 
promoters (229, 299).  SAGA can also enhance RNA PolII recruitment by interacting with GTFs 
such as TFIIA (347).  Interestingly, the Mediator and certain GTFs are required for recruiting the 
SAGA complex to SAGA dependent promoters.  Conversely, many GTFs and Mediator are 
dispensable for recruiting TFIID to promoter regions, but are required for activated transcription 
of TFIID dependent genes. Thus, there are apparent differences in the recruitment of certain 
GTFs in PIC formation on SAGA dependent versus TFIID dependent promoters.  While SAGA 
mediated activities are integral for proper cellular transcription, ICP4 mediated transcription 
from the HSV-1 genome occurs in a TFIID dependent manner, and as such, will be the focus of 
this discussion.   
After TFIID has been recruited to the promoter DNA, TFIIA and TFIIB act to stabilize 
TFIID on the promoter. Immunodepletion assays indicate that TFIIA is not necessary for PIC 
formation at all promoters, although the ability of TFIIA to interact with TBP, various other 
TAFs, activators, and coactivators suggest that TFIIA may be able to enhance TFIID binding at 
some promoters, and may increase the rate at which PIC formation occurs (157, 201, 247).  In 
the presence or absence of TFIIA, TFIIB binds to the promoter region next.  It is thought that 
TBP, TFIIB, and DNA form a stable tripartite complex that helps stabilize TFIID on the 
promoter DNA (243).  Additionally, TFIIB has been shown to form contacts with TFIIF(122) 
and RNA PolII (44, 122). 
Once TFIIB has entered the PIC, TFIIF and RNA PolII enter the complex based on 
affinities for TFIIB and each other (264, 306).  TFIIF is responsible not only for recruiting RNA 
PolII to promoters (106), but also for causing a structural change in the promoter DNA, thereby 
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increasing RNA PolII’s affinity for the promoter region (272).  TFIIF has many functions related 
to transcription initiation and elongation, including in transcription start site selection (112), 
promoter escape (367), and facilitating in RNA PolII elongation with TFIIS to decrease promoter 
proximal pausing (264, 374).  Additionally, TFIIF binding to the PIC is necessary for 
recruitment of TFIIE and TFIIH to form the fully functional PIC.   
TFIIF recruitment coincides with RNA PolII recruitment to promoter regions.  RNA 
PolII is the functional cellular DNA dependent RNA polymerase that transcribes mRNA.  RNA 
PolII consists of 12 highly conserved subunits, RPB1-12 (6).  RPBs 1 and 2 contain the majority 
of the enzymatic activity of RNA PolII as they are necessary for phosphodiester bond formation. 
RPB1 contains a motif referred to as the C-terminal Domain (CTD), which consists of a set 
number of heptapeptide (YSPTSPS) repeats.  The number of heptapeptide repeats is dependent 
on the complexity of the organism; humans have 52 (324).  The CTD of RNA PolII contains 
three serine residues, lending it susceptible to phosphorylation by a number of kinases.  
Generally speaking, serine 2 and serine 5 are heavily phosphorylated and are associated with 
recruiting 3’modifying enzymes and promoter clearance, respectively (172).  More recently, a 
role for phosphorylation of serine 7 in transcription of snRNA has been established (165).  A 
kinetic relationship between CTD phosphorylation and transcription elongation has also been 
established, in that serine 5 is heavily phosphorylated near the 5’ end of the gene whereas serine 
2 phosphorylation is more prominent near the 3’ end of the gene (31). Presumably, the complex 
phosphorylation patterns amongst three serine residues present 52 times on the CTD of RNA 
PolII leads to varying patterns of gene regulation that are in the process of being defined (84).   
Once RNA PolII and TFIIF have bound to promoter sequences, TFIIE is recruited.  
TFIIE recruitment to the promoter is stabilized by interactions with various other components of 
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the PIC, including TFIIB, TFIIF, and RNA PolII.  Additionally, TFIIE is required for TFIIH 
recruitment to the PIC (324).  TFIIE and TFIIH are both necessary for promoter melting, as 
evidence by the fact that they are both dispensable for transcription initiation from premelted 
templates (133, 248).  TFIIE is also capable of enhancing many of TFIIH’s enzymatic activities.   
TFIIH, like many of the GTFs, is composed of multiple subunits conferring many 
enzymatic functions including ATPase, helicase, and kinase activities (55, 57).  The ATPase and 
helicase functions of TFIIH are important for promoter melting (forming the “transcription 
bubble”), permitting catalysis of the first phosphodiester bond in the nascent RNA, and for 
promoter clearance.  The helicase functions are involved promoter clearance while the ATPase 
functions are involved in formation of the transcription bubble (85).  The kinase domain of 
TFIIH, also referred to the CAK, contains cyclin H and the cyclin dependent kinase 7 (CDK7), 
which is involved in phosphorylating serine 5 of the CTD of RNA PolII (211).  The Mediator 
complex enhances the catalytic activities of the CDK7 homologue in yeast.  Ser5 
phosphorylation is important for recruitment of the 5’ capping complexes and for promoter 
clearance (172).  Many studies have shown that a hypophosphorylated form of RNA PolII 
remains at the promoter region while a hyperphosphorylated form of RNA PolII can be found 
downstream of the promoter, suggesting that phosphorylation helps to drive promoter clearance.   
1.3.4 Activators and Coactivators 
Activated transcription relies not only on PIC formation on promoters, but also on 
activators and co-activators (40, 276).  Activators bind to specific DNA sequences, generally 
upstream, of the transcription start site, and make contacts with either co-activators or directly 
with components of the PIC.  The general function of activators is to increase transcription rates.  
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This is performed via a variety of functions including stabilizing PICs, increasing the affinity of 
the PIC to promoter DNA, or enhancing the kinetics of re-initiation and promoter clearance.  
Additionally, under certain conditions, activators can also act as repressors, thus increasing the 
complexity of gene regulation.  There are a wide variety of transcriptional activators that are 
activated in response to a plethora of external or internal stimuli, and as such offer a means to 
quickly activate, or repress gene expression under specific conditions (40).  The sheer number of 
activators and the varying mechanisms used to enhance, or repress, transcription under various 
physiological conditions prevents a comprehensive overview of activator function within this 
manuscript.  
Activators often function in the presence of a co-activator.  Co-activators generally act as 
a bridge between the PIC and the activator.  Just as with activators, wide arrays of co-activators 
are utilized to activate transcription (123).  Some of the more widely studied co-activators 
include p300, CBP, SWI/SNF, SAGA, and Mediator.  Co-activators usually contain a diverse 
array of proteins with varying enzymatic functions; this provides for many co-activators to be 
involved in multiple steps beyond transcription initiation.  While the importance of these co-
activators has been demonstrated in a variety of systems under varying conditions, based on the 
focus of the research presented herein, only the Mediator complex will be discussed.  
The Mediator complex is a multi-protein complex comprised of four general regions or 
modules, the head, middle, tail, and a dissociable kinase domain.  There are approximately 30 
proteins that make up the Mediator complex, which allows for interactions with a vast number of 
activators, some of which are highlighted in Figure 5 (174, 214).  The majority of activators 
function through the tail module, although interactions with the head and middle region are not 
uncommon. The ability of Mediator to interact with a wide array of activators is suggestive of 
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the broad range of genes whose activation are mediator dependent.  The importance of the 
mediator complex in development and transcription is highlighted by it’s necessity for yeast 
viability (236).  Additionally, the protein complexity of Mediator provides for functionality at a 
variety of levels in transcription including chromatin remodeling, PIC formation, promoter 
clearance, and the transition between productive initiation and elongation; many of these 
functions are interdependent on similar factors, varying activators, and each other (214). 
 
Figure 5:  Mediator Complex.   
A representative structure of the mediator complex displays the four modules that compose the 
complex.  This figure was adapted from (214).  
 
1.3.5 Elongation and Termination 
Once functional pre-initiation complexes have assembled on activated promoters and the 
initial phosphodiester bonds have been formed, RNA Pol II disassociates from the majority of 
the initiation machinery and travels along the DNA, elongating the nascent transcript.  A number 
 35 
of molecular events occur that drive the dissociation of RNA PolII and productive elongation.  
The kinase domain of TFIIH phosphorylates the serine 5 residue of the CTD of RNA PolII, 
which leads to the recruitment of elongation and processing factors, such as the 5’ capping 
enzyme (172).  The additional phosphorylation of TFIIB by TFIIH, also likely plays a role in 
promoter escape (343). DSIF (DRB Sensitivity Inducing Factor) and NELF (Negative 
Elongation Factor) play a significant role in promoter proximal pausing.  It has been 
demonstrated that in drosophila, DSIF interacts directly with nascent RNA to prevent elongation 
(227).  Phosphorylation of DSIF, NELF, and Ser2 of the RNA PolII CTD by CDK9 of pTEFb 
(positive transcription elongation factor B), causes the dissociation and alleviation of the 
repressive effects (206, 338, 365).  Once promoter clearance has occurred, elongation factors 
such as TFIIS, elongin, the super elongation complex (SEC), and TFIIF increase the processivity 
of RNA PolII by preventing its dissociation from both the DNA template and nascent RNA 
(268).  Additional chromatin remodeling factors also travel with the elongating RNA PolII, 
functioning to evict or move nucleosomes in the path of the elongating complex (15).  It should 
be noted that during elongation, splicing complexes are associated with the nascent RNA and 
promote the specific removal of introns from the transcribing RNA.  As most HSV genes are 
intronless, the mechanisms of spliceosome assembly, RNA recognition, cleavage, and ligation 
will not be reviewed.  For a recent review please refer to (154) and references therein. 
Once the elongation complex reaches the poly-A signal (AAUAAA), the newly 
synthesized transcript is cleaved and exported from the nucleus.  Just as RNA PolII 
phosphorylation of serine 5 leads to the recruitment of capping enzymes, phosphorylation of the 
serine 2 residue leads to the recruitment of the cleavage and polyadenylation specificity factors 
(CPSF), the cleavage stimulatory factor (CstF), and the associated poly-A polymerase (1).  The 
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recruitment of these complexes to elongating RNA PolII causes RNA PolII pausing and an 
endonucleolytic cleavage of the nascent RNA (79).  The capped, spliced, and polyadenylated 
mRNA is then transported through the nuclear pore complex to the ribosomes where translation 
occurs.  At the basic level, export through the nuclear pore is dependent on the TREX 
complexes, the RNA adaptor protein Aly/Ref, and the mRNA export receptor Tap-p15, in 
addition to the nuclear pore complex itself (158).  Nuclear export and transcription are coupled 
through a variety factors that interact with both the nuclear export machinery and chromatin 
remodeling, initiation, or elongation factors.   
As mentioned previously, it is believed that much of the initiation machinery, including 
TFIID, TFIIB, TFIIA, TFIIH, and Mediator remain at the activated promoter, thus allowing for 
efficient reinitiation of transcription (370).  It has been demonstrated that the CPSFs and CstF 
can interact with TFIIB causing the promoter and terminator regions of the gene to be in close 
proximity, a phenomena referred to as gene looping.  Gene looping functions to enhance the 
reinitiation kinetics of RNA PolII, thus increasing overall transcription rates (301).  Additionally, 
gene loops have been found at or near nuclear pore complexes, thus also coupling efficient 
mRNA export to transcription (320).  Figure 6 is a representative model of gene looping and 
depicts the reinitiation scaffold interacting with components of the termination machinery.   
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Figure 6: Gene Looping.   
During activated transcription a reinitiation scaffold remains at the promoter after RNA PolII has 
“escaped” the promoter.  The reinitiation scaffold can act as a “bookmark” for recycling of RNA 
PolII.  Additionally, components of the reinitiation scaffold interact with components of the 
termination machinery such as the CPSF and CtsF.  This forms the “gene loop” which puts the 
promoter region in close physical proximity to the terminator region of the gene, enhancing 
reinitiation kinetics.  Figure adapted from (292). 
 
1.4 VIRAL TRANSCRIPTION 
Viral gene expression has many of the same characteristics and mechanisms of cellular 
transcription including chromatin remodeling, PIC formation, initiation, elongation and export.  
However, there are many notable differences, which will be discussed.  Additionally, the viral 
genome is transcribed in a temporally ordered fashion.  The molecular mechanisms underlying 
viral transcription and its kinetics will be reviewed.  
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1.4.1 Chromatin states of the viral genome 
Prior to the activation of cellular gene expression, the cellular chromatin must be remodeled such 
that the DNA is accessible to the cellular transcriptional activators and RNA PolII.  Similarly, 
activation of viral transcription also requires remodeling of the chromatinized viral genome to a 
more permissive state.  The chromatin state of the viral genome is largely responsible for the 
ability of the virus to remain latent; the condensation of the majority of the viral genome into 
heterochromatin prevents the transcription of viral lytic genes.  Reactivation requires a drastic 
remodeling of chromatin to allow a more permissive state and viral transcription to ensue.  
Chromatin remodeling also appears to have a role in lytic infection of epithelial cells as well.  
Because the chromatin state of the genome directly influences the activation of transcriptional 
processes, the differences between the chromatin states of the viral genome during lytic and 
latent infection will be discussed. 
During lytic infection, viral DNA, much like cellular DNA is associated with histones in 
infected cells.  Evidence has shown that histones are absent from the encapsidated viral DNA 
within the virion, indicating that histones are derived directly from the host cell upon entry into 
the nucleus (209, 245). However, unlike cellular DNA, viral DNA is not associated in a normal 
nucleosomal structure during lytic infection.  Initial studies using micrococcal nuclease digestion 
on DNA isolated from HSV-1 infected cells demonstrated that the viral DNA did not form a 
laddered pattern, as cellular DNA did, thus suggesting that a regular distribution of nucleosomes 
did not exist (161, 195, 232).  ChIP studies have shown that incoming viral DNA associates with 
histone H3 quickly (within an hour), but that levels of H3 association decline between 3-6hpi, 
coincident with, but independent of viral DNA replication (49, 245).   Additionally, H3 can be 
found at each temporal class of promoters (49, 245) and lytic promoters are associated with 
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euchromatic marks, such as methylation of H3K4, and acetylation of H3K9 and H3K14 (129, 
139, 161).  The relevance of histone deposition on the viral genome during lytic infection is not 
fully understood, however, treatment of cells with MTA, a general methyltransferase inhibitor, 
resulted in a decrease in viral transcription and replication, indicating histone methylation may 
play an important role in the viral lifecycle (139).   
The initial deposition of histones on the viral genome may be a cellular defense against 
infection.  However, as evidenced by the reduction in H3 present on viral genomes later in 
infection, the virus has likely developed methods to counteract this cellular defense (49, 245).  
VP16 expression has been shown to reduce the amount of histone H3 deposition on IE promoters 
to promote IE gene expression.  It was demonstrated that the acidic domain of VP16 was 
responsible for the recruitment of multiple activators and co-activators to IE promoters, 
including the CBP and p300 histone acetyltransferases and the Brg1 and Brm1 components of 
the SWI/SNF complex (129, 175).  However, none of these components were found to be 
necessary for viral IE gene expression (184).  Interestingly, work from the Knipe lab has shown 
that another chromatin remodeling factor, Snf2 of ISWI, is present on IE promoters and it affects 
ICP0 gene expression (30).  The dependence of ICP0, but not ICP4 or ICP27, expression on Snf2 
suggests that different promoters may rely on different chromatin remodeling factors, perhaps 
based partially on the post-translational modifications of histone tails, and the cellular and viral 
proteins capable of binding each specific promoter (30).  While specific mechanisms for 
chromatin remodeling on IE promoters have not been established, it is likely that RNA PolII 
relies on chromatin remodeling factors to translocate along the viral DNA. 
The majority of recent research pertaining to chromatin remodeling during lytic infection 
has involved describing the mechanisms for nucleosome remodeling on IE promoters, with 
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significantly less attention to remodeling on E and L promoters.  The Knipe lab has shown that in 
the absence of the IE protein, ICP0, there is an increase in H3 deposition on E promoters, and a 
decrease in the proportion that is acetylated (active), implicating ICP0 in this process (49).  ICP0 
cannot directly bind to DNA, therefore, it is likely that ICP0 acts as a global de-repressor by 
altering the functions of histone deacetylase complexes, and as a consequence, promoting the 
acetylation of histones on genomes (53, 100, 258).  Acetylation can lead to binding of 
bromodomain containing proteins such as components of the SWI/SNF complex, perhaps 
suggesting a basic mechanism for chromatin remodeling on E and L promoters.  However, 
evidence proving the presence of chromatin remodeling complexes at E or L promoters does not 
currently exist.  Interestingly, the same study implicating ICP0 in increasing the acetylation of 
H3K9 on E promoters also demonstrated a moderate increase in H3 deposition on the viral 
genome in the absence of functional ICP4, although it was not statistically significant (49).  
Perhaps a combinatorial effect between ICP0, ICP4, and VP16 (all tegument proteins), leads to 
the activation and promoter-dependent recruitment of chromatin remodeling complexes to viral 
promoters.     
Unlike during lytic infection, during latent infection the HSV-1 genome is associated 
with nucleosomes in an ordered distribution (71).  Both euchromatic and heterochromatic 
epigenetic marks are associated with the viral genome during latency.  Euchromatic marks such 
as acetyl- H3K9 and H3K14 as well as methyl-H3K4 are enriched in the LAT region of the 
genome, perhaps partially accounting for LAT production during latency (180, 181, 237).  
Heterochromatic marks are also found on the LAT promoter, perhaps resulting in the differential 
expression of LAT.  Constitutive heterochromatic marks such as H3K9me3 and facultative 
heterochromatic marks such as H3K27me3 are found on lytic promoters on the viral genome (48, 
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185).  None of these marks appear to be focused on a specific gene class; it is postulated that the 
distribution of epigenetic marks on latent genomes is highly cell specific within the neuronal 
population.  Thus, some cells would have genomes associated with facultative heterochromatin 
while others with constitutive heterochromatin (21).  
Reactivation of the viral genome requires the reversal of heterochromatic marks to 
euchromatic marks. Upon reactivation, the acetyl- H3K9 and H3K14 euchromatic marks 
associated with the LAT promoter become deacetylated and lytic promoters become associated 
with acetylated histones (4).  Histone acetylation appears to play a major role in governing 
reactivation as treatment of latently infected cells with HDAC inhibitors results in acetylation of 
histones and increased viral gene expression (237).  It is likely that some of the same 
mechanisms governing chromatin-remodeling mechanisms during lytic infection directly apply 
to the mechanisms of chromatin remodeling during latent infection.   
Our lab has developed a model of quiescence in which a quiescent state, mimicking the 
latent state in vivo, is established with infection of an IE null virus (282).  Our lab has shown that 
expression of ICP0 contributes to a hyperacetylated chromatin state, and not only helps to 
prevent deposition of the repressive marks H3K9me3 and HP1γ, but also promotes their removal 
(99, 100).  The activities of ICP0 in chromatin remodeling stem not only from its enzymatic 
function as an E3 ubiquitin ligase, but also from its ability to interact with and disrupt the 
HDAC1/HDAC2/Rest/CoRest/LSD1 complex (91, 100, 101, 121).  Interestingly, ICP0 does not 
appear to be absolutely necessary for reactivation (262).  This suggests that alternative 
mechanisms to regulate chromatin-remodeling functions during reactivation exist.  It has also 
been suggested that VP16 is the only protein necessary for coordinated exit from latency (287, 
325), implicating VP16 contributes to chromatin remodeling during reactivation.  It is likely that 
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ICP0’s functions may be necessary for derepression of constitutive heterochromatin, whereas, 
perhaps other viral factors, such as VP16 or ICP4, could play a role in derepression from 
facultative heterochromatic states (124).  Studies investigating the chromatin states of distinct 
pools of cells based on permissivity (LAT expression) with respect to the activities of ICP0, 
ICP4, and VP16 would shed valuable light onto mechanisms of chromatin remodeling during the 
exit from latency. 
1.4.2 General mechanisms of viral transcription 
Viral transcription is necessary for lytic replication and reactivation from the latent phase of the 
viral lifecycle.  Viral transcription occurs in much the same way as cellular transcription; 
however, there are many notable differences.  These differences enable the virus to overcome 
host defenses and to alter cellular transcriptional activities to promote viral transcription over 
cellular. Transcriptional mechanisms utilized during lytic replication and during the reactivation 
from latency are likely similar, with differences potentially arising from differing chromatin 
states of the genome and cell type specific factors.  The chromatin state of the viral genome 
during lytic and latent infection has been addressed and thus, general mechanisms of viral gene 
expression and the temporal regulation of kinetic expression will be discussed.   
The activation of viral gene expression relies on the architecture of the viral promoter.  
As mentioned previously, there are two general classes of promoters, focused and dispersed.  
While the majority (~70%) of cellular promoters fall into the dispersed category, all HSV 
promoters studied to date fall into the focused category.  Additionally, while only approximately 
1/3 of focused cellular promoters contain TATA boxes (~10% of total cellular promoters), all 
HSV-1 promoters contain TATA boxes.  Additionally, HSV-1 promoters contain multiple cis-
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regulatory sites for recognition by a variety of both cellular and viral factors.  Cis-regulatory sites 
may help define the level and temporal kinetics of gene transcription. 
Much like cellular genes, viral genes are transcribed by cellular RNA PolII (3), and as 
such use many of the same cellular transcription factors as cellular promoters.  Studies have 
implicated the general transcription factors TFIID and TFIIA, as well as the activator, Sp1, and 
the coactivator, Mediator, in the formation of transcription complexes on viral promoters (162, 
198, 284, 372, 373).  The current understanding is that pre-initiation complex formation on viral 
promoters is activated by the viral factors VP16 and ICP4, leading to the recruitment of cellular 
RNA PolII to viral promoters in vivo (117, 331).  The precise composition of the viral pre-
initiation complexes has not been determined, although as mentioned, it is believed to contain 
many of the same components as cellular complexes (372).   
Once complete preinitiation complexes have formed on the promoters, RNA PolII 
promoter release, elongation, termination, and mRNA processing and export must occur.  To 
date, studies investigating HSV-1 mediated RNA PolII promoter release and transcription 
elongation have focused primarily on the phosphorylation states of the CTD of RNA PolII.  It 
has been shown that RNA PolII is alternatively phosphorylated during HSV-1 infection, with a 
loss of phosphorylation on Ser2 (108, 270) and that this leads to reduced transcription of cellular 
genes (309).  The formation of an alternatively phosphorylated form of RNA PolII is dependent 
on mechanisms mediated by the viral IE proteins ICP22 and ICP27 and the viral kinase UL13 
(63, 108, 208).  As mentioned previously, phosphorylated forms of the CTD of RNA PolII act as 
docking sites for chromatin remodeling complexes and mRNA processing factors.  It is generally 
understood that Ser5 phosphorylation is important for promoter clearance while phosphorylation 
of Ser2 is important for proper elongation and the recruitment of specific polyadenylation and 
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cleavage factors (1, 172).  Recall that during cellular transcription Ser2 phosphorylation 
generally occurs via cdk9 of pTEFb; it is speculated that because Ser2 phosphorylation is absent 
on RNA PolII in infected cells, pTEFb may not be involved in viral transcription, although 
contradictory evidence does exist (82, 269).   
The loss of Ser2 phosphorylation would, in theory, increase RNA PolII pausing, and 
prevent efficient elongation; however, the virus has evolved mechanisms to promote efficient 
elongation.  First, as mentioned previously, the viral genome is not associated with normally 
distributed histones or nucleosomes; the reduced level of histones may reduce the amount of 
RNA PolII pausing.  Second, the viral genome is essentially intronless, making the transcribed 
region shorter, which may also reduce the amount of RNA PolII pausing (269).  Third, it has 
been suggested that stalled RNA PolII, which is often present in highly transcribed regions, is 
specifically removed and degraded in a proteasome dependent manner, and that this effect is 
mediated by the phosphorylation status of the CTD of RNA PolII (63, 200).  Specific elongation 
factors such as the SEC, Elongin SIII complex, TFIIF, or TFIIS have not been specifically 
implicated in promoting viral mRNA elongation.   
The loss of Ser2 phosphorylation of RNA PolII also raises questions about the 
mechanism of recruitment of 3’mRNA processing factors.  UV crosslinking studies have shown 
that components of the polyadenylation machinery, including the CstF, are present at the 3’ end 
of viral mRNA transcripts (220), indicating that normal polyadenylation processes can occur in 
the absence of Ser2 phosphorylation.  Interestingly, ICP27 was also implicated in the 
enhancement of polyadenylation at L, but not E genes, implying that there may be differences in 
the mechanisms by which polyadenylation machinery is recruited to viral templates (220).  The 
mechanisms of recruitment of polyadenylation and cleavage factors have not yet been 
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investigated, although, with the lack of Ser2 phosphorylation on the CTD of RNA PolII, it is 
clear that HSV-1 utilizes alternative mechanisms.     
As mentioned previously, viral genes are generally intronless, and therefore do not 
require splicing.  Interestingly, however, to enhance viral transcription processes, mechanisms to 
inhibit cellular splicing exist.  The IE protein, ICP27 is involved in promoting the aberrant 
phosphorylation of some SR proteins involved in spliceosome assembly.  This aberrant 
phosphorylation pattern results in incomplete spliceosome assembly, and thus prevents the 
splicing of cellular transcripts (29, 290).  Because splicing is intimately linked to mRNA export, 
the inhibition of cellular splicing in HSV-1 infected cells likely promotes the export of viral 
mRNA over cellular.  Additionally, because viral mRNAs are mostly unspliced, and the splicing 
and export machinery are linked, viral mRNAs are not recognized by the nuclear export 
machinery in the same manner as spliced cellular mRNA.  Instead, ICP27 interacts directly with 
the viral mRNA, the TAP-p15 complex and the cellular export factor Aly/REF to mediate viral 
mRNA export.  If any of these interactions are abrogated, viral mRNA export does not occur (45, 
46, 151, 152). 
1.4.3 Regulation of the temporal kinetics of gene expression  
A series of elegant studies performed in the mid to late 1970’s demonstrated that, upon infection, 
the viral genome was transcribed in a temporal cascade with three distinct phases of gene 
expression, termed alpha, beta, and gamma, which are now referred to as immediate early (IE), 
early (E), and late (L) (135, 136, 316).  IE proteins are most abundantly expressed 2-4 hpi, E 
proteins between 4-7 hpi, and L proteins after 7 hpi (136).  IE gene expression occurs de novo 
viral protein synthesis as a consequence of a virion component, VP16, which enters the cell in 
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the tegument of the virus and translocates to the nucleus to activate IE gene expression (13, 38, 
136).  The expression of IE genes was found to be necessary for E and L gene synthesis, as 
evidenced by both the absence of E protein expression immediately after removal of protease 
inhibitor treatment at the onset of infection, and the existence of temperature sensitive mutants 
that were defective in E and L gene expression at the non-permissive temperature (77, 136, 251, 
260, 261, 350).  Many of these ts mutants have been linked to mutations within the IE 
transcriptional activator, ICP4 (16, 77, 261).  Late gene expression has the additional 
requirement of viral DNA replication, although a subset of L genes that are minimally expressed 
in the absence of vDNA replication exist; these are referred to as γ1 or “leaky late” genes.   
Interestingly, concomitant with E gene expression, IE gene expression is reduced, and likewise, 
upon viral DNA replication, E gene expression is reduced (Figure 7).  It has been established that 
the majority of IE genes are regulatory proteins, while E genes are associated with processes 
related to nucleotide metabolism and DNA replication, and L genes are primarily structural 
components of the virion (Reviewed in 277).  The specific mechanisms that dictate the 
transitions between IE, E, and L gene expression remain elusive, although the chromatin state, 
viral promoter architectures, and the nuclear milieu of cellular and viral proteins likely play a 
substantial role.  
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Figure 7:  Temporal expression of viral genes.   
Viral genes are categorized into three groups based on their requirements for expression.  This 
graph represents the expression of viral genes in a time dependent fashion with the relative 
abundance of expression on the Y-axis and the hours post infection on the X-axis.   This figure 
was adapted from (371). 
 
Generally HSV-1 promoters corresponding to the different temporal classes (IE, E, L) are 
distinguishable by the complexity of activator binding sites present within the promoter 
(reviewed in 277).  In other words, IE promoters are more complex with a higher degree of 
regulatory elements than E promoters.  Likewise, E promoters are more complex than L 
promoters (Figure 8).  Regulation of viral transcription arises in part from differences in 
promoter architecture, and the cellular factors that recognize them.  
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Figure 8:  Promoter Architectures. 
Representation of promoter architecture from each kinetic class of viral gene.  Figure was 
adapted from (371). 
 
IE promoters contain a binding site, with a consensus sequence of TAATGARAT, which 
is recognized by the IE transcriptional activator VP16.  VP16 is trafficked into the cell in the 
tegument of the virion.  Once in the cytoplasm it interacts with host cell factor (HCF), which 
promotes the translocation of both factors into the nucleus.  In the nucleus, VP16 and HCF form 
complexes on IE promoters with the octamer binding protein 1 (Oct-1) to promote the 
transcription of IE genes de novo viral protein synthesis (Reviewed in 360).    VP16 induces the 
formation of preinitiation complexes on viral DNA through interactions with multiple 
components of the cellular transcription machinery including TFIID, TFIIB, TFIIA, and the 
Mediator complex, thereby enhancing RNA PolII recruitment to IE promoters (143, 170, 204, 
205, 228, 313). Additionally, VP16 mediated transcription of IE genes appears to depend on the 
stabilization of the VP16-Oct1-HCF complex through components of the nuclear lamina (300).  
In addition to VP16 mediated activation through interaction with the TAATGARAT motif, other 
cis-regulatory elements are present in IE promoters, including GC boxes and CCAAT binding 
sites, which specify for binding of Sp1 and NF1 respectively.  Additional binding of these 
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activators likely increases the affinity and efficiency of RNA PolII binding to the promoter, thus 
promoting quick and efficient activation of IE genes.  
Concomitant with E gene activation, IE gene expression is repressed, largely through the 
influence of the IE transcriptional activator, ICP4.  ICP4 has been shown to bind to a strong site 
within its own promoter, and through the formation of a tripartite complex with TFIIB and TBP, 
prevents the activation of transcription (119, 120).  This mechanism, however, appears to be 
specific for repression of ICP4 as it is dependent on a properly positioned ICP4 binding site and 
other IE promoters do not contain them (182).  Interestingly though, in the absence of ICP4 all 
IE proteins are overexpressed, indicating alternative mechanisms for ICP4 induced repression 
exist.   
Early promoters do not contain a TAATGARAT element, making them non-responsive 
to VP16.  Instead, E genes are activated by the IE protein ICP4.  ICP4 E promoter occupancy is 
not specifically dictated by the DNA sequence in the promoter, instead ICP4 may bind to DNA 
in a “less discriminant, possibly non-specific” manner (66), which will be further discussed.  
ICP4 functions as an activator of viral gene expression by stabilizing TFIID onto viral promoters 
(117).  Additionally, ICP4 has been shown to form complexes with both TFIID and Mediator in 
infected cells (198), thus reinforcing ICP4 function as an activator of E, and L gene expression.  
In the absence of ICP4, E genes are not expressed, which is likely a result of inefficient 
recruitment of TFIID and RNA PolII to the viral promoters (284).  This underscores the 
importance of ICP4 in preinitiation complex formation and viral gene expression.  In addition to 
ICP4, E promoters contain binding sites for cellular activators including Sp1 and NF1 (87, 155).  
It is likely that Sp1, NF1, and ICP4 act together to activate E gene expression. 
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Just like IE genes, E genes are repressed after their initial expression.  A current 
mechanism for the attenuation of E gene transcription does not exist, although it is likely 
dependent on viral DNA replication and alterations in cellular factors throughout infection.  It is 
possible that nucleosome positioning on viral DNA is different early versus late in infection and 
that this could make E promoters less accessible to transcription factors.  Another potential 
mechanism could arise from the alteration in quantity or modifications of the transcription 
factors required for E gene expression.  It has been shown that the cellular transcription factor 
Sp1 becomes phosphorylated at between 4-6hpi and the phosphorylated form does not activate 
transcription as well in vitro (162).  The DNA damage response protein, ATM, phosphorylates 
Sp1 during HSV-1 infection, potentially linking the Sp1 phosphorylation event to viral DNA 
replication, a prerequisite for L gene expression and E gene repression (144).  Another potential 
mechanism for E gene repression is based on evidence from our lab that indicates TFIIA is 
strictly required for E gene activation, but is dispensible for L gene expression (372).  Additional 
work suggests that TFIIA may be depleted in cells late in infection, which may lead to reduced 
availability of TFIIA to bind to E promoters, resulting in a decrease in E gene transcription(371).   
The activation of L gene expression also relies heavily on cellular and viral activators.  L 
genes can be divided into two sub-classes based on their requirement for DNA replication; γ1, or 
leaky late, genes are minimally expressed prior to viral DNA replication, and maximally 
expressed after, whereas the expression of γ2, or true late, genes has a strict requirement for 
DNA replication. Consistent with E gene expression, L gene expression relies on the viral 
activator ICP4.  ICP4 mediated expression of L genes relies on the presence of a TATA box, 
which specifies for TBP binding and the Inr, which specifies for TAF1/2 binding.  Our lab has 
reported that the Inr sequence is necessary for ICP4 activated expression of the true late gene gC 
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(118, 163).  This is likely the result of the ability of ICP4 to function in place of TFIIA to 
stabilize PIC formation in an Inr dependent manner late in infection (373).  While leaky late 
promoters do contain binding sites for cis-regulatory elements, such as Sp1, these seem to be 
dispensable for activation (138, 202).  Instead, properly position TATA boxes and Inr elements 
appear to regulate L gene activation.    The absence of physiologically relevant cis-regulatory 
elements in L promoters provides a distinction between the potential mechanisms of activation 
between E and L genes.  
1.5 ICP4, THE MASTER TRANSCRIPTIONAL REGULATOR 
ICP4 is the major transcriptional regulatory protein encoded for by HSV-1.  There are two ICP4 
loci because of its location within the Rs region of the genome.  The presence of two ICP4 loci 
within the genome underscores its importance in the viral lifecycle.  In the absence of ICP4, IE 
proteins are over produced, E and L genes are not transcribed, DNA replication does not occur, 
and as a consequence, new viral progeny are not formed.  Many of the functional abilities of 
ICP4 arise from its biochemical and structural properties. 
1.5.1 Biochemical and structural properties 
ICP4 is 1294 amino acids and has a predicted molecular weight of approximately 
133kDa.  Extensive modifications of the protein, such as phosphorylation, adenylation, 
guanylation, and ADP-ribosylation also occur, contributing to an apparent molecular weight of 
approximately 175kDa, although in solution it exists as a 350kDa dimer (19, 20, 60, 95, 223, 
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263, 361).  While ICP4 is extensively modified, only the phosphorylation of ICP4 has been 
shown to alter its activity by affecting the DNA binding properties of the molecule (224, 250).  
ICP4 has an elongated structure, with a stokes radius of about 90 angstroms (296). These studies 
also suggest that the N-terminus of ICP4 has a more elongated structure while the C-terminus is 
more globular (296).  The shape of the molecule helps to define the functional abilities of the 
molecule; the length of the molecule in addition to its ability to multimerize on DNA increases 
its affinity for weak binding sites and may allow it to function at a distance (183).   
The sequence of ICP4 is generally conserved amongst alphaherpesviruses.  There are two 
large regions of conservation mapping to the middle and C-terminal regions of the molecule (see 
65 for a sequence comparison).  These regions correspond to a DNA binding domain, nuclear 
localization sequence, and a C-terminal transactivation domain.    Both of these regions are 
functionally important for the molecule and will be discussed below.  Additionally, there is a 
region with significantly less conservation within the N-terminus that corresponds to a N-
terminal transactivation domain.  Whilst the N-terminal portion of ICP4 is not highly conserved 
amongst alphaherpesviruses, there are small regions of conservation.  Some of these regions, 
including a polyserine tract, are important for viral growth in vivo (11, 362).  Additionally, while 
only small segments of the N-terminus are conserved, in combination with the DNA binding 
domain and nuclear localization sequence, it is sufficient to activate E gene expression (70).  
ICP4 localizes to the nucleus of the infected cell as a consequence of the nuclear 
localization sequence. Immunofluorescence assays indicate that within the infected cell nuclei, 
there are small punctate accumulations of ICP4 that generally co-localize with other components 
of the transcription machinery, and some of which localize to sites of viral genome deposition 
(207).  These punctate accumulations are referred to as pre-replication compartments.  The C-
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terminal transactivation domain appears to play a role in the formation of pre-replication 
compartments as in its absence ICP4 is evenly distributed in the nucleoplasm (207, 294).  
Interestingly, only a subset of the punctate accumulations of ICP4 localizes with viral DNA and 
expands into fully formed replication compartments.  The presence of ICP4 foci that do not 
localize with viral DNA or expand into replication compartments has not been fully explained.   
For ICP4 to function as a transcriptional activator, or repressor, it must be able to bind to 
DNA.  Genetic studies have implicated that the regions between amino acids 300-500 
approximately, are important for the DNA binding activities of ICP4, and that this region is 
necessary for the activation and repression of ICP4 mediated transcription (70, 253, 254, 295).  
Early studies suggested that ICP4 preferentially binds to DNA containing the consensus 
sequence ATCGTCNNNNYCGRC where N=any base, R=purine, and Y=pyrimidine, such as a 
site in the ICP4 promoter (93), however it was noted that other viral promoters bound by ICP4 
did not contain this specific sequence.  Thus, a looser consensus sequence was generated as 
RTCGTCNNYNYSG where S=C or G (for N, R, Y see above) (75).  However, as discussed 
previously, while the DNA binding domain of ICP4 is required for activated transcription, the 
ICP4 binding sites in the viral promoters are not specifically required for ICP4 mediated 
activation of transcription (118).  Interestingly, the ability of ICP4 to multimerize on the DNA, a 
function of the C-terminal transactivation domain, increases the affinity of ICP4 for viral 
promoters (183).  Coupled with the fact that nucleosomal deposition on viral DNA during lytic 
infection is minimal and irregular, ICP4 may bind somewhat indiscriminately to open regions of 
the viral genome as a function of its DNA binding domain and multimerization ability (48, 183, 
245).   
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ICP4 also contains two viral transactivation domains, one at the N-terminus and one at 
the C-terminus.  Aside from conferring for multimerization, the C-terminal transactivation 
domain interacts with components of the cellular transcription machinery including TAF1 of 
TFIID (41).  The C-terminus of ICP4 is necessary for viral DNA replication and L gene 
transcription, although the precise reasons are unknown.  Defects in DNA replications may result 
from reduced E gene expression in C-terminal truncation mutants.  As E genes are primarily 
responsible for nucleotide metabolism and DNA replication, it is possible that E proteins are not 
produced to a sufficient quantity to drive viral DNA replication, which is a prerequisite for L 
gene transcription.  L gene expression may also result the multimerization function of ICP4, 
which acts to increase the affinity of ICP4 to L promoters, which, recall, do not have cellular 
activator binding sites.  In fact, ChIP assays indicate that the C-terminus is required for ICP4 
binding on L promoters (284).  Additionally, as mentioned previously, L promoters contain Inr 
sequences in addition to TATA boxes; it is possible that the C-terminus of ICP4 may be 
important for forming complexes on promoters containing Inr sequences, since TAF1 recognizes 
Inr and the C-terminus of ICP4 interacts with TAF1.  Evidence herein and elsewhere suggest that 
there are redundancies within the individual transactivation domains of ICP4, and interaction 
with TFIID is one of them, implicating that even in the absence of the C-terminus, ICP4 may be 
capable of interacting with TFIID. 
The N-terminal transactivation domain, as mentioned previously, is less conserved 
amongst alphaherpesviruses.  As mentioned above, the N-terminal transactivation and DNA 
binding domains of ICP4 are sufficient to activate E gene transcription.  Large deletions within 
the N-terminus appear to have moderate effects on E and L gene transcription in cell culture (11, 
295, 362).  The N-terminus has been implicated in the repression functions of the molecule.  In 
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vitro studies implicate that the N-terminal transactivation domain of ICP4 is important for 
forming a tripartite complex with TFIIB and TBP at strong ICP4 binding sites, and that this 
complex prevents the activation of viral gene transcription (119, 182, 303).  Thus, both the N-
terminus and C-terminus have a role in interacting with TFIID through TBP and TAF1 
respectively.  Additionally, regions of the N-terminus of ICP4 have been shown to be important 
for viral growth within the trigeminal ganglia, and as a result, reactivation.  Interestingly, one of 
the regions important for viral growth in vivo is the polyserine tract, which is heavily 
phosphorylated by PKA (11, 361, 362).  As mentioned previously, differences in phosphorylated 
forms of ICP4 have been shown to have alterations in DNA binding affinity m(224).  While 
mutants lacking the polyserine tract do show a reduced ability to bind to strong ICP4 binding 
sites, as discussed, the ability of ICP4 to bind to DNA is likely indiscriminant, and relies 
partially on the multimerization properties of the molecule (340).  It is instead, more likely, that 
regions within the N-terminus of ICP4 provide a function that is necessary in neuronal cells and 
either unnecessary or redundant in epithelial cells.  Whether this function(s) is related to the 
differing chromatin states of the viral genome, or the cell type specific activators in the neuron 
has not been determined, and remains a focus of our lab. 
1.5.2 Mechanisms of action 
ICP4 is necessary for both activation and repression of viral gene transcription.  ICP4 
autoregulation requires a properly positioned ICP4 binding site, the DNA binding capabilities, 
and the formation of a tripartite complex on DNA.  Evidence has shown that the strength of the 
ICP4 binding site, and its relative position to the TATA box are important in defining 
autoregulation (119, 182, 197).  Interestingly, ICP4 binds to the major groove, and TBP binds to 
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the minor groove of DNA, and optimal repression occurs when their binding sites are ½ a helical 
turn apart (74, 197).  This is important because it was previously believed that the mechanism for 
repression was by physically blocking the promoter region, making it inaccessible to the 
transcription machinery (233).  Instead, this data argues that an alternative mechanism for ICP4 
mediated repression exists.  It was determined in the mid-1990’s that ICP4 forms a complex with 
TFIIB and TBP on DNA and that this complex was important for repression.  Mutants capable of 
binding to DNA, but incapable of forming this complex were incapable of the repression of 
transcription.  Additionally, evidence suggests that the formation of this complex prevents 
activator mediated transcriptional activation (119, 120, 182).   
Interestingly, there are only three strong ICP4 binding sites within the genome that are 
associated with repression.  They are located in the promoter regions of ICP4, LAT, and OrfP.  
The presence of strong binding sites within these promoters suggests that in the presence of 
ICP4, these transcripts would not be expressed, however in the absence of ICP4 they may be 
greatly expressed (reviewed in 66).  LAT is highly expressed during latency, when ICP4 is not 
produced.  Additionally, miRNAs targeted to ICP0, ICP4, and γ34.5 reside within the OrfP 
region of the genome, implicating that ICP4 may be capable of repressing the transcription of 
these miRNAs upon reactivation, perhaps leading to a more robust activation of viral gene 
expression (334).  These data suggest a potential role for ICP4 in the maintenance of or 
reactivation from latency.  The precise role of ICP4 in reactivation from latency and the 
significance of miRNAs in this process are not understood to date. 
The mechanisms related to the activation of gene transcription suggest that ICP4 binds to 
viral DNA (discussed above) and stabilizes TFIID on either the TATA box or Inr sequence (163, 
373). The formation of TFIID-ICP4 complexes at E viral promoters is partially dependent on the 
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TATA box, suggesting that ICP4 and TFIID cooperate in binding at viral promoters (284).  
Given the indiscriminant manner with which ICP4 binds to DNA, TFIID specific binding sites 
and potentially histone deposition may help position ICP4 at the promoter region.  TFIID 
nucleation of the core promoter is a pivotal step for pre-initiation complex for cellular 
transcription, which is likely also true for viral transcription.  It is probable that preinitation 
complexes form on viral promoters in much the same way as on cellular promoters, as most of 
the same GTFs are also necessary for viral transcription (41, 372).  It has also been recently 
demonstrated that ICP4 can form complexes with TFIID and Mediator in infected cells, 
indicating the importance not only of the general transcription factors, but co-activators as well 
(198).  This is likely a function of the large size and elongated structure of ICP4 providing 
multiple surfaces for transcription factor, activator, and coactivator binding.  To date, ICP4 has 
not been implicated in other transcriptional processes outside of preinitiation complex formation.  
It is evident that ICP4 can interact with a variety of cellular transcription factors, but the 
molecular basis for many of the aforementioned functions and interactions have not yet been 
defined.  
1.6 RATIONALE 
Herpes Simplex Virus is a ubiquitous pathogen with detrimental effects on immunocompromised 
hosts.  Infection of immunocompromised hosts, generally neonates, transplant patients, and HIV 
infected individuals, can lead to a disseminated infection, encephalitis, and in some cases death.  
Infection with HSV also leads to increased rates of HIV transmission and ocular infection can 
result in blindness.  Currently acyclovir and derivatives are available for treatment of HSV, 
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however drug resistance poses a problem, particularly in the immunocompromised.   Other drugs 
are available for HSV treatment but they are generally toxic and the delivery routes are not ideal.  
Thus, the development of new nontoxic drugs or a vaccine would be beneficial for public health.  
Additionally, the potential for HSV as a therapeutic agent is under investigation.  The 
development of novel drugs, vaccine strategies, and therapeutic agents requires an understanding 
of the basic molecular virology of HSV.   
For efficient viral replication, transcription of the viral DNA genome must occur.  The IE 
protein, ICP4, is required for transcription of approximately 80 of 85 viral genes, underscoring 
its importance in viral transcription and replication.  To activate viral transcription ICP4 forms 
complexes with components of the cellular transcription machinery, such as TFIID and Mediator 
(198).  Investigating the structure of ICP4, defining regions that are important for interactions 
with the cellular transcription machinery, and identifying novel transcription complexes with 
which ICP4 interacts can lead to advancements in the development of novel treatments.  The 
proof of principle for this exists in a study in which transgenic mice were created that contained 
a mutant form of ICP4 that reduced the activity of wtICP4 in cell culture.  The transgenic mice 
were challenged with wild type virus and the antiviral activity of the mutant ICP4 was assessed.  
The study demonstrated reduced viral replication both in the eye and the trigeminal ganglia in 
the transgenic mice (304).  Importantly, this study demonstrated that altering the activity of 
ICP4, even moderately, could greatly affect the ability of the virus to replicate in vivo. Therefore, 
the development of a drug that would disrupt ICP4 activities, such as its interactions with TFIID, 
would prevent activated transcription from the viral genome and consequently reactivation.   
 59 
Therefore, the goals of these studies were to more accurately define the molecular basis for 
ICP4 mediated functions with respect to both the structure of the molecule and the transcriptional 
complexes with which it interacts.  More specifically, the goals of this project were: 
  
i. To determine the contribution of conserved regions within the N-terminus to 
viral transcription, both in the presence and absence of the C-terminal activation 
domain  
ii. To investigate ICP4-mediated protein interactions throughout infection.   
 
These goals will be addressed in the remaining chapters of this thesis.   
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2.0  THE N-TERMINUS AND C-TERMINUS OF HSV-1 ICP4 COOPERATE TO 
ACTIVATE VIRAL GENE EXPRESSION 
 
2.1 ABSTRACT 
ICP4 activates transcription from most viral promoters.  Two transactivation domains, one N-
terminal and one C-terminal, are largely responsible for the activation functions of ICP4.  A 
mutant ICP4 molecule lacking the C-terminal activation domain (n208) efficiently activates 
many early genes, while late genes are poorly activated, and virus growth is severely impaired.  
The regions within the N-terminus of ICP4 (amino acids 1-210) that contribute to activation were 
investigated by analysis of deletion mutants in the presence and absence of the C-terminal 
activation domain.  The mutants were assessed for their abilities to support viral replication and 
to regulate gene expression.  Several deletions in regions conserved in other α-herpesviruses 
resulted in impaired activation and viral growth, without affecting DNA binding.  The single 
small deletion that had the greatest effect on activation in the absence of the C-terminus 
corresponded to a highly conserved stretch of amino acids between 81-96, rendering the 
molecule nonfunctional.  However, when the C-terminus was present, the same deletion had a 
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minimal effect on activity.  The amino terminus of ICP4 was predicted to be relatively 
disordered compared to the DNA binding domain and the C-terminal 500 amino acids.  
Moreover, the amino terminus appears to be in a relatively extended conformation as determined 
by the hydrodynamic properties of several mutants.  The data support a model where the amino 
terminus is an extended and possibly flexible region of the protein, allowing it to efficiently 
interact with multiple transcription factors at a distance from where it is bound to DNA, thereby 
enabling ICP4 to function as general activator of polII transcription.  The C-terminus of ICP4 
can compensate for some of the mutations in the N-terminus, suggesting that it either specifies 
redundant interactions or enables the amino terminus to function more efficiently.   
2.2 INTRODUCTION 
The Herpes Simplex Virus Type 1 (HSV-1) genome is transcribed in a highly regulated, 
sequential cascade (135, 136) by the cellular RNA polymerase II machinery (3).  VP16 is a 
potent transactivator that is carried into the cell in the tegument of the virion (13) and activates 
the transcription of the Immediate Early (IE) genes (13, 38, 259).  Upon subsequent protein 
synthesis, the IE protein ICP4 acts as a transcriptional activator, promoting the expression of 
Early (E) and subsequently Late (L) genes (77, 114, 260, 261, 349, 350).  In addition to the 
activation function, ICP4 can also be a repressor of transcription in some contexts (68, 120, 244, 
273).  As a consequence, temperature sensitive (ts) and deletion mutants of ICP4 over express IE 
proteins, but are highly defective for E and L gene expression (67, 77, 261, 350).  
ICP4 is a 175 kDa nuclear phosphoprotein (60, 255) that exists as a dimer in an elongated 
conformation (223, 296).  ICP4 is also a sequence specific DNA binding protein (75, 94).  The 
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binding to specific sites is required for the repression of the ICP4, LAT, and OrfP/L/ST 
promoters (97, 119, 188, 233, 273).  In contrast, while the DNA binding activity of ICP4 is 
required for activation of transcription, individual specific binding sites are not (52, 87, 90, 125, 
302). 
Alignment of the amino acid sequences from α-herpesvirus ICP4 homologues reveals 
two large blocks that are highly conserved amongst the homologues between amino acids 300-
500 and the C-terminal 500 amino acids, with respect to HSV-1 ICP4.  The extensive homology 
shared between these homologues is suggestive of the importance of these regions (219).  These 
regions have been shown to specify a DNA binding domain (253, 295) and a region important 
for transactivation, respectively (69, 70, 253, 295).  There is minimal conservation among ICP4 
homologues within the N-terminus of the molecule.  This apparent lack of homology, however, 
is not indicative of importance of this region.  This region has been shown to be important for the 
ability to activate (296) and repress transcription (119).  While the N-terminus of ICP4 shares 
little homology amongst α-herpesviruses, a sequence alignment of the N-terminus of ICP4 
homologues from HSV-1, HSV-2, and herpes B virus, reveals multiple conserved blocks of 
amino acids between the three homologues (Fig.9).  These conserved regions may confer many 
of the functions of ICP4 that are attributed to the N-terminus, such as the ability to form 
transcription complexes on early promoters (117, 284) and the ability to repress transcription in a 
promoter dependent manner (119).   It is also possible that some of these conserved blocks of 
amino acids function in conjunction with the C-terminus, perhaps forming interfaces with many 
of the same transcription factors.  
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Figure 9.  Sequence alignment of the N-terminus of ICP4 from HSV-1 strain KOS, HSV-2, and Herpes B 
Virus.   
The predicted translation products of HSV-1 strain KOS, HSV-2 strain HG42, herpes B virus 
strain E2490 ICP4 molecules were aligned using Vector NTI.  Amino acids highlighted in black 
are highly conserved among all three viruses while those highlighted in red are only conserved 
amongst two of the viruses.  The black lines above and below the alignment indicate the 
deletions constructed within the N-terminus of ICP4.  The deletions were constructed in both the 
wild type KOS background (before the backslash) and the C-terminal deletion mutant n208 (after 
the backslash). 
 
The N- and C-terminal transactivation domains are necessary to varying degrees for the 
transactivation and repression functions of ICP4.  For example, the C-terminal activation domain 
of ICP4 is necessary for efficient L gene activation, but not E gene activation (69). The N-
terminal activation domain contains the site-specific repression functions of the molecule and 
some activation functions (119, 296).  Additionally, it appears that the different regions of ICP4 
have differing roles during the lytic cycle in epithelial cells as opposed to in neuronal cells (11, 
362).  Deletion of the conserved polyserine tract within the N-terminus of ICP4 results in a 
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mutant that has minor defects in replication in Vero cells and at peripheral sites of ocular 
infection in mice, but does not replicate within the trigeminal ganglia of mice (11, 362).  Thus 
various regulatory functions of ICP4 are specified by different parts of the protein, most likely as 
a result of interactions with different components of the host transcriptional machinery, which in 
turn may be of varying importance in different cell types or at different times post infection.   
In order to more accurately define regions of importance, their functions, and whether the 
C-terminus can contribute to these functions, several deletion mutants within the N-terminus of 
ICP4 were constructed both in the presence and absence of the C-terminal activation domain.  
Mutants were utilized in transient assays and assessed for their ability to complement an ICP4 
null virus.  Additionally, the mutations were constructed within both ICP4 loci of the viral 
genome.  The viral mutants were analyzed for their ability to replicate, bind to DNA, and 
activate gene expression.  The results indicate that there are multiple regions of importance 
within the N-terminus of ICP4, and that the C-terminus of ICP4 may cooperate with the N-
terminus to regulate viral gene expression.  
2.3 MATERIALS AND METHODS 
Cells and Viruses.  Vero and E5 cells were maintained as previously described (67).  E5 cells 
express complementing levels of ICP4 (69).  Viral mutants were constructed within the 
background of HSV-1, strain KOS.  The ICP4 mutants n208(70), d8-10 (362), nd8-10 (283), 
ΔSER(11), d120 (67), and n12 (70) have been previously described.  ΔSERn7 was constructed 
by coinfecting E5 cells with n208 and ΔSER, and screening progeny plaque isolates by PCR and 
southern blot hybridization for both copies of the n208 and ΔSER alleles.  The mutants d3-8, 
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nd3-8, m20, m20n7, m90, m90n7, d143, d143n7, and nd3-10 were constructed by marker 
transfer (67).  E5 cells were cotransfected with 2µg of the mutant plasmid DNA digested with 
EcoRI and 2µg viral DNA from either KOS, n12, or n208 using Lipofectamine 2000 (Invitrogen) 
according to the manufacturers suggestions.  Plaque isolates of the transfection progeny were 
then screened by PCR and southern blot hybridization for both copies of the intended alleles.  
Mutant viruses were plaque purified a minimum of three times.   
 
Recombinant plasmids.  The plasmids pK1-2 , pn7, d3-8, nd3-8, d8-10, and nd8-10 have been 
previously described (69, 295).  pK1-2 and pn7 encode the promoter and gene for wt (strain 
KOS) and n208 ICP4, respectively.  pK1-2 and pn7 were transformed into E. coli GS1783 (gift 
of Greg Smith, Northwestern University) and site-directed deletions were constructed using the 
RecET recombination system as previously described (327, 328).  The primers used for the 
construction of the corresponding mutants were: m20, 
CCCGCATCGGCGATGGCGTCGGAGAACAAGCAGCGCCCCGGCCTGCAGGACCGCG
ACGAGCGGGGGTAGGGATAACAGGGTAATCGATTT and 
CGTCTCCGCGCCCCACCCGAGGGCCCCCCGCTCGTCGCGGTCCTGCAGGCCGGGG
CGCTGCTTGTTGCCAGTGTTACAACCAATTAACC; m90, 
GCGGGCACCGACGCCGGCGAGGACACCGGGGACGCCGTCTCGCTGCAGACGATCC
CGACGCCCGACTAGGGATAACAGGGTAATCGATTT and 
GGTCCGGGGCGGCGAGGCCGCGGGGTCGGGCGTCGGGATCGTCTCCAGCGAGACG
GCGTCCCCGGTGCCAGTGTTACAACCAATTAACC; d143, 
GCCGGCGACCGGGCCCCGGCCCGGGGCCGCGAACGGGAGGCCCTGCAGCCGCCG
GCCCAGCCGCCGTAGGGATAACAGGGTAATCGATTT and 
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CCACCGCCCGTGACGACGTCTCCGCGGCGGCTGGGCCGGCGGCTGCAGGGCCTCC
CGTTCGCGGCCGCCAGTGTTACAACCAATTAACC.  The six nucleotides in bold 
correspond to PstI sites, which were added at the site of the deletion for diagnostic purposes.  
The primers were synthesized and gel purified by IDT (Coralville, Iowa).  The kanamycin 
resistance gene from pEPKan-S (328) was amplified by PCR using the Failsafe PCR kit from 
Epicenter Biotechnologies with the following conditions: 50 ng pEPKan-S, 2uM primers, and 
0.5U Failsafe Enzyme were combined in a 1X buffer provided by the manufacturer.  The 
reactions were cycled at 96° for 5minutes, then 35 times at 96° for 30 seconds, 60° for 1 minute, 
and 72° for 1.5 minutes, and finally at 72° for 5 minutes.  The PCR product was gel purified and 
transformed into GS1783 bacterial cells containing the ICP4 plasmids pK1-2 and pn7 as 
described (328).  Transformants containing the appropriate mutant plasmids were selected for by 
resistance to kanamycin and carbanecillin and screened by restriction endonuclease and agarose 
gel analysis.  Isolates containing the appropriate insert that lacked the wt allele were grown at 
30° for 30 minutes in Luria Broth containing 1% arabinose.  The cells were transferred to 42° for 
15 min to induce the recombination system and concomitant removal of the kanamycin cassette.  
The cells were allowed to replicate for another 2 hours at 30° and plated on agar plates 
containing 100 ug/mL carbanecillin and 1% arabinose.  Colonies were screened for their 
sensitivity to kanamycin and possession of the appropriate allele by restriction endonuclease and 
agarose gel analysis.  
 
Transient complementation assay.  5 x 105 Vero cells in 35 mm petri dishes were transfected 
with 2 µg of plasmid DNA using 5µL Lipofectamine 2000 as described by the manufacturer 
(Invitrogen).  Twenty-four hours later the cells were infected with the ICP4 mutant virus d120 at 
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a MOI of 1 PFU/ml.  Twenty-four hours post infection the cells were scraped into the medium, 
disrupted by 3 freeze-thaw cycles, sonicated, and the viral lysates were clarified by 
centrifugation at 3000 rpm for 10 minutes.  Total viral yield was determined by plaque assay on 
E5 cells.   
 
Single Step Growth Analysis.  5 x 105 Vero cells in 35 mm petri dishes were infected at a MOI 
of 5 PFU/cell in 0.1 ml TBS (137 mM NaCl, 5 mM KCl, 0.5 mM MgCl, 0.68 mM CaCl2, 25 mM 
Tricine; pH 7.35), at room temperature for 1hour.  After viral adsorption, the cells were washed 
three times in TBS to remove un-adsorbed virus and 37º medium was added.  The infection was 
allowed to progress for 2, 4, 8, 12, 24, and 36 hours at 37°.  At these times, the infected cells 
were scraped into the medium, disrupted by 3 freeze-thaw cycles, sonicated, and viral lysates 
were clarified via centrifugation at 3000 rpm for 10 minutes.  Total viral yield was determined 
by plaque assay on the E5 cells.   
 
Analysis of Viral Proteins.  Viral proteins were analyzed by metabolic labeling and sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and by western blot analysis.  5 
x 105 Vero cells in 35 mm petri dishes were infected at a MOI of 10 PFU/cell in 0.1 ml TBS at 
room temperature for 1hr, after which time the inoculum was removed, 37º medium was added, 
and cells were incubated at 37° for the indicated times. The infected cells were washed in cold 
TBS containing 0.1mM N-p-tosyl-L-lysine chloromethyl ketone (TLCK) and scraped into 200µL 
sample buffer (0.05M Tris-HCl, pH 7, 2% SDS, 0.01% bromophenol blue, 5% sucrose, 5% β-
mercaptoethanol).  The infected-cell extracts were denatured at 95°C for 5 minutes and separated 
by SDS polyacrylamide gel electrophoresis (SDS-PAGE).  Polypeptides were separated through 
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a 4% polyacrylamide stacking gel (4% acrylamide, 0.19% DATD, 119mM Tris, 0.1%SDS; 
pH7.0) and a 9% polyacrylamide separating gel (9% acrylamide, 0.4% DATD, 375mM Tris, 
0.1% SDS; pH 8.8) in Tris-Glycine Electrode buffer (25 mM Tris, 192 mM glycine, 0.1% SDS; 
pH 8.5) at 100 V. 
For analysis of metabolically labeled viral polypeptides, the medium (methionine and 
cysteine free DMEM) on the infected cells was removed at 3.5, 7.5, and 11.5 h post infection and 
replaced with 1 ml 37º TBS containing 25 µCi 35S-methionone (>1000 Ci/mmole, MP 
Biomedicals).  The cultures were incubated for an additional 30 min at 37º, after which time the 
labeling medium was removed and the monolayers were washed with cold TBS containing 0.1 
mM TLCK, solubilized, and analyzed by SDS-PAGE as described above.  Following 
electrophoresis the gel was fixed in H20:methanol:acetic acid (6:3:1), dried and exposed to X-ray 
film (HyBlot CL from Denville).   
For western blot analysis, the SDS-PAGE separated polypeptides were transferred from 
the polyacrylamide gel to nitrocellulose membranes by electroblotting in 1X transfer buffer (25 
mM Tris, 192 mM Glycine, 20% Methanol) for 1.5 h at 250 mA.  The membrane was 
subsequently blocked by incubation at 4°C overnight in 5% dry milk in TBS (50 mM Tris, 150 
mM NaCl; pH 7.5) and then incubated with ICP4 specific antibodies (N15 or 58S) at a 1:500 
dilution in TBS + 0.05% Tween 20 (TBS-T) + 1% milk for 1 hour.  The immunoblot was then 
washed in 1% milk in TBS-T, 4 times for a total of 30 minutes.  It was then incubated with either 
goat anti mouse (for 58S) or donkey anti rabbit (for N15) IRDye-conjugated (LI-COR) 
secondary antibodies at a 1:10,000 dilution in TBS-T, subsequently washed 4 times for a total of 
30 minutes in TBS-T, and finally twice for a total of 2 minutes in TBS.  Images were obtained 
using the LI-COR Odyssey Infrared Imager. 
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Southern Blot hybridization.  DNA was isolated from infected cells and analyzed by Southern 
blot hybridization as previously described (282, 307).  Infected cell DNA was digested with the 
restriction endonucleases BamHI and PstI and separated by electrophoresis in a 1.2% agarose 
gel.  A plasmid containing the BamY fragment of the HSV-1 genome was used as the probe 
DNA and was labeled with 32P-CTP and 32P-GTP (GE Healthcare) using a Nick Translation 
System (Invitrogen) according to the manufacturers suggestion.  The results were visualized by 
autoradiography. 
 
Northern blot analysis.  5 x 106 Vero cells in 100 mm petri dishes were infected at an MOI of 
10 PFU/cell at room temperature for 1 hour.  The viral inoculum was removed, 37º medium was 
added, and cells were incubated at 37° for 4 and 8 hours.  The monolayers were then rinsed once 
with cold TBS, and 2 mL Trizol reagent (Invitrogen) was added.  The infected cells were scraped 
into the Trizol reagent and RNA was harvested according to the manufacturers (Invitrogen) 
guidelines.  RNA was treated with 10 U RNAse free DNAse I at 37° for 15 minutes, and ethanol 
precipitated. 
Total RNA was quantified using the NanoDrop 2000 (Thermo-Fisher).  RNA samples 
were prepared for electrophoresis by diluting 13 µg RNA into 4.5 µL water and adding 2 µL 10X 
MOPS running buffer (1X MOPS running buffer; 20 mM MOPS (3(-N-
morpholino)propanesulfonic acid), 1 mM EDTA, 5 mM sodium acetate), 3.5 µL 37% 
formaldehyde, and 10 µL formamide followed by heating the samples for 15 min at 55°.   Two 
microliters of loading buffer (50% glycerol, 1 mM EDTA, 0.4% Bromophenol blue, 0.4% 
Xylene Cyanol) was added to each sample and then the samples were run on a 1.3% agarose-
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formaledehyde gel (1.3% agarose, 8% formaldehyde in 1X MOPS running buffer) at 100 V for 4 
hours in re-circulating 1X MOPS running buffer (20 mM MOPS, 1 mM EDTA, 5 mM sodium 
acetate).  The gels were prepared for transfer by washing them for 45 min each in; water, 50 mM 
NaOH 10 mM NaCl, 100 mM Tris-HCl pH 7.5, and finally 10X SSC (1.5 M NaCl, 1.5 M 
Sodium Citrate).  The RNA was transferred to Nytran N (Whatman) overnight in 10X SSC and 
the RNA was crosslinked to the membrane using a UV-Stratalinker (Stratagene).  Membranes 
were probed with 32P-nick translated DNA specific to ICP4 (BamY fragment), ICP0 (plasmid 
pW3ΔHS8 containing the ICP0 coding sequence), tk (the SacI-Sal I fragment corresponding to 
+555 to +1217 relative to the start site), LAT (+5557 to +7559 of the BamB fragment), or gC 
(plasmid pSXgC containing the gC coding sequence) as previously described (140).  Results 
were visualized via autoradiography. 
 
DNA binding assays.  Protein extracts were prepared by scraping 106 infected (MOI = 10 
PFU/cell for 6 h) Vero cells in 60 mm petri dishes into TBS + 0.1 mM TLCK, and pelleting the 
cells at 12.5 K for 20 sec.  The pellet was then resuspended in 30 µL TE (Tris-HCl pH 8.0, 1 mM 
EDTA), and 30 µL 2X Lysis Buffer (100 mM Tris; pH 8.0, 1 M KCl, 4% NP-40) and 0.1 mM 
TLCK.  The samples were incubated on ice for 45 minutes.  Cell debris was pelleted at 12.5 K 
for 10 minutes and the supernatant was used for the binding reaction.  Binding reactions were 
prepared with 3 µL of the protein extract, 1 ng of 32P end-labeled probe DNA, and 2 ug the 
nonspecific inhibitor dI•dC (polydeoxyinosinate-polydeoxycytidylate) (Midland Certified 
Reagent Company) in binding buffer (10 mM Tris pH=7.5, 1 mM EDTA, 5% glycerol, 0.1% 
NP40, 50 mM KCl, 0.1 mM TLCK).  The probe DNA utilized in this assay was a fragment of 
the ICP4 promoter termed P4, which covers -108 to +27 bp relative to the transcription initiation 
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site of ICP4.  The binding reactions were incubated at room temperature for 30 min and then run 
on a 4% polyacrylamide gel in 0.5 x TBE (1 X TBE; 88 mM Tris, 88 mM boric acid, 1.25 mM 
EDTA) at 200 V for 1 hr 45 min.  The gel was then dried and the results were visualized by 
autoradiography.  
 
Size exclusion chromatography.  Infected cell extracts were prepared as described above for 
the DNA binding assay.  The extracts were run on calibrated superpose 6 10/300 column (GE 
Healthcare) and the fractions analyzed for ICP4 as previously described (293, 296).  The LMW 
and HMW gel filtration calibration kits (GE Healthcare) were used to calibrate the columns.  The 
Stokes radii were determined as previously described (293, 296) and shown in Figure 5. 
 
Immunofluorescence.  2 x 105 Vero cells were seeded onto glass coverslips in a 12-well plate.  
Cells were infected at a MOI of 10 PFU/cell for 1 hour with the indicated viruses at room 
temperature.  The inoculum was replaced with 37º media and the infections were allowed to 
progress at 37° for 2 hours.  The monolayers were then fixed for 10 minutes in a 4% 
paraformaldehyde solution, and subsequently washed 3 times for 5 minutes each in PBS (137 
mM NaCl, 2.7 mM KCl, 5.3 mM Na2HPO4, 1.7 mM KH2PO4; pH 7.4), followed by 
permeablization in PBS + 0.4% TritonX100 + 1% BSA for 30 min.  The permeablized cells were 
incubated with a primary antibody for ICP4 (N15; rabbit polyclonal serum) at a 1:500 dilution in 
PBS + 1%BSA.  The cells were then washed in PBS +1% BSA three times for a total of 30 min 
and twice in PBS for 20 min before being incubated in Alexa-Fluor conjugated secondary 
antibodies (Santa Cruz) at a 1:500 dilution in PBS.  The cells were then washed 6 times for a 
total of 1hr in PBS and the coverslips were mounted onto a glass slide using Immumount 
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(Electron Microscopy Services).  Images were obtained using the Olympus Fluoview FV1000 
confocal microscope. 
2.4 RESULTS 
A mutant ICP4 molecule expressed from the virus n208 lacks the C-terminal activation 520 
amino acids due to truncation.  The n208 molecule retains the ability to repress transcription 
from the ICP4 promoter, efficiently activates early promoters, but true late gene expression is 
substantially impaired, resulting in relatively poor viral growth (70).  Deletion of amino acids 30-
274 from the n208 molecule results in a dimeric protein that can bind to DNA, yet it cannot 
activate or repress transcription (118, 119, 296), suggesting a role for the N-terminal region in 
both repression and activation.  While this region may sufficiently specify interactions involved 
in repression and activation, it is also possible is that N-terminal activation domain and the C-
terminal activation domain function together to constitute the crucial functions of ICP4.  To 
investigate the functions of the N-terminal and C-terminal activation domains with respect to the 
regulatory functions of ICP4, deletions within the N-terminus of ICP4 were constructed in the 
context of the entire 1294 amino acid protein and in the background of the truncated n208 
molecule.   
Sequence alignments of ICP4 homologues between multiple members of α-herpesviridae 
showed very little homology within the N-terminus of ICP4.  However, a sequence alignment 
between the primate α-herpesviruses, HSV-1, HSV-2, and herpes B virus revealed several 
relatively conserved regions within the N-terminus of ICP4 (Fig.9).  The sequence shown for 
HSV-1 is the N-terminus of the KOS strain.  Differences between the KOS amino acid sequence 
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and strain 17 (219) are highlighted in green with the strain 17 residue given above the main 
sequence.  The sequences highlighted in black are conserved in all three viruses, while those 
highlighted in red are conserved in two out of three. 
Deletions were constructed as indicated in Fig. 9 such that a PstI site was also inserted into 
the site of the deletion.  The nomenclature for the newly constructed mutants, m90/m90n7 for 
example, represents the indicated deletion in the full-length molecule, and the C-terminal 
truncation mutant n208 (n7).  The Δser mutants were previously constructed (11).  The d3-8 and 
d8-10 mutants were also previously constructed (295), with the nd version representing the 
deletion within the n208 molecule.  The resulting clones containing the deletions of interest, 
were verified by restriction digestion and agarose gel electrophoresis.  
The mutant plasmids were assessed for their ability to complement an ICP4 null virus, d120, 
as any defects in complementation ability may be predictive of defects in viral transcription.  
Briefly, ICP4 mutant plasmids were transfected into Vero cells.  The transfected cells were used 
as hosts for infection with d120.  Transfected wt ICP4 expressed from the plasmid pK1-2 
resulted in an approximately 105– fold increase in the yield of d120 over mock-transfected cells 
(not shown).  Figure 10 displays the results of the complementation assay for each mutant as a 
percent of the yield resulting from the pK1-2 transfection.  Of the mutants containing the C-
terminal 500 amino acids, m90, d8-10 and d3-8 were partially impaired while the mutant that 
deleted the whole region d3-10 was highly impaired.  Truncation of the C-terminus (n208) 
resulted in a 300-fold decrease in the yield of d120.  The deletions within the N-terminus of the 
n208 molecule had a similar effect to the deletions within the intact molecule, with m90n7, nd3-
8, nd8-10 and nd3-10 yielding very little to no d120 in excess of mock transfections.  These 
defects in complementation ability are most likely reflective of reduced transcription of essential 
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viral genes and predictive of the possible phenotypes of viruses baring these mutations.  In 
addition, transient transfections of the plasmids followed by western blot analysis revealed that 
each mutant plasmid specified a protein of the approximate expected molecular weight 
demonstrating that defects in complementation were not the result of stability issues or 
unintended gross rearrangements (data not shown).   
 
Figure 10.  Complementation activity of mutant plasmids.   
ICP4 mutant expressing plasmids were transfected into Vero cells and their ability to 
complement the ICP4 null virus, d120, was determined as described in the materials and 
methods.  The activity is expressed as the percent yield relative to the transfection with the 
plasmid expressing wt ICP4 (pK1-2). 
 
To more thoroughly assess the effects of the mutations on the viral life cycle, the deletions 
were constructed in both ICP4 alleles within the wild type and n208 genomes, as described in the 
materials and methods.  The d3-10 construct proved to be transdominant-negative and therefore 
we were unable to construct a virus with this mutation.  The PstI insertion at the deletion in all 
the mutants was used as a diagnostic for the intended mutations.  Mutant viral DNA was digested 
with BamHI and PstI and separated via agarose gel electrophoresis.  Southern blot analysis was 
performed using the BamY fragment of the genome as a probe.  Figure 11 shows the results from 
the Southern blot analyses of the viral deletion mutants.  As expected, the wild type and n208 
genomes, which do not have a PstI site, yielded a fragment of 1.84 kb.  PstI cleaved this 1.84kb 
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fragment from the deletion mutants into two smaller fragments (Figure 11), indicating that the 
genotypes of the mutant viruses were as intended. 
 
Figure 11.  Structure of mutant virus genomes.   
(A)  Diagram of deletions relative to the ICP4 gene.  The location (PstI site) and size of the 
deletions are given by the vertical arrowhead.  The sizes (kb) of the predicted BamHI/PstI 
fragments for each mutant are also given.  (B)  Southern blot of BamHI/PstI digested viral DNA.  
The 1.84 kb BamHI “Y” fragment (part A) was used as probe. 
 
Once it was established that each viral mutant had the correct genotype, we wanted to 
ascertain; (i) that each mutant virus was expressing an ICP4 protein of the correct size, (ii) 
whether each mutant molecule localized to the nucleus of infected cells, and (iii) if mutant 
molecules retained their ability to bind to DNA.  To investigate whether mutant ICP4 molecules 
were expressed and whether the molecules were the expected molecular weight, SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blot analyses were 
performed.  The analysis was performed using the ICP4 N-terminal N15 polyclonal rabbit serum 
as a probe. Fig. 12A shows the results of the Western blot analyses.  The mutants, nd3-8 and 
nd3-10, appear as though they are not expressed within the context of viral infection.  However, 
as these mutations consist of large deletions within the N-terminus and the antibody N15 
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recognizes regions within the N-terminus, we hypothesized that the N15 antibody primarily 
recognized the regions deleted in d3-8 and nd3-8.  To address this concern in part, Western blot 
analyses were also performed using the ICP4 C-terminal monoclonal antibody, 58S.  As also 
displayed in Fig 4A, the d3-8 mutant is expressed to a similar level as wild type ICP4.  While the 
antibodies at our disposal cannot detect nd3-8 and nd3-10, we presume that these truncated 
proteins are being produced.  Additionally, all deletion mutants produced ICP4 molecules of the 
anticipated molecular weight relative to wild type ICP4 (Fig. 12A) 
Immunofluorescence assays were performed to determine whether the mutant ICP4 
molecules localized to the nucleus of the infected cells.  Vero cells grown on glass coverslips 
were infected at an MOI of 10 for two hours before being fixed and stained with the ICP4 N-
terminal antibody N15 and an AlexaFluor conjugated secondary antibody.  Staining was imaged 
on a confocal microscope at 102x magnification.  Figure 12B shows the images collected from 
the immunofluorescence assay.  Images show ICP4 staining within the nucleus of infected cells 
indicating that all mutant ICP4 molecules localize to the nucleus during infection (Figure 12B).  
Again, the d3-8, nd3-8, and nd3-10 are not strongly recognized by this antibody.  Some faint 
nuclear staining can be visualized with the d3-8 and nd3-8 mutants, however, staining is weaker 
than that of wild type virus. 
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Figure 12.  ICP4 mutant viruses produce proteins of the expected molecular weight and sub-cellular 
localization.   
(A) Whole cell extracts were collected from wild type and mutant infected Vero cells 6hpi and 
proteins were separated on a 9% polyacrylamide gel.  ICP4 proteins were detected with either the 
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ICP4 N-terminal N15 antibody (panels 1 and 3) or the ICP4 C-terminal antibody 58S (panel 2).  
(B) Immunofluorescence of ICP4 in virus infected cells. 
 
To determine whether the mutant ICP4 molecules were capable of binding DNA, 
electromobility shift assays (EMSA) were performed.   Protein extracts were collected from 
infected Vero cells and incubated with 32P end-labeled DNA corresponding to the region  -108 to 
+27 bp relative to the transcription initiation site of ICP4 in the presence of competitor DNA.  
Protein/DNA complexes were then separated on a 4% native polyacrylamide gel and the protein 
complexes bound to the radiolabeled probe were visualized by autoradiography.  The results of 
the electromobility shift assay are in Figure 13.  Bands were seen in the mock-infected lane 
indicating that some cellular proteins are capable of binding the ICP4 promoter region.  An 
additional band is visible within the KOS infected extract band indicating that wild type ICP4 
can bind the probe under these conditions.  Additionally, all the ICP4 deletion mutants, with the 
exception of n12, that is missing the DNA binding domain, retained the ability to bind to the 
probe DNA as revealed by an additional band of the anticipated mobility present that is not 
present in the mock infected cell extracts (Fig. 13).  Of importance, both nd3-8 and nd3-10, 
which were not detectable by western blot, also bound DNA, indicating that these mutant 
proteins are in fact produced in the context of viral infection.  In addition, all of the mutants that 
possess the C-terminal 520 amino acids produced gel shifts of lower mobility and intensity 
relative to the main gel shift, while the viruses lacking the C-terminus only produced the single 
gel shift.  This is due to the previously shown property of the C-terminus, which results in the 
multimerization of ICP4 on DNA (183). 
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Figure 13.  EMSA on ICP4 mutants.  
Infected Vero cell extracts were prepared and incubated with  32P end labeled DNA 
corresponding to the mRNA start site region of ICP4 as described.  The protein/DNA complexes 
were separated by native PAGE and visualized by autoradiography.  Each lane is labeled with 
the corresponding virus in which the protein extracts were collected from.   
 
An additional property of ICP4 is revealed by the mobility of the shifts in Fig. 13.  Deletions 
within the N-terminus significantly increased the mobility of the ICP4/DNA complex, whereas 
deletion of the entire C-terminal 520 amino acids (n208) had a relatively small effect by 
comparison.  Size exclusion chromatography on superose 6 was performed on the full-length 
protein (KOS), n208, d3-8, d8-10 and nd3-8 ICP4 molecules to determine their Stokes radii.  
Relatively small deletions from the primary sequence at the amino terminus (d3-8 and d8-10) 
resulted in greater reductions in the Stokes radius than deletion of the 520 amino acids at the C-
terminus.  The reduction in Stokes radii roughly corresponded to the increase in the mobility of 
the protein/DNA complex.  These data suggest that the amino terminus more greatly contributes 
to the elongated nature of the molecule.    
The fact that all ICP4 mutant molecules produced the expected size protein, retained the 
ability to bind to DNA, and localized to the nucleus indicates that any defects in the regulation of 
viral gene expression are a direct effect of the deletions within the transactivation domain(s).  To 
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determine how the deletions affect the virus life cycle, single step growth and viral gene 
expression analyses were performed on mutant virus infected cells.  For single step growth 
analysis, Vero cells were infected at an MOI of 5 for 2, 4, 8, 12, 24, and 36 hours.  Cells were 
harvested in their media, subjected to three freeze-thaw cycles, sonicated, and viral lysates were 
clarified via centrifugation.  Viral yields were determined by plaque assay on the E5 
complementing cell line and plotted versus time post infection (Fig. 14).   
At 24 hpi wild type KOS infected cells yielded approximately 109 PFU, which is 
approximately 1000 PFU per cell.  The DNA binding deficient virus n12, which contains only 
the first 251 aa of the ICP4 protein, did not produce a viral yield higher than the initial inoculum 
and was reduced by more than 4 orders of magnitude with respect to wild type.  The viral growth 
profiles of m20, m90, d143, and ΔSER did not differ significantly from wild type.  These 
mutants all contain small, approximately 10 aa, deletions within the N-terminus of ICP4.  
However, the mutants d3-8 and d8-10, which have deletions of 112 and 68 amino acids 
respectively, were reduced in viral yield by approximatly 1.5 orders of magnitude (Figure 14A).  
The yield of the C-terminal deletion mutant n208 was reduced by approximately 2.5 orders of 
magnitude, relative to wild-type virus.  In the absence of the C-terminus the m20n7 and d143n7 
mutants have growth profiles similar to n208 while the m90n7, Δsern7, nd3-8, nd8-10, and nd3-
10 had growth profiles similar to the n12 virus (Figure 14B).  Of these m90n7 and Δsern7 are 
perhaps the most interesting as in the presence of the C-terminus they have growth profiles 
similar to wild type, but in the absence of the C-terminus appear to have a relatively greater 
effect, underscoring the importance of these regions when the C-terminus is not present.  
Furthermore, the relative growth properties of the mutant viruses closely correspond to the 
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ability of the mutant plasmids from which they were derived to complement d120, strongly 
supporting that the defects of the viruses are due to the mutations in ICP4. 
 
Figure 14.  Single step growth curve analysis of mutant viruses.   
(A) Growth curve analyses of ICP4 mutants that contain the C-terminus.  (B) Growth curve 
analyses of ICP4 mutants that do not contain the C-terminal activation domain. 
 
Given that the deletion mutants displayed varying defects in viral growth (Fig. 14), it may 
be anticipated that the spectrum of viral genes expressed as a function of the mutant ICP4 
molecules will also vary, and differ considerably from that of wt virus.  To investigate this, the 
kinetics of viral polypeptide synthesis, and the abundance of representative viral mRNAs was 
determined for the mutants and wt virus.  To investigate viral protein synthesis, Vero cells were 
infected at a MOI of 10 PFU/cell with the indicated viruses, and the proteins were metabolically 
labeled with 35S-methionine at 3.5-4, 7.5-8, and 11.5-12 hours post infection.  Laemmli extracts 
of the infected cells were prepared, and subsequently separated on 9% SDS-polyacrylamide gels. 
Fig. 15 is a collage of SDS-gel profiles of mock-, wt virus-, n208-, m90n7-, nd3-10-, and n12-
infected cells.  The phenotypes of these viruses are representative of five general classes (I-V).   
The phenotypes of the remainder of the viruses are categorized into one of the five classes, and 
indicated below the representative member of the class. 
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Figure 15.  Protein expression profiles from ICP4 mutant viruses.   
Vero cells infected with the indicated viruses were labeled for 30 min at 4, 8, and 12h post 
infection.  SDS-PAGE was performed as described.  Viruses with similar phenotypes are listed 
below the examples shown.  Where possible infected cell polypeptide numbers (ICPs) numbers 
are given.  Mock infected cells (M). 
 
Class I is represented by wt virus (strain KOS).  The classic progression from IE (ICPs4, 
27) to true L (ICPs1/2, 19/20) is evident.  The viruses, ΔSER, d8-10, m20, m90, and d143 share 
this phenotype, suggesting that these mutations alone do not greatly affect the ability of ICP4 to 
function.  In contrast, class V, which is represented by the virus n12, was completely defective.  
The proteins ICPs0, 6, and 27 were highly overexpressed and later proteins were not easily 
detected, as previously shown (70).  None of the mutants in this study precisely displayed the 
phenotype of n12. 
Class II is represented by n208.  n208 has nonsense mutations in all three reading frames 
such that the molecule is truncated at amino acid 774.  Despite lacking the C-terminal 520 amino 
acids, readily detectable quantities of ICPs5, 8, gB, and 25 were detected, while the expression of 
the mutant ICP4 protein and ICP27 diminishes over time.  Importantly true late proteins were not 
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easily detectable.  This is consistent with previous findings (70).  Like their counterparts in the 
context of the otherwise wild type background, the mutations in ΔSERn7, m20n7, and d143n7 
had little effect on the n208 phenotype.  Interestingly, the 112 amino acids in the N-terminus of 
the d3-8 ICP4 (Fig. 9) had similar effects on the activity of the ICP4 molecule as the lack of the 
C-terminal 520 in n208, as determined by this assay.   
Class III is represented by m90n7.  This 15 amino acid deletion (Fig. 9) had a profound 
effect on the activity of the n208 molecule, greatly reducing the abundance of ICPs5, 8, 25, and 
gB.  The region deleted by this mutation represents the most conserved stretch of amino acids in 
the N-terminus of ICP4.  Interestingly, this deletion had a relatively small effect in the presence 
of the C-terminal region of ICP4 (m90).  nd3-8 had a similar phenotype to m90n7, consistent 
with the fact that the region deleted in nd3-8 contains the region deleted in m90n7.  The deletion 
in nd8-10 consists of 68 amino acids just C-terminal to the d3-8 deletion residues, and has a 
similar effect on the activity of the n208 molecule.  Thus two non-overlapping regions of the N-
terminus have a similar effect on the activity of the ICP4 molecule. 
Class IV is represented by the virus nd3-10.  It is the only member of this class.  The 
deletion in this virus combines the two deletions that independently resulted in a marked 
reduction in viral later gene expression in the n208 background.  As a consequence gene 
expression beyond the IE class of virus genes was very difficult to detect and similar to class V 
(n12).  The phenotypes nd3-10 and n12 subtly differ in that ICP6, 0 and 27 appear to be more 
abundantly expressed in n12-infected cells.  
To more directly assess the activities of the mutant ICP4 molecules synthesized during 
infection, the abundance of mRNAs for genes representative of different kinetic classes was 
determined by Northern blot analyses (Fig. 16).  The abundance of ICPs4 and 0 (IE), tk (E), and 
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gC and LAT (L) mRNAs were determined at 4 and 8 h post infection.  The IE transcripts for 
ICP4 and ICP0 accumulate differently during infection.  ICP4 accumulates early and then is 
reduced in abundance, whereas ICP0 continues to accumulate throughout infection (351). The 
decreased accumulation of ICP4 is due the ability of ICP4 to repress transcription as a function 
of an ICP4 binding site at the start site of ICP4 transcription.  All of the mutants show less ICP4 
mRNA at 8h relative to n12, suggesting that they all may retain the ability to repress 
transcription.  Another observation that supports this is that none of the mutants that express 
LAT demonstrate accumulation at early times.  It has been shown that the LAT promoter is 
converted to an early promoter by mutating a repressive ICP4 binding site at the start site of LAT 
transcription (271).  Interestingly, in the absence of the C-terminus of ICP4, ICP0 is still highly 
expressed at 8hpi, but is not as highly expressed as wild type.  This is true of all mutants lacking 
the C-terminus (Figure 16, panel 2), perhaps reflecting the defect in activation.  
tk (early) mRNA was not detected at this level of exposure in n12-infected (Fig. 16).  At 4h 
post infection, the abundance of tk mRNA in n12-infected cells is about 2% that of wt (strain 
KOS) virus (140).  While tk RNA was expressed in all the backgrounds containing an intact C-
terminus, its abundance was significantly reduced in m90- and d3-8-infected cells.  The larger 
growth defect (Fig. 14) and more restrictive SDS-gel profile (Fig. 15) of d3-8 relative to m90, is 
probably because of defects in later gene expression.  The abundance of the late RNAs (gC and 
LAT) in d3-8 infected cells were considerably less than in m90-infected cells (Fig. 16).  In the 
absence of the C-terminus, the abundance of tk RNA in nd3-10 infected cells was as low as in 
n12-infected cells.  tk mRNA was also significantly reduced in m90n7- and nd3-8-infected cells.  
n208 was defective in late gene expression as previously shown (70), as were all the viruses 
lacking the C-terminal 520 amino acids.  Some of the other deletions had a more modest effect 
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on tk and gC mRNA abundance.  The deletion of amino acids 142 to 210 in d8-10 resulted in a 
modest reduction in tk, gC, and LAT accumulation.  Lastly, the deletion in d143 affected the 
kinetics IE (ICP4 and ICP0) and tk expression.  Therefore, while the conserved block of amino 
acids deleted in m90 (81-96) (Fig. 9) had the greatest effect on the accumulation of the analyzed 
transcripts that ICP4 activates, determinants flanking this block also affect activation as inferred 
by the greater defect in d3-8 relative to m90.  The region deleted in d8-10 further contributes to 
activation, as inferred by the highly defective phenotype of nd8-10.  
 
Figure 16.  mRNA expression from ICP4 mutant viruses.   
RNA was isolated from cells infected at an MOI of 10 PFU/cell for 4 and 8 h.  Northern blot 
analysis was performed as described in the materials and methods, probing for ICP0, ICP4, tk, 
gC, and LAT.    
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2.5 DISCUSSION 
This study addresses the extent to which the conserved regions of the N-terminus that 
contribute to the regulatory functions of the molecule, and whether the N- and the C-termini of 
ICP4 have any redundant or overlapping functions.  To address these questions, directed 
deletions were constructed within the N-terminus of ICP4, both in the presence and absence of 
the C-terminal regulatory region and the resulting mutant viruses were compared with respect to 
viral gene expression.  We have previously shown that the region N-terminal to the DNA binding 
domain of ICP4 is important for activation and repression (41, 119, 295).  In this study we found 
that multiple regions within the N-terminus contribute to activation.  To put these findings into 
perspective it is helpful to consider some general properties of the ICP4 molecule and the N-
terminus in particular.   
ICP4 exists in cells as an obligate dimer possessing hydrodynamic properties suggestive 
of an elongated protein with a Stokes radius of about 95-100 Å (223, 296).  The N-terminus 
contributes greatly to the elongated character of ICP4 relative to the C-terminus (Fig. 13).  
Deletions in the 50 to 100 amino acid range within the N-terminus more substantially reduced 
the Stokes radius of ICP4 compared to the deletion of the entire 500 amino acids of the C-
terminus.  The N-terminus also has a greater effect on the magnitude of the mobility shift of an 
ICP4/protein DNA complex (Fig. 13).  This suggests that an ICP4 molecule bound at a fixed 
ICP4 binding site may be able to act at a considerable distance engaging in interactions between 
cellular molecules and domains within the N-terminus.   
Another property to consider is the predicted degree of order vs disorder in the ICP4 
molecule.  Disordered regions are generally of low complexity and are flexible.  The probability 
of disorder can be predicted (345) with the use of an online server, 
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http://bioinf.cs.ucl.ac.uk/disopred (344).  Figure 17A shows this prediction for the entire ICP4 
(strain KOS) protein.  There are two regions that have a fairly low probability of disorder.  The 
first is the domain between amino acids 300 and 600.  This constitutes the DNA 
binding/dimerization domain.  The second is the C-terminus of the molecule roughly from amino 
acids 900 to 1294.  This is largely the region deleted from the n208 molecule.  It is also the 
region that when deleted had a relatively small effect on the Stokes radius.  Together these 
observations suggest that this is a relatively ordered, more globular part of the ICP4 molecule.  In 
between the 2 regions of relative predicted order is a region from amino acids 700-850 that is 
predicted to be highly disordered.  This region is poorly conserved among the ICP4 homologs in 
other α-herpesviruses.  
The amino terminus is a heterogeneous mixture of ordered and disordered regions, with 
the conserved regions not necessarily corresponding to the degree of predicted disorder (Fig.17).  
A conserved disordered region may fold upon binding to a functional target, such as a cellular 
transcription factor.  Other disordered regions may serve as flexible linker regions between 
interacting regions (83).  One such region may be that corresponding to amino acids 82-97, 
which are deleted in m90 (Fig. 17C).  In the absence of the C-terminus, this region had a 
relatively large effect on the activity of the molecule.  It is also the most conserved region within 
the region within the N-terminus surveyed by this analysis (Fig. 17).  It is possible that this 
region is important with making contacts with key transcription factors such as TFIID and 
mediator, which are known to form a complex with ICP4 in infected cells (198).  However, the 
participation of any region within the N-terminus in contacts with other molecules cannot be 
ruled out.  It is likely that there are multiple regions within the N-terminus that participate in 
protein-protein interactions that are connected by flexible linker regions, enabling ICP4 to make 
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multiple contacts with the cellular transcription machinery, possibly at a distance from where it 
is bound to DNA.   
 
 
Figure 17.  Disorder prediction for the ICP4 protein.  
(A) The probability of disorder for ICP4, (strain KOS) was determined as described in the text.  
(B) Expansion of part A for the amino terminus of ICP4.  The degree of conservation between 
HSV-1, HSV-2 and B virus from Fig. 9 is also shown along the axis depicting the residue 
number.  (C) The relative locations of the deletions examined in these studies. 
 
The presence of the C-terminus almost completely masked the deleterious effects of the 
m90 deletion.  Therefore, the C-terminus independently substitutes for the activity of the deleted 
amino acids, or it augments the activity of the N-terminus that remains when these amino acids 
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are deleted.  The n208 molecule interacts with TBP and TFIID on DNA (117, 303), and the 
contributing protein-protein interactions are specified by the amino acids spanning 30-274 (117, 
119).  However, the C-terminus of ICP4 specifies an interaction with TAF1 enabling ICP4 to 
interact with TFIID in solution (41).  Therefore, there are regions within both the carboxyl- and 
amino-terminal regions that specify interactions with TFIID that could potentially synergize to 
recruit TFIID.  The regions of ICP4 involved in interactions with mediator are unknown at 
present.  However, since mediator is ubiquitously involved in polII transcription, as is TFIID, 
regions interacting with these two central complexes will be operationally redundant to some 
extent. 
The region deleted in d8-10 (142-210) had a considerable effect on activation, particularly in 
the absence of the C-terminus.  Part of this is due to contribution of the region deleted in d143.  
Because d8-10 still retains sequences deleted in m90, it likely functions in gene activation by a 
distinct mechanism.  At present it is not clear whether this contribution is as a spacer or due to 
interactions with different transcription factors, or both.   
It is likely that the entire region comprising the N-terminal 200 amino acids is involved in 
interactions with multiple transcription factors.  The hydrodynamic properties of mutants in this 
region suggest that it extends out from the DNA binding domain, and is potentially flexible, 
allowing it to contact multiple transcription factors and act at a relative distance from where 
ICP4 is bound to DNA.  This region, along with the DNA binding domain functions as an 
activator, resulting in the activities characteristic of n208.  It is important to note that while n208 
is relatively defective for viral growth compared to wt virus, some viral growth does occur (Fig. 
14).  Perhaps the more globular and conserved C-terminal region (amino acids 774-1294) 
“augments” the activities of the N-terminus either by specifying redundant interactions with the 
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N-terminus, or interactions affecting the location of ICP4.  One example of the latter type of 
interaction is that the C-terminal 500 amino acids allow ICP4 to multimerize on DNA, increasing 
its affinity for DNA (183).  This would enhance the ability of the interactions specified by the N-
terminus to contribute to activation.  Further studies are underway to test this model. 
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3.0  A FUNCTIONAL RELATIONSHIP BETWEEN HSV-1 TRANACTIVATION 
DOMAINS FACILITATES INTERACTIONS WITH TFIID AND MEDIATOR 
3.1 ABSTRACT 
The HSV IE protein, ICP4, is crucial in regulating viral gene expression; in its absence E and L 
gene expression do not occur.  Multiple studies have defined regions of ICP4 that are important 
for viral gene expression.  The C-terminus of ICP4 plays a critical role in activating L gene 
expression.  The previous chapter suggested that the N-terminus is important for Early gene 
expression, although the specific functions were not defined.  For the purposes of this study, a 
stable cell line expressing a mutant ICP4 deleted for the N-terminal transactivation domain, 
comprised of amino acids 30 through 210 (d3-10), was created and termed D14.  Infection of d3-
10 expressing cells with an ICP4 null virus yielded no viral progeny and showed a severe 
deficiency for Early mRNA and protein expression as assessed by qRT-PCR and SDS-PAGE 
analyses, respectively.  The defects observed in transactivation of E genes were a direct result of 
the loss of functions executed by the N-terminus, as the DNA binding and localization functions 
remained intact.  The absence of early gene expression coincided with a defect in the recruitment 
of RNA polymerase II to Early promoters.  Interestingly, immunofluorescence data indicated that 
the mediator complex was not recruited to sites of ICP4 deposition, while TFIID was.  Perhaps 
most interestingly, while TFIID localized to sites of ICP4 deposition, it did not form a complex 
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with d3-10 in affinity purification experiments.  Additionally, when d3-10 was combined with 
the ICP4 mutant n208, which is missing the C-terminal transactivation domain, the defects 
observed were complemented and viral progeny were produced.  This was the result of the 
formation of functional heterodimers, indicating that one functional N- and C-terminal 
transactivation domain within a dimer is sufficient for ICP4 mediated gene expression. 
3.2 INTRODUCTION 
ICP4 of HSV-1 is a 1294 amino acid protein consisting of two transactivation domains separated 
by a DNA binding domain and a nuclear localization sequence (253). It is well established that 
the DNA binding activity of ICP4 is crucial for activation and repression (253, 254, 295).  The 
N-terminal and C-terminal transactivation domains mediate transcription, in part, by interacting 
with several host transcription factors including TBP, TAF1, and the Mediator complex (41, 117, 
198, 303).  It is presumed that through these interactions, RNA Polymerase II is preferentially 
recruited and stabilized on viral promoters, thus driving the initiation of viral transcription (284). 
Genetic and biochemical studies of ICP4 indicate that the protein has a modular structure 
and that individual domains contribute to the activities of the protein differently.  Expression of 
an ICP4 mutant lacking the C-terminal activation domain, n208, displayed reduced levels of E 
gene transcription and biochemically undetectable levels of L gene transcription (70, 295).  
Chromatin immunoprecipitation assays showed that RNA PolII and TBP E promoter occupancy 
was decreased and L promoter occupancy was undetectable in n208 infected cells, probably 
accounting for the reduced levels of E and L gene expression (284).  Interactions with TAF1 of 
TFIID have been mapped to the C-terminus of ICP4, suggesting that the transcriptional defects 
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observed in n208 infected cells were the result of the molecule being less able to stabilize TFIID 
onto promoters (41).  The additional removal of the N-terminal transactivation domain yielded a 
viral mutant (X25) that was not capable of IE gene repression or E or L gene transcription, but 
retained the ability to bind to DNA, suggesting that the C-terminus of ICP4 augmented activities 
specified by the N-terminus (296).  The activities of the C-terminal transactivation domain in the 
absence of the N-terminal transactivation domain have not been determined. 
The N-terminus of ICP4 is structured such that it is largely disordered with small 
conserved structurally ordered regions throughout (340).  Deletion of these regions demonstrated 
that they contribute to the transcriptional activities of ICP4.  The additional removal of the C-
terminal transactivation caused detrimental defects to viral growth, demonstrating that the N-
terminus and C-terminus of ICP4 contain redundant functions (340).  Additionally, these studies 
suggested that regions in the N-terminus may have combined activities, possibly due the 
contributions of these regions in forming contacts with multiple transcription complexes.    
To address whether the N-terminal transactivation domain contained regions specifying 
for combined activities and to determine the sufficiency of the C-terminal transactivation 
domain, a deletion mutant (d3-10) was constructed that deleted amino acids 30-210 from the 
amino terminus of ICP4.  This region contains the majority of the proposed functional region of 
the N-terminus of ICP4, without interfering with regions defining DNA binding activities (254, 
295).  Biochemical analyses indicated that d3-10 is defective in activating E gene transcription, 
probably the result of insufficient recruitment of RNA polymerase II to early promoters as a 
consequence of the inability of the mutant molecule to form complexes with TFIID and possibly 
Mediator.  Additionally, the observed defects of d3-10 could be complemented by the addition of 
a molecule specifying for the N-terminal 774 amino acids.  These data suggest that the C-
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terminal activation domain is not sufficient to support viral transcription and that the N-terminal 
and C-terminal transactivation domains contain combined activities. 
3.3 MATERIALS AND METHODS 
Cells and Viruses.  Vero cells (African Green Monkey Kidney cells) were cultured in 
Dulbecco’s Modified Eagle Medium with 5% FBS and maintained as suggested by ATCC.  E5 
cells are stably transformed with a wtICP4 encoding plasmid, pk1-2 (69), and psV2neo and have 
been describe previously (69).  D14 cells were constructed by transfecting Vero cells with 6ug of 
a plasmid containing the d3-10 mutant and 2 ug psV2neo (see below).  I3 cells were constructed 
by transfecting Vero cells with 6 ug of a plasmid encoding TAP-d3-10 and 2 ug psV2neo (see 
below). 
The viruses KOS, d120 (67), n208 (70), and n12 (70) have been described previously and 
with the exception of KOS, were propagated on E5 cells.  Briefly, d120 has the majority of the 
ICP4 coding sequence deleted, n12 expresses only the first 251 aa, n208 expresses only the first 
774 aa, and KOS is the wild type strain used in these assays.   
Production of stably expressing d3-10 and TAP-d3-10 cell lines.   2 x 106 Vero cells were 
transfected with 2 µg psw2neo and 6 µg d3-10 or TAP-d3-10 plasmid DNA using 15 µL 
lipofectamine 2000 according to the manufacturers suggestion (Invitrogen).  The d3-10 plasmid 
contains the ICP4 d3-10 deletion mutant driven by its own promoter (295).  The TAP-d3-10 
plasmid contains a streptavidin binding peptide and a calmodulin binding peptide (Stratagene) N-
terminal to the d3-10 ICP4 under control of its endogenous promoter.  Two days post 
transfection the cells were trypsinized, counted, and approximately 10,000 cells were plated on 
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100 mm dishes in DMEM with 10% FBS.  The following day the medium was replaced with 
DMEM containing 10% FBS and 800 µg/mL G418 (Invitrogen), allowing for selection of 
neomycin resistant cells.  Medium was replaced every 3-4 days for 17 days until sufficient 
colonies of cells were visible.  Forty colonies were isolated from 9 plates of cells, expanded, and 
characterized for d3-10 protein expression.  Eighteen colonies were isolated from 10 plates of 
cells, expanded, and characterized for TAP-d3-10 expression. Cultures from isolated colonies 
were maintained in DMEM with 5% FBS and 500 µg/mL.  Nine of the 40 and 5 of the 18 clones 
were positive for expression of the d3-10 or TAP-d3-10 protein, respectively, as determined by 
infection with the ICP4 null virus d120 followed by Western blot analysis.  An isolate expressing 
comparable level of the d3-10 protein to wtICP4 from KOS infected cells was utilized for the 
assays described herein.  The isolate expressing the most TAP-d3-10 (I3) was utilized for the 
affinity purification assays.   
SDS PAGE and Western Blot Analyses.  SDS-PAGE assays and Western blot analyses were 
performed as previously described (340).  Briefly, 10% polyacrylamide Tris-HCl gels (Biorad) 
were loaded with samples diluted in Laemmli buffer (0.05 M Tris-HCl, 2% SDS, 5% β-
mercaptoethanol, 0.01% bromophenol blue, 5% sucrose).  Electrophoresis was carried out using 
Tris-Glycine Electrode buffer pH 8.5 (25 mM Tris-HCl; 192 mM Glycine; 1% SDS) at 140 V for 
1.25 hours.  Samples subjected to Western blot analyses were transferred to a nitrocellulose 
membrane in transfer buffer (25 mM Tris-HCl; 192 mM Glycine; 20% methanol) at 250 mA for 
1.5 hours.  Immunoblots were blocked in a 5% milk TBS-T (50 mM TrisHCl, 150 mM NaCl, 
0.05% Tween20; pH 7.5) overnight. Immunoblots were incubated with primary antibodies for 
ICP4 (58S; 1:500) for 1hour at ambient temperature.  Immunoblots were washed 4 times for a 
total of 30minutes in 1% milk TBS-T, then incubated with IRDye conjugated secondary 
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antibodies (LICOR) in TBS-T (1:10,000) for 1hour, rinsed 4 times for a total of 30 minutes in 
TBS-T, twice for 5 minutes in TBS (50 mM TrisHCl, 150 mM NaCl pH 7.5), and finally 
visualized using the LI-COR Odyssey Infrared Imager.   
Metabolic Labeling of Polypeptides.   Metabolic Labeling experiments were performed as 
previously described (54, 340) with the following modifications.  Five hundred thousand Vero, 
E5, or D14 cells were infected at an MOI of 1 with KOS or an MOI of 10 with d120 for 1hr at 
room temperature.  The infections were allowed to progress at 37° for 3.5, 7.5, 11.5, or 23.5hrs at 
which time the cysteine and methionine-free medium was removed and cells were incubated 
with 22 µCi 35S-Methionine (>1000 Ci/mMol, MP Biomedical) in TBS for 30minutes at 37°. 
Labeled proteins were separated through a stacking gel (4% acrylamide, 0.2% DATD, 0.1% 
SDS, 119 mM Tris, pH7.0) and then through a separating gel (9% acrylamide, 0.2% DATD, 375 
mM Tris, 0.1% SDS, pH 8.8) at 100V.  The gel was fixed in fixing solution (water: methanol: 
acetic acid at a 6:3:1 ratio) and subjected to autoradiography.   
Immunofluorescence Assays.  Two hundred thousand Vero, E5, or D14 cells were grown on 
glass coverslips in 12-well trays.  Cells were infected at the indicated MOIs (1 for PML 
experiments, 10 for all other experiments) for 1hr at room temperature.  The inoculum was 
removed and fresh media was added.  The infections were carried out at 37° for the indicated 
period of time.  Cells were washed in PBS and then fixed in 4% PFA for 10 minutes.  If the cells 
were detergent extracted, they were rinsed in PBS containing a 1X protease inhibitor cocktail 
(Roche), and extracted in extraction buffer (10 mM Hepes pH 7.4, 300 mM sucrose, 100 mM 
NaCl, 3 mM MgCl2, 0.5% Triton-X-100) on ice for 2 minutes before fixation with PFA.  Fixed 
cells were permeablized in PBS containing 1% BSA and 0.4% Triton-X-100 for 30 minutes.  
Cells were blocked in PBS containing 1% BSA for an additional 30 minutes.  Cells were 
 97 
exposed to primary antibodies for 1 hour [ICP4: N15 1:500, 58S 1:500; Trap220: (Santa Cruz, 
sc-8998) 1:250; TBP: (Santa Cruz, sc-273) 1:150], washed in PBS+ 1% BSA for 30 minutes, and 
washed in PBS 3 times for a total of 30 minutes.  Cells were incubated with Alexa-Fluor 
conjugated secondary antibodies at a 1:500 dilution for 45 minutes before being washed 6 times 
for a total of 60 minutes in PBS and mounted to glass slides using Immu-Mount (Thermo-
Fisher).  Fluorescence was visualized using the Olympus Fluoview 1000.   
Complementation Assays.  5 x 105 Vero, E5, or D14 cells were infected at an MOI of 5 for 1 
hour at room temperature.  The inoculum was removed, the cells were washed three times in cold 
TBS, and fresh media was added.  At 24 hpi, infected cells were harvested in their own media, 
freeze-thawed three times, sonicated for 45 sec, and the viral lysates were clarified.  Total viral 
yields were determined by plaque assay on E5 cells. 
Affinity Purification.  5 x 105 Vero, E5, D14, or I3 cells were infected at an MOI of 10 with 
KOS, n208, TAP-ICP4, TAP-n208, or d120 for 1hr at 37°.  The inoculum was removed, fresh 
media was added, and infected cells were placed at 37° for 5 hours longer.  Cells were washed 
once with TBS + 0.1 mM TLCK, and scraped into 10mL TBS + 0.1 mM TLCK.  Nuclear 
extracts were collected as previously described by Dignam (76).  Briefly, the cells were pelleted 
at 3 K for 5 minutes, and resuspended in 5 mL Hypotonic buffer (10 mM Hepes pH7.9, 1.5 mM 
MgCl2, 10 mM KCl).  The cells were allowed to swell on ice for 10 minutes before being 
dounced.  Trypan blue staining assessed the douncing efficiency.  Nuclei were pelleted for 10 
min at 3 K.  Nuclei were resuspended in ½ the pellet volume low salt buffer (20 mM Hepes pH 
7.9, 20% glycerol, 1.5 mM MgCl2, 20 mM KCl) and ⅓ the total volume of high salt buffer (20 
mM Hepes pH 7.9, 20% glycerol, 1.5 mM MgCl2, 1.4 M KCl) was added dropwise.  Extracts 
were rotated end over end for 30minutes at 4° and spun at 12.5 K for 30 minutes.  The nuclear 
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extracts diluted with 2X low salt streptavidin buffer (20 mM Hepes pH 7.9, 20 mM KCl, 4 mM 
EDTA, 0.2% NP40) and were then combined with 100 µL streptavidin beads (Pierce) and rotated 
overnight at 4°.  The beads were washed in Streptavidin Binding Buffer (SBB) (20 mM Hepes 
pH 7.9, 200 mM KCl, 2 mM EDTA, 0.1%NP40) 6 times for 10 minutes.  500 µL Laemelli buffer 
was added to the beads.  These samples were subjected to SDS-PAGE and Western blot analysis. 
RNA Extraction and Quantification.  RNA extraction and quantitation experiments were 
carried out as previously described with modifications (101).  Vero, E5, or D14 cells were 
infected at an MOI of 10 with the indicated viruses.  RNA was extracted from the cells using the 
RNAqueous-4PCR Kit from Ambion and the included protocol.  
One microgram of RNA was reverse transcribed to cDNA using the Retroscript Kit from 
Ambion following the included protocol.  Briefly, 1 µg total RNA was combined with 2 µL 
Oligo(dT) in a final volume of 12 µL and heated to 85° for 3 minutes.  The RNA-oligo(dT) 
mixture was combined with 2 µL 10X RT Buffer, 4 µL dNTP mix, 1 µL RNAse Inhibitor, and 1 
µL MMLV-RT.  The RNA was reverse transcribed at 42° for 1 hr.  The MMLV-RT was 
inactivated by heating the reaction to 92° for 10 minutes.   
Chromatin Immunoprecipitation.  Chromatin Immunoprecipitation assays were carried out as 
previously described (99-101, 198, 284). Briefly, 5 x106 Vero, E5, or D14 cells were plated onto 
100 mM dishes.  Cells were infected with the indicated viruses at an MOI of 10 for one hour at 
room temperature.  Following adsorption fresh DMEM + 5% FBS was added to each plate and 
the plates were incubated at 37° for 3 hours 15 min at which time the medium was removed and 
crosslinking reagent (1% formaldehyde, 0.15% sodium bicarbonate, in DMEM + 5% FBS) was 
added.  The samples were crosslinked for 10 minutes at 37°.  Formaldehyde was quenched by 
the addition of glycine to the medium to a final concentration of 125 mM.  Cells were washed 
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twice in TBS and scraped into TBS.  The cells were briefly pelleted, resuspended in 500 µL 
SDS-Lysis Buffer, (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1) and incubated on ice for 
30 minutes. The cells were sonicated 6 times for 10 sec each time at a 30% output using a probe 
sonicator.  The cell debris was pelleted at 12.5 K for 15 minutes and the sonicated chromatin was 
diluted 11 times in ChIP dilution buffer (0.01% SDS, 1.1% TritonX100, 1.2 mM EDTA, 20 mM 
Tris-HCl pH 8.1, 167 mM NaCl).  The samples were pre-cleared twice for two hours using 120 
uL of protein A agarose + ssDNA beads (Milipore) each time.  The pre-cleared samples were 
divided into five samples and the immunoprecipitations were performed overnight using 30 µL 
Protein A agarose + ssDNA beads and either 5 µL of 58S antibody for ICP4 and 2 µL 8WG16 
antibody for RNA Polymerase II.  Beads containing the precipitated protein/DNA were washed 
twice for 4minutes each in Low Salt Buffer (0.1% SDS, 1% Triton X 100, 2 mM EDTA, 20 mM 
Tris-HCl pH 8.1, 150 mM NaCl), twice for 4minutes each in High Salt Buffer (0.1% SDS, 1% 
Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 500 mM NaCl), once for 4 minutes in 
LiCl Buffer (0.25 mM LiCl, 1% NP40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 
8.1), and three times for 4 minutes each in TE Buffer (10mM Tris-HCl pH=8.0, 1mM EDTA).  
The samples were eluted from the beads in 250 µL of Elution Buffer (1% SDS, 0.1 M sodium 
bicarbonate) twice for 15 minutes each.  Twenty microliters of 5 M NaCl was added to each 500 
uL sample and samples were incubated at 65° overnight to reverse the crosslinks.  Thirty-one 
microliters of a Proteinase K Mix (1:2:1 0.5 M EDTA: Tris-HCl pH 6.5: 20 mg/mL ProteinaseK) 
was added to each tube and samples were incubated at 55° for 2 hours.  DNA was purified using 
phenol chloroform extractions.  The purified DNA was precipitated with ethanol, resuspended in 
60 µL DNAse/RNAse free water and analyzed using qPCR with primers for the tk promoter 
were 5’CAGCTGCTTCATCCCCGTGG and 5’AGATCTGCGGCACGCTGTTG.    
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qPCR.  qPCR reactions were set up such that they contained 7.5 µL SYBER Green 2X PCR 
mix, a final concentration of 0.3 µM primers (see charts below), and 3 µL cDNA (from RNA 
experiments) or DNA (from ChIP experiments) in a total volume of 15 µL.  The reactions were 
carried out in a StepOnePlus Real Time PCR machine from Applied Biosystems under the 
following conditions: 95° for 10 minutes followed by 40 cycles of 95° for 15 seconds and 60° for 
1 minute.  A melt curve was also included with the following conditions: 95° for 15 seconds, 60° 
for 1 minute followed by +0.3° to 95° for 15 minutes.  For cDNA quantification the primers used 
were 5’ACCCGCTTAACAGCGTCAACA3’ and 5’CCAAAGAGGTGCGGGAGTTT3’ for tk 
and 5’ACTTAATCAGGTTGTTGCCG3’ and 5’GAAGTTGTGGACTGGGAAGG3’ for ICP4.   
3.4 RESULTS 
The HSV-1 protein ICP4 temporally regulates viral gene expression by promoting 
transcription of E and L genes while concomitantly downregulating transcription of IE 
genes.  These functions can be attributed to the abilities of ICP4 to bind DNA through its DNA 
binding domain and to interact with cellular transcription factors through two transactivation 
domains. It has been established that each of the transactivation domains is required to different 
extents for activation and repression. According to earlier findings, regions within the N-
terminus of ICP4 significantly contribute to E gene transcription (11, 69, 340). Additionally, 
non-overlapping regions of the N-terminus have detrimental, but different, effects on early gene 
transcription; deletion of amino acids 30-142 resulted in lower levels of E transcripts while 
deletion of amino acids 142-210 resulted in the delayed accumulation of E transcripts (340).  
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Based on these observations, the extent to which the N-terminal transactivation domain of ICP4 
contributed to the activation of E gene transcription was investigated.   
A mutant, d3-10, containing a deletion of amino acids 30-210 was constructed to 
investigate the contributions of the N-terminus of ICP4 to viral transcription.  This region 
comprises the majority of the amino terminal transactivation domain without interfering with the 
DNA binding domain (9, 11) (Figure 18 A).   Because constructing the deletion within the viral 
genome was not possible, probably due to the transdominant nature of the molecule (data not 
shown), a cell line stably transfected with a plasmid encoding d3-10 under control of the wt ICP4 
promoter was constructed.  Several clonal isolates were tested for expression of the d3-10 protein 
via Western blot analysis (data not shown) and the D14 clonal isolate was chosen for use in these 
studies because it expressed comparable levels of ICP4 protein as KOS infected Vero cells 
(Figure 18B).  Results from Western blot analysis of samples collected from mock, KOS, or and 
ICP4 null virus, d120 (67), infected Vero, E5, or D14 cells, are shown in Figure 18B.   The 
presence of immunoreactive bands at 175 and 125 kDa of similar intensities established that E5 
cells and D14 cells, expressed similar levels of wild type or mutant ICP4, respectively, as KOS 
infected Vero cells.   
To determine if deletion of amino acids 30-210 interfered with the ability of the molecule 
to localize to and bind viral genomes, immunofluorescence and chromatin immunoprecipitation 
assays were performed.  It has been previously reported that viral genomes localize to PML 
bodies in infected cells and that ICP4 localizes juxtaposed to viral genome containing PML 
bodies (92, 142).  Accordingly, Vero, E5, or D14 cells were infected with d120 at a multiplicity 
of 1 pfu/cell and processed for immunofluorescence at 2 hpi (Fig 18C).  White arrows in the 
merged panels indicate the juxtaposed ICP4 and PML foci.  A d3-10 focus can clearly be 
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observed next to a PML focus in infected D14 cells indicating d3-10 localized to sites of viral 
genome deposition.   
Chromatin immunopreciptation (ChIP) assays were performed to determine if d3-10 
bound viral DNA.  Vero or D14 cells were infected with d120, at multiplicity of 10 pfu/cell for 
3.25 hours.  KOS infected Vero cells were used as a positive control in this assay, while i13 or 
d120 infected Vero cells served as negative controls (284).  The viral mutant i13 produces a full 
length ICP4 protein that is defective in binding to DNA due to a small insertion within the DNA 
binding domain (293).  A monoclonal antibody that reacts with the C-terminus of ICP4, 58S 
(298), was used in the ChIP experiment, and the percentage of genomes containing ICP4 bound 
to the tk promoter was analyzed.  The results from a representative assay are shown in Figure 
18D.  The ChIP assays were performed on three independent biological samples (Figure 18E).  
d3-10 and wtICP4 bound more genomes at the tk promoter than the negative controls in each 
independent sample.  Taken together, the Western blot, immunofluorescence, and ChIP analyses 
demonstrated that D14 cells produced the d3-10 protein to comparable levels as a KOS infection 
and that the d3-10 protein localized to and bound viral DNA.   
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Figure 18:  Characterization of d3-10 Expressing Cells.   
(A) Schematic of the primary structure of ICP4 mutant molecules. (B) Western blot analysis of a 
d3-10 expressing cell line (D14 cells).  Cells were mock infected or infected with KOS or the 
ICP4 null virus d120 at an MOI of 10.  Infected whole cell extracts were subjected to western 
blot analyses using an antibody against the C-terminus of ICP4 (58S).  (C) The localization of 
wtICP4 and d3-10 was compared to viral genome distribution (PML bodies) via 
immunofluorescence assays.  (D) The ability of d3-10 to bind to viral DNA was assessed via 
chromatin immunoprecipitation.  Data is presented as the percentage of input genomes bound by 
ICP4. (E)  ChIP assays results from 3 independent biological samples.  
 
ICP4-mediated Activation of E gene Expression Requires the N-Terminal Activation 
Domain. 
The previous experiments established that the regions deleted in d3-10 did not affect the 
ability of the molecule to localize to or bind viral DNA, therefore the contributions of the deleted 
region to viral transcription and replication were addressed. To determine the contributions of 
amino acids 30-210 in viral replication, the ability of the d3-10 protein to complement an ICP4 
null virus, d120, was examined.  Vero, E5, or D14 cells were infected with d120 at a multiplicity 
of 10 pfu/cell.  Viral lysates were harvested 24 hours post infection (hpi) and viral yields were 
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determined by plaque assay on the complementing E5 cell line.  Figure 19A shows average viral 
yields from this assay.  d120 infection of the wtICP4 producing E5 cells produced nearly 108 
pfu/mL while infection of either Vero cells or D14 cells produced less than 104 pfu/mL.  These 
data demonstrated that the d3-10 protein did not complement an ICP4 null virus, indicating a 
severe defect in ICP4 function.   
The inability of the d3-10 protein to complement d120 suggested that d3-10 may be 
defective for the activation or repression of viral transcription.  To investigate this, qRT-PCR 
was used to determine the relative quantities of tk and ICP4 mRNA present in d120 infected cell 
extracts at 4 hpi.  Figure 19 B shows the percentage of tk mRNA quantities relative to that of E5 
cells.  Vero cells, which do not produce ICP4, expressed only 4.1% of the amount of tk mRNA 
as E5 cells.  This represents transcription independent of ICP4 activation, and is similar to 
previously reported levels of tk RNA expression in the absence of functional ICP4 (141).  
Similarly, infection of D14 cells yielded only 4.6% of the amount of tk mRNA as E5 cells, 
indicating that the d3-10 protein was not capable of promoting E gene transcription. 
ICP4 mRNA quantities from KOS, d120, or n12 infected Vero, E5, and D14 cells, were 
analyzed to determine whether amino acids 30-210 contributed to the repression of viral 
transcription.  Upon activation of E genes, ICP4 binds to a site within its own promoter and 
prevents the activation of transcription, thus causing reduced accumulation of ICP4 mRNA (176, 
177, 233). The viral mutant n12 expresses only the first 251 aa of the ICP4 protein, and as such, 
lacks the DNA binding domain rendering it defective for the repression of transcription (70).  
n12 infection of Vero cells yielded approximately 3 times more ICP4 mRNA than did infection 
of E5 cells, demonstrating the expected defect of n12 in repression (Figure 19 C).  Conversely, 
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n12 infection of D14 cells yielded similar amounts of ICP4 mRNA as either KOS infected Vero 
cells or n12 infected E5 cells, indicating that the d3-10 protein retained repression activity.  
While mRNA quantification data indicated amino acids 30-210 were dispensable for the 
repression functions but necessary for the activation functions of ICP4, these conclusions were 
drawn based on two representative genes.  To obtain a better understanding of global expression 
patterns, protein synthesis profiles from d120 infected Vero, E5, and D14 cells were analyzed.  
Vero, E5, and D14 cells were infected at a multiplicity of 10 pfu/cell in methionine free medium 
for 3.5, 7.5, or 11.5 hours, at which point S35-Methionine was added to cultures and allowed to 
incorporate into synthesizing polypeptides for 30 minutes.  The polypeptides were separated by 
SDS-PAGE and visualized by autoradiography.  Results of these assays showed reduced levels 
of IE protein synthesis in d120 infected D14 cells compared to Vero cells, despite equal amounts 
of cellular extract being loaded (Figure 19D; see ICP4, ICP0, ICP22, ICP27 and actin).  
Interestingly, D14 cells showed only IE protein synthesis; E and L protein expression was absent 
in D14 cells when compared to E5 cells (Figure 19D; see VP1/2, ICP8, gB, pgB, VP16). Taken 
together, the complementation, mRNA abundance, and protein expression data indicated that the 
amino acids 30-210 of the N-terminal transactivation domain are necessary for the activation of 
E gene transcription, but not IE gene repression.  
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Figure 19: The N-terminus of ICP4 is Necessary For Trans-activation But Not Repression. 
(A) Viral yield from d120 infected cells.  Vero, E5, or D14 cells were infected at a multiplicity 
of 10 pfu/cell with the ICP4 null virus, d120.  Viral lysates were collected 24 hpi, and viral 
yields were assessed by plaque assay on the E5 complementing cell line.  (B) tk or (C) ICP4 
mRNA expression levels in infected cells.  RNA was harvested from Vero, E5, or D14 cells 
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infected with the indicated virus at a multiplicity of 10 pfu/cell for 4hrs.  1 ug of mRNA was 
reversed transcribed into cDNA, and tk and ICP4 mRNA was quantified using qRT-PCR.  (B) 
Numbers are representative of the percentage of tk expression compared to that in wtICP4 
expressing E5 cells.  (D) Protein synthesis in d120 infected cells.  Vero, E5, or D14 cells were 
infected at a multiplicity of 10 pfu/cell for 3.5, 7.5, or 11.5 hours with d120, or D14 cells were 
mock infected (M).  Cells were incubated with 22 uCi 35S-Methionine for 30 minutes.  Labeled 
polypeptides were separated via SDS-PAGE and visualized via autoradiography.  Protein 
identities are labeled.   
 
The N-terminus of ICP4 is required for transcription complex formation 
To address the basis for the reduced levels of E and L transcription in d3-10 expressing 
cells, the ability of PolII to bind to viral promoters was examined using a ChIP assay.  Vero or 
D14 cells were infected with d120, i13, or KOS at a multiplicity of 10 pfu/cell for 3.25 hours.  
Immunoprecipitation was performed with an antibody directed against PolII and 
immunoprecipitated DNA was amplified with primers specific to the tk promoter.  The results 
from the ChIP assays demonstrated that PolII bound larger percentages of genomes at the tk 
promoter in KOS infected cells than in d3-10 expressing cells.  The percentage of genomes 
bound by PolII at the tk promoter in d3-10 expressing cells was similar to that observed in d120 
or i13 infected Vero cells (Figure 20A).  ChIP assays were performed in triplicate on 
independent biological samples and results are shown in Figure 20B.  These data demonstrated 
that PolII is absent on a representative E promoter in d3-10 expressing cells, explaining the 
defects observed in E gene transcription (Figure 19).  
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Figure 20:  RNA PolII does not bind to Early promoters in d3-10 expressing cells.  
(A) Percentage of genomes bound by PolII at the tk promoter.  (B) Results from 3 independent 
biological samples.   
The results from the ChIP assays demonstrated that the observed defects in E gene 
transcription in d3-10 expressing cells were the result of reduced PolII recruitment to viral 
promoters.  TFIID and Mediator are largely involved in recruiting and stabilizing RNA PolII to 
TATA driven promoters and wtICP4 exists in complexes with these factors (198).  To determine 
whether amino acids 30-210 were important for TFIID and Mediator interactions, 
immunofluorescence and affinity purification assays using d3-10 expressing cells were 
performed.   
The cellular localization of TFIID and Mediator relative to d3-10 was investigated using 
immunofluorescence assays.  Vero, E5, or D14 cells were infected with d120 at an MOI of 10 for 
6 hr.  Samples were processed for immunofluorescence with antibodies directed against ICP4 
and TBP (Figure 21 A) or Med1 of Mediator (Figure 21 B).  At 6 hpi wtICP4 was present in 
large replication compartments that included both TFIID and Mediator, consistent with previous 
findings (Figure 21 A & B) (198).  Replication compartments are indicative of both high levels 
of transcription and DNA replication (375).  d3-10 expressing cells were defective in E gene 
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transcription, and consequently would not replicate viral DNA, therefore, replication 
compartments did not form (Figure 21).  Instead, d3-10 remained localized in small punctate foci 
within the nucleus, which are referred to as pre-replication compartments (Figure 21).  TBP and 
d3-10 co-localized in some pre-replication compartments (Figure 21A, panel 3), suggesting that 
TBP and d3-10 formed a complex in infected cells.  Interestingly, Mediator was not present in 
pre-replication compartments (Figure 21B, panel 3), suggesting a role for amino acids 30-210 in 
interactions with Mediator.  To demonstrate that Mediator localized to pre-replication 
compartments with wtICP4, d120 infected E5 were also processed for immunofluorescence at 2 
hpi, which coincides with pre-replication compartment formation in wild type infection.  It is 
evident from the co-localization of wtICP4 and Mediator at 2 hpi, that Mediator was present in 
pre-replication compartments with wtICP4.  
 110 
 
Figure 21: TBP is recruited to d3-10 complexes but Mediator is not.   
Immunofluorescence assays of d120 infected cells. (A) ICP4 and TBP at 6 hpi. (B) ICP4 and 
Trap220 of Mediator at 6 hpi.  (C).  ICP4 and Trap220 at 2 hpi.  
 
To assess whether d3-10 could form complexes with TFIID in infected cells, affinity 
purification of the d3-10 protein was performed.  The d3-10 protein was genetically engineered 
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to contain a Tandem Affinity Purification (TAP) tag (Stratagene) at the N-terminus of the 
protein, and a stable cell line (I3) expressing the TAP-d3-10 under the ICP4 promoter was 
created.  The TAP tag consists of a calmodulin binding peptide N-terminal to a streptavidin 
binding peptide.  The TAP-tagged protein can then be purified using a streptavidin conjugated 
matrix, eluted with biotin, and further purified on a calmodulin-conjugated matrix if necessary.  
For the purposes of these studies purification using the streptavidin conjugated matrix was 
sufficient.  As a control a TAP-tagged version of wtICP4 was constructed within the context of 
the viral genome and also purified over a streptavidin-conjugated matrix.  Untagged versions of 
wtICP4 from KOS and d3-10 from D14 cells served as negative controls.  
To identify whether TFIID was present d3-10 purified samples, immunoblots with 
antibodies directed against ICP4, TBP, or TAF1 were performed (Figure 22).  The presence of 
strong immunoreactive bands at the correct molecular weights on the immunoblot of ICP4 
indicated that TAP-ICP4 and TAP-d3-10 were isolated to significant quantities using this 
procedure (Figure 22; panel 1).  Despite having approximately equal amounts of both TBP and 
TAF1 in all of the infected cell nuclear extracts, TBP and TAF1 were only present in the TAP-
ICP4 samples, not the TAP-d3-10 (I3) samples (Figure 22; panels 2 & 3).  This is evident by the 
absence of strong immunoreactive bands in the I3 pull down lanes of both the TBP and TAF1 
immunoblot (Figure 22; panels 2 & 3).  This result was perhaps surprising as TBP co-localized 
with d3-10 in infected cells.  This may suggest that d3-10 can very weakly associate with TFIID 
in infected cells, but that this association is lost upon manipulation of the protein.  Conversely, 
this may suggest that the d3-10 protein cannot associate with TFIID, and that the TFIID co-
localization with d3-10 is ICP4 independent.    
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Figure 22: d3-10 does not co-purify with TFIID from infected cells.   
KOS expresses wtICP4, TAP expresses TAP-ICP4, D14 cells express d3-10 and I3 cells express 
TAP-d3-10 upon infection with d120.  ICP4 complexes were purified and the presence of TBP 
and TAF1 were determined by immunoblot for ICP4, TBP, and TAF1.  Nuclear extracts (NE) 
and pull downs (PD) were used. 
 
Intragenic Complementation of ICP4 
ICP4 mutants can function together to complement the defects observed within each 
individual mutant (293, 294).  For example, a mutant defective in DNA binding (d2) can be 
paired with a mutant defective for transactivation (n208) to form a functional molecule (294).  
The formation of a functional molecule can be attributed to the dimerization properties of ICP4.  
In this respect, it can be hypothesized that d3-10, which is missing the N-terminal transactivation 
domain, and n208, which is missing the C-terminal transactivation domain could form a 
functional heterodimer and complement the defects observed in gene expression (69, 70).   
To investigate this a complementation assay was performed.  Vero, E5, and D14 cells 
were infected with n208 at a multiplicity of 5 pfu/cell, infected cell lysates were harvested at 24 
hpi, and viral yields were determined by titration on the complementing E5 cell line.  In 
accordance with previously published data, yields from n208 infected Vero cells were reduced 
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by more than 1.5 log when compared yields for the complementing E5 cell line (Figure 23 A) 
(70, 340).  Interestingly, n208 infection of D14 cells yielded similar levels of viral progeny as 
infection of E5 cells (slightly under 107 pfu).  Therefore, n208 and d3-10 complement each other.  
n208 has previously been shown to be defective in forming replication compartments, a 
hallmark of DNA replication and L gene expression (294).  As shown in Figure 21, d3-10 
expression alone did not result in the formation of replication compartments.  Instead, d3-10 
formed small aggregates in the nucleus, consistent with pre-replication compartments (169, 207). 
It was hypothesized that n208 infection of D14 cells would result in the production of viral 
replication compartments because n208 and d3-10 complement at the level of viral replication.  
To more closely investigate the nuclear distribution of n208 in infected D14 cells, 
immunofluorescence assays were performed.  D14 cells were infected with n208 for 6 hours and 
samples were processed for immunofluorescence (Figure 23 B).  d3-10 was detected with the C-
terminal ICP4 antibody 58S while n208 was detected with the N-terminal antibody N15.  
Immunofluorescence assays demonstrated that, consistent with previously published data, n208 
expression in Vero cells yielded a robust nuclear stain, with no discernable foci or replication 
compartments (Figure 23 B panel 1) (294). Conversely, n208 infection of D14 cells yielded cells 
with large nuclear replication compartments (Figure 23 B single cell), indicative of increased 
viral transcription and viral DNA replication.  The replication compartments formed in n208 
infected d3-10 cells were similar in morphology to previously published work and would be 
consistent with the increased viral yields seen in Figure 23 A (169, 375).  
To determine whether d3-10 and n208 complementation was the result of the formation 
of functional heterodimers, a TAP-tagged version of n208 was utilized.  To establish that d3-10 
and n208 could form a heterodimer, D14 cells were infected with n208 or TAP-n208, TAP-n208 
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containing complexes were affinity purified, and the presence of d3-10 in these complexes was 
assessed via immunoblotting.  Figure 23 C is an immunoblot for n208 (N15) and d3-10 (58S).  
As a control, n208 infected Vero and E5 cells were also utilized in this assay.  Affinity 
purification of TAP-n208 from E5 cells yielded two bands in the pull down (PD), one 
corresponding to n208 (red) and one corresponding to wtICP4 (yellow).  This indicated that 
wtICP4 and TAP-n208 could form heterodimers and validated the use of this assay.  
Additionally, a portion of wtICP4 (green) remained in the flow through (FT), and corresponded 
to wtICP4 homodimers.  Affinity purification of TAP-n208 from infected D14 cells resulted in 
the presence of two bands in the PD (both d3-10 [green] and n208 [red]; lane 12), and only one 
band in the flow through (lane 11) corresponding to the d3-10 protein that did not form 
heterodimers with TAP-n208.   
Affinity purification data suggested that the defects observed with the d3-10 mutant were 
a result of ablated interactions with TFIID.  To determine whether the formation of an n208-d3-
10 heterodimer reconstituted this function, TAPd3-10 expressing cells were infected with n208 
and complexes were affinity purified over a streptavidin matrix (Figure 23 D).  This provided for 
isolation of proteins in complex with only TAPd3-10 homodimers and TAPd3-10-n208 
heterodimers. As controls, Vero cells were infected with either KOS or TAP, which contains a 
TAP-tagged full length ICP4, and D14 and I3 cells were infected with d120.  The presence of an 
immunoreactive band in the TAP PD but not I3 PD lanes in an immunoblot for TBP indicated 
that TBP was isolated with TAP-ICP4, but not with TAPd3-10 (Figure 23 D, lanes 4 and 12).   
Significantly, purification of TAPd3-10-n208 heterodimers resulted in isolation of TBP (Figure 
23D, lane 8).  Taken together, these data support a model in which the complementation of n208 
and d3-10 occurs through the ability of the two proteins to form a more functional dimer.  
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Figure 23: Intragenic complementation of ICP4.   
(A) Complementation assay from n208 infection of Vero, E5, and D14 cells.  (B) 
Immunofluorescence with antibodies specific for d3-10 (58S; green) and n208 (N15; red).  (C) 
Western blot analysis of TAP purified ICP4 complexes.  Both the flow through (FT) and pull 
down (PD) were analyzed.  Antibodies for d3-10 (58S; green) and n208 (N15; red) were used for 
the immunoblot.   (D) Western blot analyses of affinity purified d3-10-n208 heterodimers.   
 
3.5 DICUSSION 
ICP4 has two discontinuous regions that are involved in the transactivation of 
transcription, one N-terminal and one C-terminal to the DNA binding domain.  Previous studies 
demonstrated that the N-terminal transactivation domain is sufficient for viral growth (70).  This 
study investigated the requirement of the N-terminal transactivation domain to the activities of 
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ICP4 with respect to viral gene transcription, and the possible sufficiency of the C-terminal 
transactivation domain. The data demonstrated that the N-terminus of ICP4 was necessary for 
ICP4 mediated transcription, as early gene expression was ablated when the d3-10 mutant 
protein was expressed.  The C-terminus and the DNA binding domains were unable to activate 
transcription, however, supplying the N-terminus in trans could complement this defect.  The 
proposed causes for the transcription defects observed are discussed below.  
It has been previously demonstrated that ICP4 interacts with a variety of transcription 
factors including TFIID and Mediator to stabilize transcription initiation machinery on HSV 
promoters (41, 117, 198, 284, 373).  The data presented herein demonstrated that amino acids 
30-210 of the N-terminal transactivation domain were required for the activation of viral 
transcription through the activities of these regions in forming complexes with TFIID and 
Mediator.  The N-terminus of ICP4 contains several stretches of 10-20 highly conserved amino 
acids that individually contribute to viral growth or transcription (340).  Here we show that 
deletion of all of these regions, in addition to the degenerate, disordered regions flanking them 
resulted in the ablation of E transcription.  This suggests that the N-terminus may form a tertiary 
structure that enhances the binding of transcription complexes, such as TFIID and Mediator.  
The N-terminus of ICP4 contains stretches of amino acids that are conserved in other 
ICP4 analogs and are predicted to be relatively disordered, respectively (340).  The flexibility of 
the disordered regions and the specificity of the conserved regions likely allow ICP4 to interact 
with multiple surfaces of transcription complexes.  A key example of this is the interaction with 
and stabilization of TFIID.  The C-terminus of ICP4 has been shown to interact with TAF1 while 
the N-terminal 774 amino acids were sufficient for interactions with TBP, both components of 
TFIID (41, 303).  Deletion of amino acids 81-96 in addition to the C-terminal transactivation 
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domain eliminated ICP4 mediated viral transcription, perhaps suggesting that both of these 
regions stabilize interactions with TFIID (340).  Interestingly, deletion of amino acids 30-210, in 
the presence of the C-terminus, completely abolished interactions with TFIID, while deletion of 
amino acids 81-96 alone presumably did not.  The inability of d3-10 to form complexes with 
TFIID is probably the result of deletion of multiple TFIID interfaces within the N-terminus, 
without which the C-terminal interfaces may be too weak to compensate, suggesting that the 
activities of the N-terminal transactivation domain are augmented by functions of the C-
terminus.  Alternatively, amino acids in the C-terminus and N-terminus affect the conformation 
of each other.   
ICP4 exists as a dimer within infected cell nuclei (223). Previous studies have shown that 
individual defects in ICP4 can be complemented by the formation of a heterodimer.  For 
example, coinfection of a virus encoding an ICP4 molecule deficient in DNA binding activities, 
d2, and the C-terminal truncation mutant, n208 yielded a heterodimer that was capable of 
binding to DNA, suggesting that one functional domain within a dimer was sufficient for 
function (294).  Additional electromobility shift and supershift assays revealed that the 
conformation of the C-terminal transactivation domain of wtICP4 was negatively altered in a 
heterodimer consisting of wtICP4 and the mutant X25, in which both the N-terminal and C-
terminal transactivation domains were deleted (296).  This strongly suggested that the structure 
of one molecule within the dimer directly affected that of the other.  The functional contributions 
of the N-terminal and C-terminal transactivation domains to the formation of a functional dimer 
had not been established. Infection of d3-10 expressing cells with n208 yielded complementation 
at the level of viral production, but more importantly reconstituted the ability of the d3-10 
molecule to interact with TFIID.  This demonstrated not only that one functional N-terminal and 
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C-terminal transactivation domain are sufficient for viral replication, but also that the N-terminus 
and C-terminus of ICP4 cooperate to mediate the activities of ICP4.  Additionally, this implies 
that the N-terminal and C-terminal transactivation domains of opposite molecules within the 
dimer are capable of functioning together, perhaps suggesting a conformation in which they are 
in close proximity within the dimer. 
The data presented here demonstrated that the N-terminal transactivation domain is 
absolutely necessary for ICP4 mediated transcription, yet this region remains very poorly 
conserved amongst alphaherpesviruses.  Interestingly, while ICP4 and the VZV homolog IE62 
have minimal sequence homology within the amino terminus, IE62 can partially complement for 
the absence of ICP4 (98).  This suggests that these viruses evolved to contain similar functions, 
without maintaining sequence homology.  Interestingly, the Ruyechan lab has shown that the N-
terminus of IE62 specifies for interactions with the Mediator complex, a function that, as shown 
here, at least partially resides within the N-terminus of ICP4 (366, 368).   
The work presented herein suggests that ICP4 is a structurally complex molecule 
functioning to provide an interface between multiple viral transcription complexes and viral 
promoters.  The ability of ICP4 to interact with components of the general transcription 
machinery is the direct result of the structural conformations adopted by the dimeric complex.  
The functions provided by ICP4 are integral for viral replication, and as such ICP4 contains 
redundancies throughout the molecule to ensure its function within infected cells.   
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4.0  HSV-1 ICP4 PROVIDES A PLATFORM FOR THE ASSEMBLY OF 
TRANSCRIPTION COMPLEXES 
4.1 ABSTRACT 
Herpes Simplex Virus utilizes general transcription factors (GTFs), activators, and RNA 
polymerase II from the host cell to transcribe its genome.  In addition to cellular factors, the viral 
encoded transactivator, ICP4, promotes the transcription of viral genes by stabilizing 
transcription machinery onto viral promoters.  Previously, our lab has shown that ICP4 forms 
complexes with TFIID and Mediator in infected cells.  Here, we use affinity purification of ICP4 
and western blot analyses to show that there is an ordered recruitment of these factors into ICP4 
containing complexes.  TFIID is present at higher levels in ICP4 containing complexes earlier in 
infection than mediator, indicating a temporal regulation of transcription factor and activator 
recruitment.  Additionally, we can show that the N-terminal 774 amino acids of ICP4 are 
sufficient to form a complex with TFIID and mediator, although these interactions are not as 
strong as with wtICP4.  Perhaps most strikingly, we demonstrate that ICP4 is not only isolated 
with components involved in transcription initiation, but also chromatin modification, 
transcription elongation, and potentially mRNA processing.  Our data show that ICP4 can be 
isolated with the chromatin remodeling factors SWI/SNF, NURD, and the Ino80 complex, 
indicating that ICP4 may have a significant role in chromatin remodeling.  Additionally, the 
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elongation related factors TFIIH and the elongin/SIII complex were isolated in ICP4 containing 
complexes.  Together these data indicate that ICP4 plays a significant role in mediating HSV 
transcription, and that ICP4 may act as hub for cellular transcription factor recruitment, affecting 
multiple steps in the formation of transcription complexes. 
4.2 INTRODUCTION 
ICP4 is an essential viral protein that enhances RNA PolII transcription of viral genes. The 
activities of ICP4 are defined by two transactivation domains separated by a DNA binding 
domain and a nuclear localization sequence (70, 253, 254, 295).  The DNA binding activities are 
essential, but not sufficient, for both the transactivation and repression functions of the molecule 
(117, 253, 254, 295).  The N-terminal and C-terminal transactivation domains are also necessary 
for viral transcription, although to different extents (340).  We have recently shown that the N-
terminal transactivation domain of ICP4 is necessary for E, and as a consequence, L, gene 
transcription (Chapters 2 and 3).  The C-terminal 500 amino acids are necessary for abundant L 
gene expression; without the C-terminus viral growth is attenuated by approximately 100 fold 
(69, 70, 295, 340).  The defect observed in viral growth in the absence of either the N-terminus 
(d3-10) or C-terminus (n208) may be an effect of diminished interactions between ICP4 and 
cellular transcription machinery (Chapter 3).   
ICP4 has been shown to interact with a number of components of the cellular 
transcription machinery.  It was demonstrated that ICP4 directly interacts with the TAF1 and 
TBP components of TFIID (41, 119, 303, 373). These interactions have been mapped to the C- 
and N-termini of ICP4, respectively, suggesting that multiple surfaces of ICP4 contact the TFIID 
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complex (41, 182, 373).  The interaction with multiple subunits of TFIID on differing surfaces of 
ICP4 underscores the importance of this interaction.  Additionally, it is probable that only a 
subset of these interactions are necessary for stabilization of TFIID on promoters, as it has been 
shown that ICP4 contains redundant functions within the N- and C-termini (340).  More recently, 
ICP4 has been shown to co-purify and localize with Mediator in infected cells (198).  The 
structural requirements for interactions with Mediator have not yet been clearly defined, 
although the N-terminus appears to be important (Chapters 2 and 3).   
The current model for viral transcription suggests that the transcription complexes 
formed on the promoters of E and L genes partially defines the temporal kinetics of viral 
transcription.  Interestingly, it has been shown that TAF1 is necessary for L gene expression 
(73).  The C-terminus of ICP4 is necessary for both interactions with TAF1 and L gene 
transcription (41, 70).  These data suggest a potential mechanism of activation of L genes that 
relies on the ability of ICP4 to interact with TAF1 to drive Inr dependent transcription of L genes 
(163).  Likewise, it has been shown that TFIIA is critical for the activation of early, but not L 
genes, partially due to its ability to stabilize TBP, and hence TFIID, to TATA boxes (372, 373), 
providing yet another means for regulation of temporal transcription.  Thus, the tertiary structure 
of ICP4 defines the transcription complexes with which it can interact, which in turn, defines 
temporal transcription from the viral genome.   
The goals of this study were to investigate the structural and temporal basis for ICP4 
mediated interactions with components of the transcription machinery and to isolate novel ICP4 
containing complexes.  To isolate ICP4 containing protein complexes, wtICP4, and the C-
terminal truncation mutant n208, were genetically engineered within the viral genome to contain 
a tandem affinity purification (TAP) tag.  ICP4 containing complexes were purified using a 
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streptavidin conjugated matrix and associated proteins were identified using LC-MS-MS and 
confirmed via western blot analysis.  Data indicates that ICP4 interacts with TFIID prior to the 
Mediator complex and that the N-terminal 774 amino acids are sufficient, but sub-optimal, for 
these interactions.  Additionally, ICP4 co-purifies with components involved in all steps of 
transcription including chromatin remodeling, initiation, elongation, and possibly mRNA 
processing and export.  Together the data suggest that ICP4 may play a significant role in 
regulating transcription at multiple levels.   
4.3 MATERIALS AND METHODS 
Cells and Viruses.  Vero cells (African Green Monkey Kidney cells) were cultured in 
Dulbecco’s Modified Eagle Medium with 5% FBS and maintained as suggested by ATCC.  E5 
cells express complementing levels of wtICP4, and have been described previously (69).  The 
viruses wild type strain KOS and n208 (70) have been previously described.  TAP-KOS and 
TAP-n208 were generated for this study via marker transfer with the TAP-pK1-2 and TAP-pn7 
plasmids (described below), plaque isolated a minimum of three times, and the genotypes were 
confirmed via southern blot and Sanger sequencing.   
 
Recombinant Plasmids.  TAP-ICP4 plasmids were constructed such that the TAP sequence 
would be in frame and 5’ to the ICP4 start site.  wtICP4 and n208 plasmids, pk1-2 and pn7 
respectively, were utilized to construct the TAP-pk1-2 and TAP-pn7 plasmids via RecET 
recombination system, as described previously (327, 328).  Briefly, primers were designed such 
that they would amplify the TAP sequence and a kanamycin resistance cassette from the pTAP-
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KANinv plasmid (a gift of Dr. Paul Kinchington, University of Pittsburgh) and contained 
homology to ICP4 –60 to –20 and -7 to +31, respective to the ICP4 transcription start site (tss).  
The sequences for the primers used to construct the mutants were 
5’CTACCGTGCTACGTCCGCCGTCGCAGGCCGTATCCCCGGAGGTTTAGTGAACCGTC
AGATCCGCTAG3’ and 
5’GAGCCGGGGCGCTGCTTGTTCTCCGACGCCATCGCCGATGGATCCGCCCGGGCGC
CCAGCTTGCAG3’.  Primers were synthesized and gel purified by IDT (Coralville, IA).  
Purified PCR product was transformed into GS1783 cells (a gift of Greg Smith, Northwestern 
University) containing pk1-2 or pn7.  The appropriate colonies were selected for their resistance 
to kanamycin and screened via restriction endonuclease and agarose gel analysis.  Colonies 
containing the appropriate insert were induced with 1% arabinose at 42° to allow for production 
of the SceI enzyme and recombination to occur.  The resultant colonies were screened for 
sensitivity to kanamycin and possession of the appropriate allele via restriction endonuclease and 
agarose gel analysis.   
The m90-GST plasmid was constructed using standard cloning techniques to insert the 
m90 region downstream of a sequence encoding GST in the pGEX-2T plasmid (gift of Dr. 
Martin Schmidt, University of Pittsburgh).  Briefly, the m90 region of ICP4 (+224-+307 bp 
relative to the transcription start site) was amplified via PCR using primers with homology to 
ICP4 and such that EcoRI and BamHI endonuclease recognition sites flanked the m90 region.  
The primers, 5’AGCTTTGGGTGAACAGGATCCGACGCCGTCTCGCCGCGACAGCTG3’ 
and 5’AAATTGGTAACTGCTGAATTCTGCGTCGGGATCGTCCGGACGGCCTC3’, were 
synthesized by IDT (Coralville, IA).  Amplified, PCR product and plasmid pGEX-2T were 
subjected to restriction endonuclease digestion followed by ligation using T4 DNA Ligase 
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according to the manufacturers suggestions (NEB).  Ligated products were transformed into 
DH5α E.coli.  Colonies were selected based on resistance to carbanecillin and the genotype was 
verified via restriction endonuclease and agarose gel analysis and Sanger sequencing (Genewiz, 
South Plainfield, NJ).   
 
Streptavidin Affinity Purification:  2x108 Vero cells were infected at a multiplicity of 10 
pfu/cell with KOS, TAP-ICP4, n208, or TAP-n208 for 3, 6, or 12 hours at 37° prior to 
harvesting.  Cells were rinsed twice with TBS containing 0.1 mM N-p-tosyl-L-lysine 
chloromethyl ketone (TLCK) and scraped into 50 mL TBS + 0.1 mM TLCK.  Cell pellets were 
collected via centrifugation at 5 K for 5 min in the Sorvell RC5 centrifuge.  Nuclei were 
collected and proteins were extracted in 0.4 M KCl as described previously (76, 198).  Nuclear 
extracts were diluted in half in 2 X low salt streptavidin binding buffer (2 X LS SBB) (20 mM 
Hepes KOH pH 7.9, 20 mM KCl, 4 mM EDTA, 0.2% NP40), treated with 300 U benzonase 
nuclease (Novagen) and incubated with 500 µL streptavidin conjugated agarose beads (Pierce) 
overnight at 4° with end over end rotation.  Beads were washed 4 times in 10 mL of streptavidin 
binding buffer (SBB) (20 mM Hepes KOH pH 7.9, 200 mM KCl, 2 mM EDTA, 0.1% NP40).  
Samples were eluted from the beads using 500 µL streptavidin elution buffer (SBB + 2 mM 
Biotin).  Two elutions, each 30 min, and one elution, overnight, were combined and either 
concentrated in 7 mL / 9 kDa iCon concentrator (Pierce) and used for western blot analyses, or 
sent to MS Bioworks (Ann Arbor, MI) for TCA precipitation, in gel digestion, and LC-MS-MS 
analysis.   
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GST Purification.  DH5α cells containing either m90pGEX-2T or pGEX-2T were grown in 
Luria Broth at 37° to an OD600 of 0.5.  Protein expression was induced with 0.1 mM Isopropyl β-
D-1-thiogalactopyranoside (IPTG) for 2hrs.  Cells were harvested, washed in 1 X PBS (137 mM 
NaCl, 2.68 mM KCl, 10.14 mM NaHPO4, 1.76 mM KH2PO4, pH 7.4), and proteins were 
extracted via sonication for 12-20 second pulses at a 50% output (Misonix sonicator 3000 with 
microtip).  GST tagged protein extracts were incubated with 150 µL of 50% slurry of 
equilibrated glutathione sepharose 4B beads (GE#17-0756-01) in PBS.  Unbound proteins were 
washed away with five 5 minute washes in PBS and one 5 minute wash in Low Salt Buffer (100 
mM KCl, 1.5 mM MgCl2, 20% Glycerol, 20 mM Hepes) in the presence of protease inhibitor 
cocktail (Roche).  Nuclear extracts from uninfected HeLa cells (372) were incubated with the 
m90GST and GST peptides immobilized on the glutathione conjugated beads.  Unbound proteins 
were removed with 6 washes for a total of 30minutes in Low Salt Buffer + 0.1 mM TLCK. 
Proteins were eluted in 500 µL Elution Buffer (10 mM Glutathione, 200 mM NaCl, 50 mM Tris-
HCl, pH 8.8) 3 times for 30 minutes each at 4°.  Eluates were concentrated using iCon 7 ml / 9 
KDa Concentrators (Pierce).  Samples were analyzed via silver stain, Western blot, and LC-MS-
MS.   
 
LC-MS-MS Analysis.  Elution samples were sent to MS Bioworks (Ann Arbor, MI) for 
processing.  Briefly, protein samples were precipitate with TCA as previously described(148).  
Proteins were separated on a 10% Bis-Tris Novex mini-gel using a MES based system, stained 
with Coomassie stain, and the gel was separated into 10 equal sized slices.  Gel fragments were 
processed using the ProGest (DigiLab) robot.  The gel slices were washed with 25 mM 
ammonium bicarbonate followed by acetonitrile.  The samples were reduced with 10 mM 
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Dithiothreitol (DTT) at 60° followed by alkylation with 50 mM iodoacetamide at room 
temperature.  The protein samples were digested with trypsin (Promega) for 4 hours at 37° which 
was quenched with formic acid.  The supernatant was then loaded onto a Waters NanoAcquity 
HPLC system interfaced to an Orbitrap Velos Pro (Thermo-Fisher).  Data was analyzed against 
the Rhesus macaque and HHV-1 proteomes using the MASCOT program and validated using 
Scaffold software.   
 
Electrophoresis, Silver Stain, and Western Blot.   SDS polyacrylamide gel electrophoresis 
was carried out as previously described (340) with the following modifications.  Samples were 
loaded onto either a 7.5% (ICP4, Med1, TAF1, Brm1), 10% (p62), any kD (TBP, Elongin B), or 
4-15% (Silver stain) Tris-HCl mini protein gel containing a 4% stacking gel (Biorad).  For silver 
staining, gels were processed according to the manufacturers directions (Pierce).  For western 
blotting, proteins were transferred to either polyvinylidine fluoride (PVDF; Amersham) for 
chemi-luminescent detection or nitrocellulose membranes for infrared detection as previously 
described (340).  Membranes were probed with the following antibodies in TBS-T containing 
1% milk; N15, polyclonal rabbit serum, for ICP4 (1:500), Trap220 for Mediator1 (sc8998-X) 
(1:250), TAF1 (sc735) (1:500), TBP (233-R Covance) (1:250), p62 of TFIIH (sc292-X) (1:250), 
Brahma of SWI/SNF (sc6450) (1:250), and Elongin B of SIII (sc11447) (1:250).  Membranes 
were processed as described previously (340) with the following modifications.  For 
chemiluminescent detection, blots were probed with secondary HRP conjugated goat anti-rabbit, 
goat anti-mouse, or donkey anti-goat antibodies (Promega) at a 1:5000 dilution for 30 minutes.  
Membranes were then exposed to ECL detection agent (Amersham) according to the 
manufacturers instructions, and exposed directly to film (Hyperfilm; Amersham).  For infrared 
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detection, membranes were incubated with IRdye conjugated donkey anti-rabbit or goat anti-
mouse secondary antibodies at a 1:10,000 dilution for 30 minutes.  Infrared signals were detected 
using the LI-COR Odyssey infrared imager.   
4.4 RESULTS 
The goal of this work was to investigate the complexity of ICP4 mediated interactions 
throughout viral infection.  In this regard, the temporal kinetics and genetic requirements of said 
interactions were investigated.  The identification of novel protein complexes that play an 
integral role in the regulation of ICP4 activated transcription was also a goal.  To address these 
goals, affinity purification of wtICP4 and the C-terminal truncation mutant n208, followed by 
proteomic analyses were preformed. 
Construction and characterization of TAP-ICP4 and TAP-n208 
To investigate the protein components of ICP4 complexes, an affinity purification 
approach was taken.  To affinity purify ICP4 containing complexes a Tandem Affinity 
Purification (TAP) tag (Stratagene) was placed at the amino terminus of the ICP4 protein.  The 
TAP tag consists of a Calmodulin Binding Peptide (CBP) N-terminal to a Streptavidin Binding 
Peptide.  Using the RecET system of recombination that has been previously described (327, 
328), the sequence for the TAP tag was inserted into an ICP4 or n208 coding plasmid N-terminal 
to the ICP4 start site and such that it would be in frame with ICP4.  The TAP tagged ICP4 or 
n208 containing plasmids were then used in a marker transfer assay to insert the TAP tag into 
both ICP4 loci within the viral genome.  The genotypes of the resultant viruses were verified via 
Southern blot analyses and protein expression was verified via Western blot analyses (data not 
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shown).  Both viruses had the correct genotype and expressed similar quantities of ICP4 with a 
decreased mobility when compared to the parent virus, corresponding to the addition of the TAP 
tag.  
Characterization of ICP4 containing complexes. 
To determine the composition of the protein complexes with which ICP4 interacts during 
infection, TAP-ICP4 or TAP-n208 were affinity purified using a streptavidin conjugated matrix, 
unbound proteins were washed away, and purified complexes were eluted three separate times 
using 2 mM biotin.  To initially examine the composition of the ICP4 containing complexes, 
proteins were separated via electrophoresis and visualized using silver stain.  Figure 24 is a 
representative silver stain for KOS and TAP-ICP4 purified at 6 hpi.  It was evident from the 
presence of a strong band below 200kDa in the TAP-ICP4 elutions E1, E2, and E3 lanes that 
TAP-ICP4 was highly enriched using this procedure.  Additionally, numerous other protein 
bands were visualized in the TAP-ICP4 elutions that were either not present or underrepresented 
in the KOS samples, indicative of the purification of ICP4 interacting proteins.   
 
Figure 24:  Silver stain analysis of ICP4 purification.   
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Vero cells were infected at a multiplicity of 10, nuclear extracts were collected 6 hpi, and ICP4 
containing complexes were purified over streptavidin conjugated agarose beads.  (NE: nuclear 
extract; E1-E3: Elutions 1-3). Note that each lane contains 1/20 of the eluted sample.  
 
Mass Spectrometry. 
ICP4 differentially regulates E and L transcription.  Because E and L genes differ in their 
requirements for activation and because the core promoter elements are different between E and 
L genes, the temporal affect of ICP4 mediated protein interactions were investigated.  KOS and 
TAP-ICP4 infected samples were collected at 3, 6, and 12 hpi and ICP4 containing complexes 
were affinity purified.  Additionally, the viral mutants n208 and TAP-n208, were also purified to 
investigate the genetic requirements for ICP4 mediated protein interactions. 
To identify the protein composition of each TAP sample, the three eluted fractions were 
combined, precipitated, and liquid chromatography coupled with tandem mass spectrometry 
(LC-MS-MS) analyses were performed.  As a control, all experiments were performed with 
viruses containing untagged versions of ICP4 and n208 and were included for LC-MS-MS 
analyses.  Proteins containing the peptides identified via LC-MS-MS were identified using the 
MASCOT search engine and verified using Scaffold.  Search results were filtered to contain 
proteins that were at least 4x more abundant in the TAP-tagged samples than in the untagged 
samples and had a minimum of 5 spectral counts.  Based on these criteria, 82, 141, 215, and 188 
proteins were identified in the TAP-ICP4 3, 6, and 12 hpi, and TAP-n208 samples respectively.   
ICP4 mediated TFIID interactions precede those of Mediator. 
Using a similar tandem affinity purification approach, our lab has previously 
demonstrated that TFIID and Mediator can be co-purified with ICP4 (198).  LC-MS-MS 
analyses from the experiments herein confirmed these findings.  The percent coverage of each 
TAF and TBP from TFIID identified by LC-MS-MS is listed in Table 1.  The data indicated that 
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ICP4 and TFIID formed complexes as early as 3 hpi and that these interactions are retained 
throughout infection.  Presumably, the spectral counts correlate with the quantity of protein 
purified; higher spectral counts equate to a greater amount of that protein in the sample.  Under 
this presumption, TAFs 4, 5, 6, and 9 were present in the greatest amounts in purified ICP4 
samples.  Interestingly, these TAFs, along with TAF12 have been suggested to be the “core” 
components of TFIID and are thought to initiate the assembly of holoTFIID (356).  The 
abundance of these TAFs in affinity purified samples is either the result of ICP4 directly 
contacting a core component of TFIID or is reflective of the stoichiometry of holo-TFIID (285).  
 
Table 1:  Isolation of TFIID. 
TFIID components isolated with TAP-ICP4 at 3, 6, and 12 hpi represented in spectral counts 
(SpC) and percent coverage (% Coverage).  
 
In addition to isolating TBP and 12 TAFs from TFIID, 18 of the approximately 30 
subunits of the Meditator complex were purified with ICP4 containing complexes (Table 2).  
Subunits from each module of Mediator (head, middle, tail, and kinase) were isolated in ICP4 
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containing complexes (Table 2).  Interestingly, at 3 hpi only 5 subunits of the total 18 identified 
were identified by LC-MS-MS.  The percent coverage of the 5 subunits identified at 3 hpi was 
relatively low, ranging from 1.4 - 15%, compared to at 6 hpi where the percent coverage of those 
same 5 subunits ranged from 17 - 29%.  This indicates that ICP4 mediated interactions with 
Mediator were not present initially in infection as they appeared to be with TFIID (Table 1), 
implying that ICP4-TFIID interactions preceded those of Mediator. 
 
Table 2:  Isolation of Mediator.   
Mediator components isolated with TAP-ICP4 at 3, 6, and 12 hpi.  Numbers represent the 
percent coverage.  Colors signify the Mediator module to which the component belongs (red= 
head, orange=middle, yellow=tail, green=kinase).  Med1 is thought to act as a bridge between 
the middle and tail regions.   
 
To verify the results obtained from LC-MS-MS, independent samples were subjected to 
western blot followed by protein quantification analyses. Figure 25 A represents the results of 
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the western blot analyses while Figure 25 B represents the results from the protein quantification 
analyses.  For the purposes of directly comparing one protein between different samples, the 
spectral counts obtained from LC-MS-MS, or the number of individual peptides corresponding 
to the protein, are listed above the relative abundances of each protein (Figure 25 B). The 
western blot data confirmed that TAP-ICP4 was purified at both 3 hpi and 6 hpi as evidenced by 
the presence of immunoreactive bands in the TAP-ICP4 lanes, but not the KOS lanes (Figure 
25A, panel 1).  To account for the differences in quantity of ICP4 purified in each sample, 
protein quantification for all other proteins (TAF1, TBP, MED1) were normalized to the amount 
of ICP4 isolated within that specific sample.  Western blot analyses indicated that both TAF1 
and TBP were present in TAP-ICP4 purified samples at 3 hpi and 6 hpi, as determined by the 
presence of immunoreactive bands present at around 250 and 37kDa respectively (Figure 25 A 
panels 2 & 3).  In accordance with LC-MS-MS data, protein quantification analyses indicated 
that TAF1 and TBP were more abundant in the 3 hpi sample than in the 6 hpi sample, with a 2-3 
fold reduction in levels of TAF1 or TBP at 6 hpi compared to 3 hpi (Figure 25 B).  Additionally, 
MED1 was not detectable by western blot analysis in TAP-ICP4 samples purified at 3 hpi, but 
was detectable at 6 hpi (Figure 25 A panel 4).  Protein quantification analyses indicated a 3 fold 
increase in the amount of MED1 present in samples collected at 6hpi compared to 3 hpi, 
confirming the LC-MS-MS data.  Together these data suggest that ICP4-mediated TFIID 
interactions preceded those of Mediator.  
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Figure 25: TFIID Quantification 
A Western blot analyses of ICP4, TAF1, TBP, and MED1 from nuclear extracts (NE) and 
streptavidin affinity pull downs (PD).  Samples were harvested from KOS and TAP-ICP4 (Tap) 
infected cells at 3hpi and 6hpi as labeled above.  B Quantification of A, expressed as relative 
intensity.   
 
The C-terminal Transactivation Domain of ICP4 Stabilizes Interactions with TFIID and 
Mediator 
The viral mutant n208 lacks the C-terminal transactivation domain rendering it severely 
deficient for L gene expression (70).  To determine whether n208 interacted with the same 
components of the transcription machinery as wtICP4 in vivo, TAP-n208 was purified at 6 hpi, 
the co-purified proteins were identified via LC-MS-MS, and compared to proteins isolated with 
TAP-ICP4 at 6 hpi.   
The purification of components of TFIID and Mediator with TAP-ICP4 and TAP-n208 
were compared (Tables 3 and 4).  Notably, all 12 TAFs and TBP were isolated with TAP-n208, 
albeit some TAFs were less abundant compared to when isolated with TAP-ICP4.  Comparison 
of the core components of TFIID indicated that the abundance of some TAFs in TAP-n208 
samples was decreased, while the abundance of others remained approximately equal.  For 
instance, TAFs 4 and 12 appeared to be present at similar levels in both the TAP-ICP4 and TAP-
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n208, while TAFs 5 and 6 were decreased in TAP-n208 samples compared to TAP-ICP4 
samples and TAF9 was significantly increased (Table 3). The decreased levels of some, but not 
all, core components of TFIID in TAP-n208 samples could be indicative of direct interactions 
between the N-terminus of ICP4 and certain core components of TFIID such as TAF9, however 
this remains to be experimentally determined.  Of note, many TAFs were present in non-TFIID 
associated complexes suggesting that the differences in abundance of some TAFs may be the 
result of interactions, not only between ICP4 and TFIID, but also other TAF containing 
complexes.  Interestingly, of the non-core TAFs, both TAF1 and TBP were less abundant in 
TAP-n208 samples compared to TAP-ICP4 samples as assessed by both the percent coverage 
and spectral counts.  The reduced levels of TAF1 present in the TAP-n208 purified samples is in 
accordance with previously published data indicating that the C-terminus of ICP4 is necessary 
for TAF1 mediated interactions (41).  It is perhaps not surprising that levels of TBP were also 
reduced in TAP-n208 samples, as TAF1 and TBP are known to directly interact (217, 317, 376); 
without ICP4-TAF1 interactions, stabilization of TFIID may not occur.   
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Table 3: TFIID components affinity purified with n208.  
TFIID components co-purified with TAP-ICP4 or TAP-n208 at 6 hpi.  Numbers represent the 
percent coverage of the identified protein. 
 
A comparison between the purification of components of the Mediator complex in TAP-
ICP4 and TAP-n208 samples revealed that, as with TFIID, the C-terminus of ICP4 may not be 
necessary for interactions with Mediator, but instead may have a combined function with the N-
terminus in stabilizing Mediator-ICP4 interactions.  Many components of the Mediator complex 
were isolated at similar levels in TAP-n208 purified samples compared to TAP-ICP4 purified 
samples, including MEDs 4, 6, 14, 18, 20, 23, 27, and 31 (Table 4).  Additionally, many 
components of the Mediator complex were reduced in TAP-n208 purified samples, including 
MEDs 1, 7, 12, 13, 15, 16, 17, 23, 25, 31, cyclin C, and cyclin dependent kinase (CDK) 8.  
Interestingly, many of the components that were reduced in abundance in the TAP-n208 sample 
(8/12) belong to the tail and kinase region of the Mediator complex, perhaps suggesting an 
interaction between the C-terminal transactivation domain of ICP4 and a component of the tail or 
kinase region of the mediator complex.  This would be in accordance with published data 
indicating that co-activators frequently contact the tail region of the Mediator complex, allowing 
the head region to interact directly with RNA PolII.   
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Table 4: Mediator components isolated from n208 purified samples.   
Mediator components co-purified with TAP-ICP4 and TAP-n208 at 6hpi.  Numbers represent the 
spectral counts (SpC) or the percent coverage (% Coverage) of the identified protein.   
 
To verify results obtained from LC-MS-MS regarding TAP-n208 mediated interactions 
with TFIID and Mediator, western blot and protein quantification analyses were performed on 
independently isolated samples.  Western blot analyses were performed with antibodies for ICP4, 
TAF1, TBP, and MED1.  As evident by the presence of immunoreactive bands at approximately 
250, 37, or 220 kDa in the TAP-n208 PD lanes, TAF1, TBP, and MED1, respectively, were co-
precipitated in TAP-n208 samples (Figure 26 A).   Protein quantification data indicated that 1.3 
fold more n208 was purified during the procedure, and as such, all further protein quantification 
was normalized to the quantity of the ICP4 molecule purified.  Protein quantification confirmed 
that TAF1, TBP, and MED1 were isolated to a lesser extent than with TAP-ICP4 (Figure 26 B).  
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Western blot and protein quantification analyses were in accordance with LC-MS-MS data and 
indicated that both TFIID and Mediator were isolated in TAP-n208 purified samples, but to a 
lesser extent than in TAP-ICP4 purified samples.   
 Figure 26: TFIID and Mediator purification from n208 infected cells.  
A. Western blot analyses of KOS, TAP-ICP4, n208, and TAP-n208 purified samples.  
Antibodies directed against ICP4, TFIID (TAF1 and TBP), and Mediator (MED1) were utilized 
to determine the relative abundance of these protein complexes in purified samples.  B. 
Quantification of A. Spectral counts as determined by LC-MS-MS are listed above the relative 
intensities. 
 
Elongation Factors 
Interestingly, in addition to cellular components involved in transcription initiation, many 
cellular components related to transcription elongation were co-purified with ICP4, including 
components of TFIIH and the SIII complex (Elongin). TFIIH is a multi-subunit protein involved 
in promoter clearance (107, 111, 211, 291).  It is composed of a “core” including the XPB, p44, 
p62, p52, and XPD subunits and a dissociable “catalytic activating kinase” (CAK) region 
composed of MAT1, cyclinH, and CDK7.  All 5 core components of TFIIH were isolated with 
purified ICP4, while cyclinH and CDK7 of the CAK were not (Figure 27 A).  The kinetics of 
ICP4-TFIIH interactions were similar to those of the Mediator, with more components being 
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present and at higher levels later in infection (6 and 12 hpi) compared to early (3 hpi).  As with 
TFIID and Mediator, components of TFIIH also co-purified with n208, although these 
components generally appeared to be less abundant in TAP-n208 purified samples compared to 
TAP-ICP4 purified samples.  The presence of an immunoreactive band at approximately 62 kDa 
in a western blot analysis with antibodies directed at the p62 component of TFIIH verified that 
p62 was isolated with ICP4 and n208 at 6 hpi (Figure 27 B). 
  
Figure 27: TFIIH is isolated in ICP4 containing complexes.  
A. Components of TFIIH isolated during purification of ICP4, represented as the number of 
spectral counts.  The number prior to the backslash represents the spectral counts in the untagged 
sample. No backslash indicates protein was not detected in the untagged sample.  B.  Western 
blot analysis using an antibody directed at the p62 component of TFIIH.   
 
In addition to TFIIH components, the SIII (Elongin) complex also co-purified with TAP-
ICP4 and TAP-n208.  The SIII complex is involved in releasing or overcoming RNA PolII 
pausing on elongating RNA transcripts (318).  The SIII complex is composed of three subunits: 
Elongins B and C, which are the regulatory subunits, and Elongin A, which is associated with 
transcriptionally active RNA PolII (26, 27).  All three components of the SIII complex co-
purified with TAP-ICP4 late in infection (6 and 12 hpi), while only the regulatory subunits, 
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Elongins B and C, co-purified with TAP-n208 (Table 5). While Elongins A and C were also 
present in the untagged samples at 3 and 6 hpi, Elongin A was enriched more than 5 fold in the 
TAP-ICP4 sample at 6 hpi.   
 
Table 5: Isolation of the Elongin Complex.   
Components of Elongin SIII isolated with purified ICP4, represented as number of spectral 
counts.  The number prior to the backslash represents spectral counts in the untagged sample, 
whereas the number after the backslash represents the spectral counts in the TAP-tagged sample.  
No backslash indicates that the protein was not identified in the untagged sample.     
 
In an attempt to identify regions of ICP4 that are responsible for direct protein-protein 
interactions, a small highly conserved, biologically relevant 20 amino acid region corresponding 
to amino acids 80-100 within the N-terminus of ICP4 (340) was engineered to contain a GST tag 
(m90GST).  The 20 amino acid peptide was then bound to GST-conjugated beads and incubated 
with HeLa nuclear extract.  Non-specific proteins were washed away and the GST-m90 peptide 
with bound proteins was eluted from the beads using 10 mM glutathione.  Eluted samples were 
concentrated and analyzed via LC-MS-MS and western blot.  Interestingly, the bound m90 
peptide was capable of interacting with Elongins B and C (Figure 28).  Elongin A was not found 
in either the GST-purified m90 samples or in n208 containing complexes (Table 5 and Figure 
28). These data suggest that perhaps the C-terminus of ICP4 is important for interactions with 
Elongin A.  Elongin A is the transcriptionally active component of the SIII complex, therefore, 
the reduction in transcription of E and L genes displayed by n208 could potentially be due to an 
inability of the molecule to recruit/stabilize Elongin A.  This data, combined with the TAP-ICP4 
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purification data (Table 5), suggest that the SIII complex is a bona fide component of ICP4 
containing complexes, although further experimentation is needed to verify this.   
 
Figure 28: Elongin SIII purification with m90-GST.   
Elongin components isolated with GST by itself or m90-GST, represented as spectral counts.  
Samples containing GST only or GST-m90 were bound to GST conjucated beads, and either 
incubated with HeLa nuclear extract (+NE) or not (-NE).  Samples incubated with nuclear 
extract were analyzed via LC-MS-MS.  A. LC-MS-MS results, represented in spectral counts.  B. 
Western blot analysis with antibodies directed against Elongin B.   
 
Chromatin Remodeling Factors: 
 In addition to the many components related to transcription initiation and elongation, 
multiple components of the SWI/SNF, Nurd, and Ino80 chromatin remodeling complexes were 
isolated in ICP4 containing complexes.  Chromatin remodeling complexes hydrolyze ATP to 
provide the energy to disrupt histone/DNA interactions, thus allowing them to move, slide, or 
replace histones on the DNA (Reviewed in 47, 126).  As such, a common characteristic of 
chromatin remodeling complexes is the presence of an ATPase domain.  The ATPase containing 
proteins of the SWI/SNF, Nurd, and Ino80 complexes are Brahma related gene 1 (Brg1) & 
Brahma (Brm), CHD3&4, and RUVBL1&2, respectively.  Interestingly, with the exception of 
Brg1, each of these ATPases was co-purified with ICP4 from infected cells (Figure 29 A, C, D).  
The co-purification of Brahma was verified using western blot analysis (Figure 29 B).  The 
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presence of an approximately 220 kDa immunoreactive band in the TAP-ICP4 6 hpi and TAP-
n208 samples validated the LC-MS-MS identification Brahma.  In addition to the ATPase 
containing proteins, multiple adaptor proteins from each of these complexes were isolated.  
These included SMARCA4, SMARCC2, and Bzb1 kinase from the SWI/SNF complex, HDAC2 
from the Nurd complex, and Apr5 from the Ino80 complex (Figure 29).   
With respect to the kinetics of ICP4-chromatin remodeling complex interactions, the 
Ino80 complex appeared to be more prevalent late in infection (Figure 29 D).  This is perhaps not 
surprising, as the Ino80 complex has been implicated in stabilizing replication forks during DNA 
replication (249, 297).  The recruitment of Ino80 to ICP4 containing complexes may be the result 
of the recognition of branched concatemers as replication forks.  This is supported by the fact 
that Ino80 components are found to higher extents later in infection (6 and 12 hpi) when viral 
DNA is replicating, and not in cases where DNA replication does not occur such as early in 
infection or in n208 infected cells (Figure 29 D). 
 
Figure 29: Chromatin remodelers isolated in ICP4 containing complexes.   
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A. Components of the SWI/SNF complex. B. Western blot analysis using antibodies directed 
against Brahma of the SWI/SNF complex.  C. Components of the Nurd complex identified via 
LC-MS-MS.  D. Components of the Ino80 complex.  Data is represented as the number of 
spectral counts identified for each protein.  The numbers listed prior to the backslash represent 
the number of spectral counts in the untagged samples.   
 
ICP4 and mRNA processing: Capping to Export 
 In addition to components involved in chromatin remodeling, transcription initiation, and 
elongation, many components related to RNA processing were also isolated in ICP4 containing 
complexes (Table 6).  Twenty-six protein components constituting a portion of the spliceosome 
were isolated in ICP4 containing complexes.  This was surprising, as the vast majority of HSV-1 
genes are not spliced (339).  The isolation of the spliceosome components with ICP4 may reflect 
either the isolation of ICP4 containing complexes involved in cellular gene regulation, or 
conversely may suggest that ICP4 sequesters components of the splicing machinery to aide in the 
inhibition of cellular splicing.  It has been shown that in HSV-1 infected cells, a Ser2 
phosphorylated version of RNA PolII localizes to nuclear foci containing components of the 
spliceosome (108).  It was also shown that some of these sites are juxtaposed to ICP4 containing 
foci (108), providing a potential link between ICP4 and splicing factors.   
Additionally, components involved in the cleavage of nascent RNA transcripts were 
isolated.  These include cleavage and polyadenylation specificity factors (CPSF) 1, 2, 3L, 4, 7 
and FIP1L1.  Multiple components involved in mRNA export were isolated, including members 
of the TREX complex.  The overwhelming number of components related to mRNA processing 
isolated in ICP4 containing complexes, in part, substantiates itself, however, western blot 
analyses will provide further validation of this data.  The presence of the numerous components 
involved in gene transcription, but the absence of certain notable proteins such as RNA 
Polymerase II, TFII A, B, E, and F, other strong DNA binding proteins, and viral proteins leads 
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us to believe that the majority of the proteins identified are bona fide components of ICP4-
mediated transcription complexes.  The potential roles of the mRNA processing factors, 
chromatin remodeling complexes, and elongation factors in ICP4 mediated viral gene expression 
will be discussed at length.     
 Function TAP 3 TAP 6 TAP 12 TAP-n208 
Poly-
Adenylation 
     
CPSF4 makes mature mRNA; cleavage 2/9 0/8 0/7 0/16 
CPSF2 makes mature mRNA; cleavage 6/16 0/12 3/31 9/0 
CPSF1 makes mature mRNA; cleavage 9/20 5/18 5/31 22/51 
CPSF7 makes mature mRNA; cleavage 4/6 0/8 0/6 7/10 
CPSF3 like makes mature mRNA; cleavage 0/11 4/8 2/10 6/3 
FIP1L1 subunit of CPSF; stimulates 
poly(A)polymerase activity 
0/8 0/9 0/20 9/7 
      
Splicing      
HCC-1 Coactivator involved in splicing 11/9 4/4 0/23 4/4 
Pre-mRNA 
processing factor 
6 
bridge between U5 and U4/U6 3/6 6/36 4/46 4/7 
Pre-mRNA 
processing factor 
38 
spliceosome assembly 6/9 0/5 0/7 0/13 
splicing factor 1 spliceosome assembly 9/20 5/18 5/18 4/6 
snRNP40 component of U5 spliceosome 0/6 0/14 0/23 0/9 
PRPF4 component of U4/U6 
spliceosome 
0/0 0/9 0/3 6/6 
hnRNP A/B many functions; part of the 
spliceosome; binds to tk 
promoter 
4/9 6/11 0/7 0/8 
SmD1 like protein spliceosome 9/21 6/9 3/27 6/8 
Luc7-like (similar 
to U1) 
spliceosome 3/6 0/0 0/12 0/20 
ETFUD2 component of U5 33/19 31/45 15/78 27/65 
U4/U6.U5 tri-
snRNP associated 
protein 
involved in U2 spliceosome 
splice site recognition 
0/0 0/14 0/41 4 
RNA binding 
protein 10 
regulation of alternative 
splicing 
9/4 8/3 0/5 0/0 
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pre-mRNA banch 
site protein p14 
contacts branch site for first 
catalytic step of splicing 
8/8 0/0 0/5 0/5 
RNA Binding 
protein 25 
alternative splicing/site 
selection 
4/18 4/62 4/24 4/107 
pre-mRNA 
processing factor 
8 
spliceosome; aligns 5' and 3' 
exons for ligation 
33/87 33/139 20/212 56/100 
Serine/arginine 
rich splicing 
factor 4 
alternative splice site selection 17/11 13/0 0/10 0/0 
snRNP D2 spliceosome 7/7 0/2 0/8 0/15 
snRNP200 component of U5 37/86 38/128 15/165 54/77 
PUF60 splice site recognition; also 
inhibits active txn via TFIIH 
8/38 8/92 0/119 8/148 
U2AF component of U2; binds to pre-
mRNA branch site 
22/51 14/57 0/51 2/174 
Imp3 component of U3; spliceosome 12/5 4/0 0/10 4/4 
splicing 
regulatory 
glutamine/lysine 
rich protein1 
regulates other splicing factors 0/3 0/10 0/13 0/21 
snRNP E part of U7 complex; 3' histone 
processing 
3/4 0/4 0/7 0/3 
PRPF3 associates with U4/U6 0/0 0/10 0/7 2/3 
splicing factor 3B 
subunit2 
anchors U2 to the branch site 10/6 17/4 0/13 4/6 
snRNPB component of U2 11/5 2/4 0/8 2/15 
      
Export      
T-rex complex 1 packages mRNA for export 0/7 0/7 0/3 0/4 
Mahog component of EJC 10/8 3/0 0/14 0/0 
hnRNP L-like mRNA packaging/export 16/8 12/6 0/6 12/6 
Nuclear Cap 
binding protein 
subunit 2 
component of CBC; interacts 
with ALYREF/T-rex; meditates 
intronless mRNA export 
7/5 5/6 0/6 4/2 
T-rex complex 6 packages mRNA for export 0/7 2/9 0/0 0/0 
nuclear cap 
binding protein 
subunit 1 
component of CBC; interacts 
with ALYREF/T-rex; meditates 
intronless mRNA export 
11/11 3/3 0/10 11/0 
      
RNA Helicases      
DDX50 rRNA synthesis/processing 13/12 0/0 0/11 10/0 
DDX6 P-body associated; translation 5/4 0/5 0/4 6/0 
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suppression and mRNA 
degradation 
DDX23 unknown 0/0 0/0 3/0 0/0 
DDX47 shuttles between nucleus and 
cytoplasm 
24/20 6/15 5/9 20/9 
DDX41 intracellular DNA sensor 27/50 9/53 5/50 17/62 
DDX39B splicing factor required for U2 
association with pre-mRNA 
8/5 9/9 3/10 11/0 
DDX23 like component of U5 snRNP 8/8 3/24 3/44 11/23 
DDX49 unknown 4/3 0/5 0/2 0/3 
DDX8 releases RNA from spliceosome 
to facilitate nuclear export 
0/0 0/0 0/8 4/37 
      
mRNA stability      
Serpine1 mRNA 
binding protein 
binds 3'end of RNA to stabilize 
mRNA; interacts with CHD3 
0/3 0/6 0/5 6/9 
Mahog component of EJC 10/8 3/0 0/14 0/0 
      
Unknown      
RNA binding 
protein 26 
unknown 4/0 0/0 0/9 0/8 
RNA binding 
protein 15 
unknown 19/8 8/9 0/7 14/2 
Nop5/Nop58 methylation of rRNA? 36/35 25/21 8/43 47/30 
pre-mRNA 
processing protein 
40A 
splicing? 8/19 2/66 4/17 3/127 
Luc7 Like2 RNA binding 16/42 4/60 0/73 0/197 
Serine/Arginine 
rich splicing 
factor 11 
may play a role in pre-mRNA 
processing based on structure 
0/11 0/11 0/18 0/33 
 
Table 6: mRNA processing factors isolated in ICP4 containing complexes.   
Data is represented as spectral counts.  Numbers prior to backslash are from untagged samples, 
numbers post backslash are from TAP-tagged samples. 
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4.5 DISCUSSION 
The purposes of these studies were to i) determine the temporal kinetics of ICP4 mediated 
interactions, ii) determine the structural requirements for these interactions, and iii) identify 
novel proteins in ICP4 containing complexes.  Affinity purification of ICP4 was performed, and 
co-purified proteins were identified via LC-MS-MS and verified via western blot analyses.  
Here, we have shown that ICP4 mediated interactions with TFIID precede those of Mediator, and 
that the N-terminal 774 aa of ICP4 are sufficient, but sub-optimal, for both of these interactions.  
Additionally, we show that ICP4 containing complexes also contain proteins involved in 
chromatin remodeling, elongation, and mRNA processing and export.   
Time Couse Analyses of Transcription Complex Assembly 
 The data presented here strongly suggest that ICP4 interacts with TFIID prior to the 
Mediator complex.  This may be reflective of the kinetics of PreInitiation Complex (PIC) 
formation on E viral promoters.  During transcription initiation, TFIID, facilitated by TFIIA, 
binds to a core promoter element, such as a TATA box or Inr element.  This triggers the 
subsequent assembly of TFIIB, PolII and TFIIF, and TFIIE on the promoter to form a functional 
PIC (Reviewed in 275).  It was originally demonstrated that TFIID binding to a core promoter 
element is a rate-limiting step in PIC assembly (357).  More recently, the Roeder lab 
demonstrated that the interaction of TFIID and Mediator on the promoter is the rate-limiting step 
for the initiation of basal transcription, and suggested that a TFIID-Mediator complex must be 
present on promoter DNA to initiate basal transcription (7).  Studies investigating activator 
dependent recruitment of Mediator, indicate that Mediator is not always recruited to activated 
genes (96), suggesting, that TFIID-Mediator interactions may not always be the rate limiting step 
in the initiation of activator dependent transcription.   
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Our lab has shown that TFIID and Mediator are present on viral promoters, and that their 
recruitment is dependent on the presence of ICP4, thus demonstrating that viral transcription 
occurs in an activator (ICP4)-Mediator dependent manner (198, 284). Data establishing that 
ICP4 and TFIID form complexes prior to interactions with the Mediator complex suggest that 
ICP4-TFIID complexes are likely formed early, presumably on DNA, prior to other components 
of the initiation machinery.  The mechanism of Mediator recruitment to viral promoters has not 
been elucidated.  It is possible that ICP4-TFIID interactions may be required for the recruitment 
of Mediator to viral transcription complexes.  ICP4 likely plays an integral role in the 
recruitment of the Mediator complex, as other co-activators were not isolated in ICP4 containing 
complexes, despite the presence of several activator-binding sites within the promoter region of 
E genes. Nonetheless, the possibility that other cellular/viral factors or post-translational 
modifications, promote the recruitment of Mediator to viral genomes cannot be ruled out.  
Chromatin Remodeling, and Late Gene Expression. 
 The ICP4 mutant n208 is missing the C-terminal 500 amino acids corresponding to the C-
terminal transactivation domain, yet retains the DNA binding domain, NLS, dimerization motif, 
and N-terminal transactivation domain.  n208 is capable of activating E, but not L gene 
expression, and does not replicate DNA efficiently.  The data herein demonstrated that n208 is 
capable of interacting with TFIID and Mediator, yet these interactions are not sufficient for DNA 
replication or L gene expression.  This is perhaps reflective of a presumably lower affinity 
interaction between n208 and TFIID and potentially Mediator.  The C-terminus of ICP4 has been 
established as being important for interactions with TAF1 of TFIID (41).  Consequently, in 
n208-infected cells approximately 4 fold less TAF1 was isolated.  Additionally, TAF1 and TBP 
have been shown to directly interact (217, 317, 376), thus, approximately 4 fold less TBP was 
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also isolated from n208 infected cells.  The reduced level of isolation of TFIID in n208 
containing complexes may potentially result in unstable interactions with the Mediator complex, 
as we and others have suggested that TFIID-Mediator interactions may be a limiting step in the 
initiation of transcription (7).  The ability of n208 to interact with TFIID at all is presumably a 
result of the redundant functions encoded by ICP4; the N-terminus of ICP4 also stabilizes 
interactions with TFIID through TBP (303, 340, 373).   
The inability of n208 to activate L gene expression may be due to reduced stabilization of 
TFIID and mediator on viral promoters, however, as viral DNA replication is dependent on E 
gene transcription, in addition to ICP4-TFIID interactions, other factors and mechanisms may be 
involved.  One such factor may be the Ino80 complex.  In this system three components of the 
Ino80 complex, RuvBL1, RuvBL2, and Arp5 were isolated in ICP4 containing complexes, but 
not in n208 containing complexes.  Additionally, significant amounts of the Ino80 complex were 
not isolated until 6 hpi, after the onset of vDNA replication in this system.  The Ino80 complex 
contributes to DNA replication fork progression, and stabilization (249), presumably through 
remodeling chromatin components associated with the replicating DNA (Reviewed in 56). While 
this is the first study implicating the Ino80 complex in HSV DNA replication, the mechanisms 
underlying chromatin remodeling, transcription, and DNA replication are still being elucidated.  
Recent advances in chromatin dynamics during lytic infection indicate that viral DNA associates 
with histones, histone variants, and SWI/SNF chromatin remodeling complexes (Reviewed in 
212).  In addition to its role in DNA replication, the Ino80 complex has also been shown to 
promote the activation of transcription via chromatin remodeling (56).  In this manner, the Ino80 
complex may have a dual function in both transcription and DNA replication during HSV lytic 
infection.  Based on these findings we propose a model in which the C-terminus of ICP4 may be 
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involved in promoting viral DNA transcription and replication, perhaps through its ability to 
multimerize on DNA (183) and interact with components involved in chromatin remodeling and 
replication fork stability.   
Gene Looping. 
Perhaps one of the most interesting findings in this study is the association of ICP4 with 
components involved in mRNA processing and export.  The shear number of proteins isolated 
that are involved in mRNA processing indicates that ICP4, which was primarily viewed as a 
DNA dependent transcription factor, may play an integral role in mRNA processing.  Within the 
last decade the view of transcription and mRNA processing has evolved to support a model in 
which the steps of mRNA processing are intimately linked co-transcriptionally (226).  Many 
actively transcribing genes undergo a process referred to as “gene looping”.  After a productive 
round of transcription, RNA PolII is released from the terminator and can re-associate with a 
reinitiation scaffold at the promoter that is comprised of several GTFs and activators.  By linking 
the terminator and promoter regions of genes, hence forming a gene loop, reinitiation is made 
more efficient (Reviewed in 292).  The cleavage and polyadenylation specificity factors 
(CPSFs), which are involved in cleaving the polyadenylated nascent transcript, have been 
intimately linked to gene looping as they provide an interface for interaction with several GTFs 
and coactivators including TFIIB, TFIIH, and PC4 (36, 221).  PC4 is one of very few proteins 
that contain sequence similarity to ICP4 (110).  PC4 interacts with CPSF and TFIIB, thus 
providing a direct link between the promoter and terminator regions of actively transcribing 
genes (36).  Additionally, mRNA processing and gene looping have been shown to be coupled to 
mRNA export.  Based on the similarity between ICP4 and PC4 and the purification of multiple 
CPSFs and mRNA export proteins, we propose a new model for ICP4 mediated transcription in 
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which ICP4 directly interacts with CPSFs providing a structural link between the promoter and 
terminator region of HSV genes (Figure 30).  The function of gene looping in HSV transcription 
may be to increase the efficiency of re-initiation, although HSV genes are not particularly long as 
they are generally intronless.  As such, the formation of gene loops may not be necessary for 
HSV transcription, and may be a consequence of the transcription process.  Interestingly, 
integrated HIV provirus also forms gene loops, which enhance transcription rates (256).  During 
HIV transcription, elongation appears to be an integral part of the formation of gene loops, as 
initiation is not sufficient to drive their formation.  The data herein simply suggest that ICP4 may 
bind to CPSFs to establish a gene loop.  However, direct evidence demonstrating gene looping 
and its function in HSV infection needs to be established, and are currently under investigation. 
The data presented herein suggest that ICP4 is involved in a variety of processes related 
to transcription.  Given the large size and elongated structure of the molecule, ICP4 likely 
provides a binding surface for a variety of transcription complexes.  In addition, many of the 
aforementioned cellular transcription processes are coupled to each other, thus increasing the 
rates of cellular transcription.  Activated transcription from the viral genome requires a delicate 
balance between the mechanisms evolved by the host cell to combat viral infection and the 
molecular mechanisms developed by the virus to overcome these barriers.  It is not surprising, 
given the size and structure of ICP4, that ICP4 would be intimately linked to many of these 
processes.   
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Figure 30: Model of ICP4 mediated gene looping.   
ICP4 interacts with CPSF forming a structural link between the promoter and terminator regions 
of HSV genes.  This process may influence reinitiation kinetics. 
 
4.6 ACKNOWLEDGMENTS 
The construction of the m90-GST tagged construct and the associated purifications and western 
blot analyses were performed by the skilled technician, Fran L. Sivrich.  
 
 152 
5.0  THESIS SUMMARY AND GENERAL DISCUSSION 
5.1 SUMMARY OF THESIS 
ICP4 functions at the level of transcription and is capable of interacting with components 
of the transcription machinery, including TFIID and Mediator (198).  Two transactivation 
domains and a DNA binding domain help mediate the transcriptional activities of ICP4.  While 
the contributions of the transactivation domains to viral transcription have been investigated, a 
comprehensive understanding of how these domains function individually and together has not 
been established.  We hypothesized that regions within both transactivation domains contribute 
individually and together to the activities of ICP4.  Therefore, the goal of this project was to 
more accurately define the contributions of the transactivation domains to the activities specified 
by ICP4.  Given that ICP4 functions through transcriptional complexes, the complexity of ICP4 
mediated interactions throughout infection was also investigated. 
To investigate the contribution of the transactivation domains to ICP4 activities, deletion 
mutants spanning the N-terminal transactivation domain were constructed in the presence and 
absence of the C-terminal transactivation domain.  The contributions of these regions were 
assessed with respect to viral growth and the kinetics and levels of mRNA and polypeptide 
expression.  The data demonstrated that in the absence of the N-terminal transactivation domain, 
viral transcription was abolished and ICP4 was no longer found in complexes with TFIID.  
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Additionally, the data suggested that interactions with TFIID could be restored by the formation 
of a heterodimer consisting of a N-terminal deletion mutant and a C-terminal deletion mutant, 
ultimately resulting in restored viral growth.  Further characterization of the N-terminal 
transactivation domain failed to yield specific regions that were necessary for viral growth, 
although some regions specified functions related to the levels or kinetics of transcription in cell 
culture. Multiple independent regions affected the levels of viral growth and gene expression to 
varying degrees, indicating that interactions with transcriptional machinery likely occur on 
multiple surfaces of the molecule.  The deletion of amino acids 81-96 within the N-terminal 
transactivation domain had no effect on viral growth in a cell culture model, however, the 
additional deletion of the C-terminal transactivation domain resulted in attenuated viral 
transcription and growth, indicating that regions in the N-terminus and C-terminus both 
contribute to a specific function of the molecule.  
ICP4 functions through transcription complexes.  Therefore, one of the goals of this work 
was to more accurately define the transcription complexes with which ICP4 interacts and 
determine how these interactions change throughout infection.  Affinity purification followed by 
LC-MS-MS and western blot analyses determined that ICP4 is involved in a variety of 
transcription complexes.  The kinetic analyses indicated that ICP4 forms a complex with TFIID 
prior to other components of the transcription machinery such as Mediator or TFIIH.  
Additionally, proteins involved in chromatin remodeling, initiation, elongation, cleavage and 
polyadenylation, and nuclear export were isolated in ICP4 containing complexes indicating that 
ICP4 functions at multiple levels beyond transcription initiation.   
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5.2 GENERAL DISCUSSION 
Structural Requirements for ICP4 Activities: 
The work presented in this study provides insight into structural requirements for ICP4 
mediated functions.  Electromobility shift assays, predictions of disorder, and the values obtained 
for stokes radii suggested that ICP4 has an elongated structure with the N-terminus being more 
elongated than the C-terminus (293, 340).  The elongated N-terminal transactivation domain of 
ICP4 is required for viral transcription and interactions with at least TFIID.  Affinity purification 
and LC-MS-MS analyses indicate that n208 was capable of interacting with the same 
transcription complexes as wtICP4, although these complexes appeared less stable.  Together 
this data suggested that the N-terminal transactivation domain may contribute significantly to the 
majority of ICP4 mediated protein interactions.  The elongated structure of the N-terminus likely 
provides ample surface area for transcription complex binding and activators to function at a 
distance while the C-terminal activation domain is integral to stabilizing interactions between 
ICP4 and the transcriptional machinery, and perhaps in stabilizing the disordered N-terminal 
portion of the molecule upon factor binding, which will be discussed below.  
Data indicated that the N-terminal transactivation domain of ICP4 was necessary for the 
associated transcriptional activities.  Interestingly, an amino acid sequence comparison of ICP4 
from multiple alphaherpesviruses demonstrates that there are two highly conserved regions 
corresponding to the DNA binding domain and the C-terminal transactivation domain (66).  
Thus, it is noteworthy that the conserved C-terminal transactivation domain is dispensable for E 
gene transcription while the more degenerate N-terminal transactivation domain is not.  This is 
likely the result of the structure, or lack there of, of the N-terminus; it contains small highly 
conserved ordered regions that are flanked by largely disordered regions.  It is likely that many 
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of these highly conserved regions provide binding surfaces for a variety of transcription 
complexes.  The presence of disordered regions of ICP4 suggests that these regions are flexible, 
potentially providing for a variety of conformational changes upon factor binding.  Affinity 
purification data suggested that ICP4 interacts with multiple protein complexes; the wide array 
of proteins with which ICP4 interacts could be partially dependent on changes in conformation 
of the flexible regions within the N-terminus. Additionally, the shear length of the molecule, 
provided largely by the N-terminus, may be important for allowing ICP4 to act at a distance, thus 
the transcription defects observed with deletion of amino acids 30-142 and 142-210 may be the 
result of not only the deletion of conserved binding sites, but also disruption of the length of the 
molecule.  This could prevent ICP4 from interacting with activators at a distance, even if the 
regions responsible for those protein-protein interactions are retained.  
It is particularly interesting that the N-terminal 774 amino acids of ICP4 are sufficient to 
interact with the same transcription complexes as wtICP4 and yet viral DNA replication and L 
gene expression are greatly diminished.  Thus, the C-terminus must have a role in these 
functions.  The reduced levels of viral DNA replication in n208 infected cells is particularly 
interesting because ICP4 has never been directly implicated in viral DNA replication.  
Presumably, the lack of DNA replication observed in n208-infected cells is the result of the 
decreased abundance of the E proteins involved in DNA replication.  However, at the mRNA 
level, n208 accumulated similar levels of tk mRNA as either d3-8 or d8-10, which both replicate 
DNA and were only moderately reduced in viral growth.  Comparisons between the levels of 
viral DNA replication and the quantities of E proteins produced, particularly those involved in 
DNA replication, would be of interest.  
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Another explanation for reduced levels of DNA replication in n208 infected cells arose 
from the affinity purification and LC-MS-MS data that indicated that n208 does not strongly 
associate with the Ino80 chromatin remodeling complex, while wtICP4 does.  This complex has 
been linked to chromatin remodeling during cellular DNA replication in addition to replication 
fork stabilization (56).  The association of ICP4 with the Ino80 complex may be the result of 
viral DNA replication, or conversely, viral DNA replication could require the association of the 
Ino80 complex. It would be intriguing if the C-terminus of ICP4 directed this complex to the 
viral DNA to allow for efficient DNA replication.  The contributions of the Ino80 complex to 
HSV transcription and DNA replication have not yet been investigated.  In this respect, it would 
be beneficial to determine i.) whether the Ino80 complex associates with the viral genome, ii.) if 
it localizes to either OriL or OriS during viral DNA replication, iii.) if it is necessary for viral 
DNA replication or transcription, and iv.) the impact of ICP4 on its association with the viral 
genome.   
 Interestingly, DNA replication is not a prerequisite for wtICP4 to bind to L promoters, 
yet n208 is not present at the gC promoter (284).  The defects in L gene transcription are 
partially the result of the inefficient formation of transcription complexes on L promoters (284).  
The comparatively lower abundances of proteins isolated with n208 indicates a reduced affinity 
for these transcriptional complexes. Additionally, n208 does not multimerize on viral DNA, 
which results in a decreased affinity of ICP4 for DNA (183).  The architecture of L promoters 
differs significantly from that of E promoters in that they are generally devoid of binding sites 
for cellular activators.  Thus, the defects observed in L gene expression may arise from the 
decreased affinity of n208 for both transcription complexes and viral DNA, in addition to the 
lack of upstream activators to help stabilize ICP4 and transcription machinery on DNA.   
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As suggested above, the N- and C-terminal transactivation domains likely function 
together to form multiple protein contacts.  Deletion of amino acids 81-96 (m90), which 
corresponds to a highly conserved, ordered region within the N-terminus had minimal effect on 
viral growth in cell culture.  The additional deletion of the C-terminus of ICP4 (m90n7) rendered 
the molecule completely defective for viral transcription.  This data implies that the N-terminus 
and C-terminus of ICP4 contain redundant functions.  It is likely that these regions both act to 
stabilize a particular transcription complex, perhaps TFIID or Mediator, on viral promoters.  It is 
probable that ICP4 contacts multiple subunits of both TFIID and Mediator.  For example, the N-
terminal transactivation domain is known to contact TBP while the C-terminal transactivation 
domain contacts TAF1.  The presence of either of these interactions may be sufficient for the 
ICP4-TFIID interactions; however, the loss of both regions could ablate this interaction.  Similar 
effects were observed with deletion of amino acids 30-142 (d3-8 and nd3-8) and 142-210 (d8-10 
and nd8-10).  Studies aimed at determining the functional deficiencies in m90n7, nd3-8 and nd8-
10, compared to their full length counterparts would help delineate the surfaces of ICP4 that 
interact with the transcriptional machinery.  It is striking that the virus has evolved to provide 
functional redundancies within the molecule in addition to maintaining two genomic copies of 
ICP4.  This underscores the importance of ICP4 to the viral lifecycle.    
When evaluating the structure of ICP4, the fact that ICP4 exists and functions as a dimer 
must be taken into account (223).  It is established that coinfection with viral mutants differing in 
defective functions can lead to complementation between the two peptides (294).  It has been 
shown that coinfection of n208 with a mutant that does not bind to DNA (d2) leads to a novel 
protein-DNA complex and that transcription of L genes is restored.  Thus, the DNA binding 
defect in d2 was complemented by n208 and the functional C-terminal domain of d2 
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complemented the defects in L gene transcription exhibited by n208.  The presence of novel 
protein-DNA complexes in coinfected cell extracts suggests that a heterodimer between n208 
and d2 was present on the DNA (294).  Additionally, it has also been established that the 
structure of one molecule within a heterodimer can negatively alter the conformation of the 
opposite molecule (296), suggesting that the structures of C-terminal and N-terminal 
transactivation domains directly affect each other.  This implies that the N-terminal and C-
terminal transactivation domains may be in close proximity to each other, and that the dimer may 
be structured in a head to tail orientation.   
Data collected in these studies were also aimed at enhancing the understanding of the 
structure of the ICP4 dimer.  An ICP4 mutant lacking the N-terminal transactivation domain, d3-
10, failed to interact with TFIID resulting in undetectable levels of E and L gene transcription.  
Infection of d3-10 expressing cells with n208 resulted in complementation, with increased viral 
progeny, L gene expression, and the formation of d3-10-n208 heterodimers that were capable of 
interacting with TFIID.  Studies herein demonstrated that n208 itself is capable of interacting 
with TFIID.   Thus, the n208 molecule within the heterodimer may provide for the recruitment of 
TFIID while the C-terminus of d3-10 may allow for mulitmerization or recruitment of other 
complexes (perhaps Ino80) important in viral DNA replication and L gene transcription.  
Additionally, the C-terminus of d3-10 may act to stabilize the interactions with TFIID that are 
moderately unstable with n208 alone.  This data implies that the N-terminus and C-terminus of 
opposite molecules within the dimer can function together to stabilize TFIID binding on L 
promoters.  This reinforces the hypothesis that ICP4 dimers may be structured with the N-
terminus and C-terminus of the opposite molecules close together.   
ICP4: A hub for transcription complexes.   
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It has been established that ICP4 is involved in the formation of TFIID and Mediator 
complexes on viral promoters (198).  Data presented herein suggest that ICP4 may function at 
more levels than transcription initiation.  Affinity purification, LC-MS-MS, and Western blot 
analyses suggest that ICP4 interacts with multiple components of the transcription machinery, 
including those involved in initiation, elongation, mRNA processing, and mRNA export.   
 TFIID nucleating the core promoter is regarded as the initial step of PIC formation on 
TATA driven promoters, and as such, is required for most components of the transcription 
machinery to properly position on viral promoters.  Interestingly, most of the ICP4 mutants 
studied to date either eliminate or reduce the stability of TFIID interactions, thus affecting 
complex formation with other factors, such as Mediator.  A mutant that retains stabilized binding 
with TFIID, but not other transcription complexes has not been isolated.  However, some 
deletion mutants display differing phenotypes with respect to both the levels and kinetics of E 
gene expression.  In particular, the mutant d8-10 was capable of activating E gene transcription, 
but increased levels of mRNA transcripts did not accumulate until 8hpi.  Conversely, the mutants 
d3-8 and n208 showed generally reduced levels of E gene transcription.  n208 does not form 
particularly stable interactions with TFIID, therefore it can be hypothesized that the regions 
deleted in d3-8 are also involved in stabilization of TFIID.  However, the differing phenotype of 
d8-10 suggests that amino acids 142-210 may have a distinct role in the formation of 
transcription complexes. In this respect, affinity purification of d3-8 or d8-10 and analyses of the 
associated transcription complexes would provide insight into mechanisms of ICP4 mediated 
transcriptional activation.   
Upon the formation of transcription complexes on viral promoters, RNA PolII mediated 
elongation occurs.  The CTD of RNA PolII is alternatively phosphorylated in HSV infection and 
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lacks the Ser2 phosphorylation (108) that is generally associated with the recruitment of mRNA 
processing factors.  Alternative phosphorylation of RNA PolII appears to be mediated by the 
virus as a mechanism to subvert RNA PolII from cellular transcription  processes to viral 
transcription processes (208).  Interestingly, Med26, a variable component of the mediator 
complex, was not isolated with wtICP4 in infected cells.  Med26 acts as a switch between 
preinitiation and elongation by interacting with components of TFIID during PIC formation, then 
exchanging those interactions for components of the super elongation complex (SEC), which 
includes pTEFb/cdk9 and the elongation factors ELL and EAF (319).  Our data suggest that 
ICP4 may form transcription complexes with components of the Elongin SIII complex, not the 
SEC.  Additionally, components of the 3’mRNA processing factor CPSF were isolated with 
wtICP4. Both of these complexes associate with the elongating form of RNA PolII (Phospho-
Ser2 and Ser5).  While RNA PolII is not phosphorylated on Ser2 throughout HSV infection, 
mechanisms to recruit the transcription elongation and mRNA processing machinery must be in 
place.  It is possible that ICP4 may functionally replace Med26 and recruit elongation complexes 
(albeit different ones) and 3’mRNA processing complexes that normally require Ser2 
phosphorylation.   
Recruitment of 3’ processing factors, in addition to components of Mediator and TFIID 
suggests a novel role in viral transcription.  Cellular transcription has been shown to occur via a 
mechanism referred to as gene looping (292).  Upon the onset of transcription initiation, many 
components of the transcription machinery remain at the promoter element, acting as a 
reinitiation scaffold.  The reinitiation scaffold has been linked to the cleavage and 
polyadenylation specificity factor (CPSF) through interactions with TFIIB (301).  These 
interactions form a “gene loop” that functions to enhance reinitiation of transcription and 
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establish “transcriptional memory”.  Gene loops additionally enhance transcript export as they 
have been localized to regions near the nuclear pore (320). The findings herein support a model 
for viral transcription in which gene looping occurs.  Work from the Knipe lab suggests that 
active transcription complexes form at the nuclear lamina (300).  This implicates that these 
transcription complexes are at the periphery of the nucleus and may be in close proximity to 
nuclear pore complexes.  The additional isolation of components of the export machinery with 
affinity purified ICP4 further supports this notion.  Additionally, integrated HIV provirus forms 
gene loops in a TAT, TAR and CPSF dependent manner, providing an example of an RNA PolII 
dependent virus that utilize this mechanism to enhance viral transcription rates (256).  Studies 
determining i.) gene loops are formed on the viral genome during HSV infection, ii.) the 
functional relevance of gene loops to HSV transcription, and iii.) the activities of ICP4 in their 
formation, would enhance the current understanding of transcription from DNA viruses.  It is 
possible that this is a common mechanism utilized by many DNA viruses to increase the 
efficiency of viral transcription.    
ICP4 Mediated Exit from Latency: 
ICP4 has been shown to be important for viral replication in a mouse model of ocular 
infection.  These studies indicated that regions contained within amino acids 142-210 were 
particularly important for viral replication in trigeminal ganglia, and as a consequence for 
efficient viral reactivation (11, 362).  Interestingly, one mutant studied, ΔSER, showed no 
growth defect in cell culture yet failed to replicate in vivo (11).  Some regions within the N-
terminus have significant sequence homology between HSV-1, HSV-2, and Herpes B Virus, yet 
in cell culture, had no effect on viral replication when deleted either in the presence or absence of 
the C-terminal domain.  This suggests that these regions either i. have redundant functions 
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encoded within the N-terminus, or ii. like ΔSER, have a significant role in vivo.  Investigating 
the combined functions of these regions, specifically those deleted in ΔSER, m20, m90 and 
d143, would address whether these regions contain redundant functions in a cell culture model.  
The function of these regions in viral replication within the trigeminal ganglia, and the 
establishment and reactivation from latency are currently being investigated within the lab.   
The differences observed in viral replication between the trigeminal ganglia and a cell 
culture model as a consequence of specific regions of ICP4 suggests that ICP4 has functions that 
are either redundant or dispensable within a cell culture model.   The transcription environments 
in neurons and epithelial cells are likely different, implying that ICP4 may function differently 
based on the cellular transcription environment. The differences in transcriptional environments 
may arise partially from differing chromatin states of the genome.  Studies presented herein 
demonstrated that ICP4 co-purified with ATP dependent chromatin remodeling complexes such 
as SWI/SNF, Ino80, and Nurd.  It is possible that during the acute infection of the trigeminal 
ganglia, ICP4 mediated interactions with chromatin remodeling complexes may promote viral 
replication over the establishment of latency.  Additionally, the potential for ICP4 to alter the 
chromatin conformation of the latent viral genome exists.  In this respect, ICP0 would promote a 
general derepression of the viral genome (53, 100) and interactions between ICP4 and chromatin 
remodelers would promote efficient activation of viral transcription on a chromatinized template.  
In this manner, regions of ICP4 may be important for reactivation, which are otherwise 
dispensable for lytic infection.  Studies to this affect are also ongoing within the lab. 
The data presented in this thesis examined the structural and functional requirements of 
ICP4 mediated transcriptional activities.  Together, these data advance the understanding of how 
ICP4 forms interactions with the transcription machinery and suggests new roles for ICP4 in 
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mediating viral transcription.  Understanding the mechanisms underlying viral transcription can 
help advance fields aimed at developing novel drugs and vaccines against HSV as well as those 
aimed at utilizing HSV as a therapeutic agent.   
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